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There is increasing evidence from yeast to humans that splicing is mainly a co-
transcriptional process, and it is becoming well established that splicing, transcription 
and chromatin are functionally coupled such that they influence one another. The 
present work explored the links between splicing and transcription and links between 
splicing and chromatin in the budding yeast Saccharomyces cerevisiae. 
Currently, there is little mechanistic insight into the contribution of the core 
transcription elongation machinery to co-transcriptional spliceosome assembly and 
splicing. To understand how members of the core transcription elongation machinery 
affect splicing, I used the auxin-inducible degron (AID) system to conditionally 
deplete essential and non-essential transcription elongation factors and I analysed the 
effects on RNA polymerase II, co-transcriptional spliceosome assembly and splicing. 
The transcription elongation factors that I analysed are all conserved from yeast to 
mammals and include: Spt5, Paf1, Ctk1, Bur1 and Bur2.  Most notable were the effects 
of depletion of the transcription elongation factor Spt5, mutations in which were 
known to cause splicing defects. Here, Spt5 depletion resulted in reduced recruitment 
of the U5 snRNP to intron-containing genes, meaning proper co-transcriptional 
activation of the spliceosome was inhibited, explaining how loss or mutation of Spt5 
results in splicing defects. This effect was not dependent on phosphorylation of Spt5, 
however, the unphosphorylated form of Spt5 enhanced co-transcriptional formation of 
the catalytically activated spliceosome. Together, these data indicate a two-part 
function for Spt5 in co-transcriptional spliceosome assembly in S. cerevisiae.  Firstly, 
the physical presence of Spt5 is required for proper co-transcriptional recruitment or 
stable association of the U5 snRNP and B complex formation. Secondly, the loss of 
Bur1 kinase activity and at least the unphosphorylated form of Spt5 enhances co-
transcriptional formation of the catalytically activated spliceosome and splicing. 
There is correlative and causative evidence that splicing affects chromatin structure 
and vice versa. Of particular interest to the present work are links between splicing 
and Histone 3 Lysine 4 trimethylation (H3K4me3), a chromatin mark associated with 
promoters of active genes. H3K4me3 has been shown to influence and be influenced 
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by splicing in mammalian cells. However, the molecular basis of this is unknown. To 
further understand the links between splicing and H3K4me3, I used the AID system 
to conditionally deplete essential splicing factors that act at different stages of the 
splicing cycle and analysed the effects on H3K4me3. Whilst depletion of splicing 
factors that affect the first or second catalytic step of splicing reduces H3K4me3 on 
intron-containing genes, notably, depletion of the late-acting factor Prp22 reduces 
H3K4me3 in the absence of defects in splicing catalysis, suggesting a more direct role 
for Prp22.  Prp22 is an RNA-dependent ATPase that proofreads to product of the 
second step of splicing and promotes mRNA release from the post-spliceosome. 
Interestingly, the effect of Prp22 on H3K4me3 is dependent on its ATPase activity. 
Furthermore, Prp22 and Set1 were found to interact in a pull-down assay and depletion 
of Prp22 results in reduced recruitment of Set1 to intron-containing genes. These data 
show a previously unknown link between Prp22, Set1 and H3K4me3 in S. cerevisiae. 
Collectively, these analyses provide new mechanistic insight into the links between 
























The DNA of most organisms is comprised of a mixture of both non-coding sequences 
(‘introns’) and coding sequences (‘exons’). In order to make a protein, the DNA 
sequence must first be copied into RNA during a process called transcription. Before 
a functional protein is made, the non-coding sequences (introns) must be removed in 
a complex biochemical process called splicing. Splicing is conserved from simple 
unicellular organisms such as yeasts to more complex multicellular organisms like 
humans, and failures in splicing can be of great consequence to the functioning of 
individual cells and whole organisms. From yeast to humans, splicing occurs during 
transcription (‘co-transcriptionally’) of DNA into RNA, and interestingly there are 
known links between splicing and transcription such that these processes can influence 
one another. These links between splicing and transcription are important for splicing 
outcome. During my PhD I have tested the effects of loss of proteins that regulate 
transcription on splicing in the model yeast Saccharomyces cerevisiae, which has 
revealed novel links between core proteins involved in transcription and co-
transcriptional splicing.  
 
Interestingly, in addition to splicing and transcription influencing one another, it is 
known that there are links between splicing and the higher-order structure of DNA. 
DNA is not a naked molecule and is packaged by proteins into a higher order structure 
called chromatin. Unlike the DNA sequence, the way in which DNA is packed is 
highly changeable – and various biochemical modifications determine this, giving rise 
new levels of regulation of gene expression. Splicing occurs in close-proximity to 
chromatin, and it has been shown that splicing and chromatin affect each other, 
potentially serving as a splicing ‘memory’ in order to facilitate future rounds of 
splicing. During my PhD studies I have tested the effects of inhibiting splicing on 
chromatin structure in the model yeast Saccharomyces cerevisiae and found a 
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Chapter 1. Introduction 
 
1.1 Gene expression in eukaryotes 
 
DNA encodes the information to make functional proteins, which are the building 
blocks of life, but does not direct protein synthesis. In a process called transcription, 
DNA is copied into RNA and the RNA molecule serves as a template for protein 
synthesis or translation. The fact that DNA makes RNA and RNA makes protein is 
known as the central dogma of molecular biology. Transcription in the nucleus 
generates precursor RNA (pre-mRNA) which is processed in various ways in order to 
generate a mature RNA (mRNA) that is exported to the cytoplasm for translation into 
a protein. RNA processing in eukaryotes is coupled to transcription. The first RNA 
processing event is capping at the 5’ end of the pre-mRNA transcript, during which a 
5’ methyl cap is added to the newly made RNA and helps to distinguish protein-coding 
RNAs from other types of RNA, in addition to preventing premature degradation at 
the 5’ end, regulating nuclear export and enhancing translation. Next, certain 
sequences are removed from the pre-mRNA.  
 
Genes of most eukaryotes are comprised of a mixture of non-coding sequences 
(‘introns’) flanked by coding sequences (‘exons’). Introns and exons are transcribed 
and are present in pre-mRNA, and in order to generate a functional protein, introns 
must be excised and exons ligated together in a process called pre-mRNA splicing. 
The 3’ end of the pre-mRNA is processed by cleavage followed by polyadenylation, 
during which approximately 200 adenosine nucleotides are added to the 3’ end. This 
gives the RNA a poly(A) tail that promotes export and translation, as well as 
preventing premature degradation. The pre-mRNA can then be exported from the 
nucleus to the cytoplasm, where it is translated into a protein by the ribosome.  
Eventually, the mRNA is degraded in a step-wise process: degradation is triggered by 
the shortening of the poly(A) tail (deadenylation) by exoribonucleases, followed by 





1.2 Transcription in eukaryotes 
 
In eukaryotes, DNA is transcribed into RNA by three RNA polymerase (RNAP) 
enzymes: RNAPI, RNAPII and RNAPIII, each transcribing a specific gene type. In 
contrast, prokaryotes have only one RNAP enzyme. RNAPI transcribes genes 
encoding ribosomal RNAs (28S, 18S, and 5.8S) which collectively comprise the 
majority of RNA in a cell. RNAPIII transcribes genes encoding transfer RNAs 
(tRNAs) and other small RNAs, including the smallest ribosomal RNA. RNAPII 
transcribes genes encoding all proteins (mRNAs), micro RNAs, small nuclear RNAs 
(snRNAs) (except for U6 which is transcribed by RNAPIII) and small nucleolar RNAs 
(snoRNAs). All three RNAP enzymes are multi-subunit complexes, for example, 
RNAPII is a large (approximately 500 kDa) complex comprised of 12 distinct subunits 
that are conserved from yeast to humans (Rpb1-Rpb12) (reviewed in Liu et al., 2013). 
 
Broadly, there are three main stages of RNAPII transcription: initiation, elongation 
and termination (reviewed in Shandilya et al., 2012). During initiation, RNAPII is 
recruited by general transcription factors and positioned at promoters of the gene to be 
transcribed and synthesises short sequences of RNA. After which, RNAPII undergoes 
conformational rearrangements that allow transcription elongation into the gene. At 
the end of the gene, RNAPII encounters a DNA sequence that is transcribed into RNA, 
which signals 3’end cleavage and ultimately termination of transcription. Nascent 
RNA transcripts synthesised by RNAPII after cleavage are degraded by a 5’-3’ 
exonuclease (as they lack a 5’ cap) which eventually triggers the release of RNAPII 
from the DNA template. It is important to understand the context in which RNAPII 
transcription occurs - in eukaryotes, DNA is packaged into nucleosomes that form a 
barrier to transcribing RNAPII. 
 
1.3 Transcription through chromatin  
 
Eukaryotic genomes are packaged into chromatin, the basic unit of which is the 
nucleosome. Packaging DNA into nucleosomes enables the genome to fit into the 
confined space of the nucleus. Nucleosomes are comprised of 147 base pairs of DNA 
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that are wrapped 1.65 times around histone octamers – two heterodimers of H3-H4 
and two heterodimers of H2A-H2B (Luger et al., 1997). Histones make extensive 
contacts with DNA via positively charged amino acids – the core histones are enriched 
in positively charged (lysine and arginine) amino acids that bind the negatively 
charged DNA backbone, so that any DNA sequence can potentially be bound by 
histone proteins. Nucleosomes form repetitive arrays that are analogous to “beads on 
a string” (reviewed in Struhl and Segal, 2013). Each nucleosome within the array is 
separated from the next nucleosome by a sequence of unwrapped linker DNA that 
varies from 20 to 90 base pairs in length, depending on species and even cell type 
(reviewed in Szerlong and Hansen, 2011). The nucleosome arrays do not remain in 
this linear “beads on a string” arrangement; nucleosomes are compacted on top of one 
another to varying degrees of compaction (reviewed in Li and Reinberg, 2011). The 
highly condensed form of chromatin is known as heterochromatin, and the less 
condensed form is known as euchromatin. Heterochromatin is a repressive 
environment for transcription whereas euchromatin is a transcriptionally permissive 
environment as DNA that is more tightly packaged is more inaccessible by RNAPII in 
comparison to a more open chromatin structure.  
 
Though necessary to compact the genome, nucleosomes present a physical barrier to 
RNAPII elongation. In vivo, promoter regions are relatively depleted of nucleosomes, 
and this enables recruitment of transcription factors to certain DNA sequences that 
facilitate recruitment of RNAPII (Yuan et al., 2005; reviewed in Zaret and Carroll, 
2011). Once recruited, RNAPII faces a barrier of ordered nucleosomes present in gene 
bodies that RNAPII must overcome for productive transcription elongation. Even on 
a “naked” DNA template, RNAPII stalls and backtracks (Dangkulwanich et al., 2013), 
therefore transcription through the nucleosome barrier presents a challenge to RNAPII, 
especially as a single nucleosome is sufficient to slow RNAPII transcription and 
induce RNAPII pausing in vitro (Knezetic and Luse, 1986; Lorch et al., 1987; Kireeva 
et al., 2005; Hodges et al., 2009). In order to transcribe the nucleosome barrier, histone 
chaperone proteins (such as the FACT complex) associated with histones and RNAPII 
loosen the interactions between DNA and histones by competition and disassemble 
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and reassemble nucleosomes in the wake of RNAPII transcription (reviewed in 
Hammond et al., 2017).  
 
Most genomic DNA forms nucleosomes, however there are some regions of genomes 
that are lower in nucleosome density compared to others, and some regions are 
completely nucleosome-free. Common regions of genes that are nucleosome depleted 
between species are enhancer, promoter and terminator elements. These nucleosome-
free regions are conserved from S. cerevisiae to humans. In S. cerevisiae, a 
nucleosome-free region upstream of transcription start sites is flanked by two well-
positioned nucleosomes -1 and +1, and towards the 3’ end of genes nucleosomes 
become less well positioned (Mavrich et al., 2008; Shivaswamy et al., 2008). Though 
the presence of a highly positioned +1 nucleosome is conserved between species, the 
precise location of the +1 nucleosome position relative to the TSS is less well 
conserved between species (Mavrich et al., 2008).  
 
Nucleosome positioning is at least partly governed by DNA sequence – some DNA 
sequences are more thermodynamically favourable for nucleosome location than 
others. Regions of the genome that are nucleosome-poor and regions of the genome 
that are nucleosome-dense can be predicted by DNA sequence alone in approximately 
50% of cases (Segal et al., 2006). How a DNA sequence is more favourable to be 
wrapped around histones is determined by the flexibility of the DNA sequence. Each 
histone heterodimer has three DNA binding motifs spaced approximately 10 bp apart, 
and specific DNA dinucleotides are more favourable than others in their ability to 
interact with nucleosomes (Satchwell et al., 1986; Widom, 2001). The most favourable 
dinucleotides for wrapping around histones are A:T or T:A, as they are more bendy 
than others. Recent mapping of DNA sequences wrapped around histones in S. 
cerevisiae showed approximately 10 bp repeats of AA/AT/TA/TT dinucleotides in 
interaction surface of the histones which were interspersed with CC/CG/GC/GG 
nucleotides not present on the interaction surface (Segal et al., 2006; Brogaard et al., 
2012). Long stretches of A:T or C:G base pairs are not favourable for winding around 
histones and stretches of A:T are common in promoter regions in S. cerevisiae and C. 
elegans which enable accessibility for transcription factor binding and are important 
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determinants of nucleosome organisation. These sequences are predictive of 
nucleosome occupancy in higher eukaryotes such as humans (Nelson et al., 1987; 
Kunkel and Martinson, 1981; Iyer and Struhl., 1995; Suter et al., 2000; Field et al., 
2008).  
 
Though in vitro and in vivo studies suggest DNA sequence is a determinant of 
nucleosome positioning, it is not the sole-determinant. For example, the +1 
nucleosome observed in vivo is not observed in vitro, and this is thought to be due to 
interaction of transcription factors to the nucleosome depleted promoter region (Zhang 
et al., 2009). Therefore, RNAPII transcription and factors associated with RNAPII 
machinery can affect nucleosome organisation (reviewed in Struhl and Segal, 2013). 
 
Though in vitro studies showed that RNAPII pauses on DNA templates, it was only 
relatively recently that this phenomenon was shown genome-wide and to correlate 
with nucleosome density (by using 3’end sequencing techniques that map with base 
pair resolution densities of RNAPII in the genome). Native elongating transcript-
sequencing (NET-SEQ) takes advantage of the strong ternary RNAPII:DNA:RNA 
structure formed during transcription, and involves a native pull-down of engaged 
RNAPII followed by purification of associated nascent RNA transcripts (spliced and 
unspliced) and sequencing the 3’ ends (Churchman and Weissman, 2011). NET-SEQ 
has shown that RNAPII density peaks just before nucleosomes and pauses throughout 
gene bodies at positions that correlate with nucleosome density in S. cerevisiae 
(Churchman and Weissman, 2011).  
 
Using global run-on sequencing (GRO-SEQ), where a nuclear run on reaction is 
incubated with brominated nucleotides, and nascent RNA purified and sequenced, it 
was shown that RNAPII occupancy correlated with nucleosome density at the 3’ ends 
of genes in mammalian cells (Grosso et al., 2012). Using precision nuclear run-on 
sequencing (PRO-SEQ), where a nuclear run on reaction is incubated with biotinylated 
nucleotides which allows purification of nascent RNA and 3’end sequencing, it was 
shown that RNAPII accumulates at the +1 nucleosome, and over exons in Drosophila 
(particularly the 5’ end) (Kwak et al., 2013). Further, in S. cerevisiae a technique called 
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modification cross-linking and analysis of cDNA (mCRAC), where a tagged protein-
of-interest (in this case RNAPII) is cross-linked in vivo to its associated RNAs which 
are isolated and sequenced, showed that RNAPII occupancy correlated with 
nucleosome density (Milligan et al., 2016). In mammalian cells, it was also shown 
using NET-SEQ that promoter-proximal pausing of RNAPII occurs just before the +1 
nucleosome (Mayer et al., 2015). These studies correlate RNAPII occupancy with 
nucleosome density and show the importance of nucleosomes for RNAPII 
transcription.  
 
Despite nucleosomes presenting an obstacle to RNAPII in vitro and the above studies 
demonstrating correlation of RNAPII occupancy with nucleosome density, in vivo 
transcription rates are comparable to in vitro transcription rates reported on ‘naked’ 
DNA templates (1-4 kb/minute) (Ardehali and Lis, 2009). This suggests that there 
must be mechanisms in place for RNAPII to overcome the nucleosome barrier and 
transcribe efficiently. In vitro evidence suggests that RNAPII does not separate 
contacts between DNA and histones but relies on other proteins to loosen these 
contacts in order to overcome nucleosome barriers (Hodges et al., 2009). In order to 
facilitate RNAPII transcription, chromatin structure is dynamically remodelled in 
various ways, including: nucleosome disassembly, nucleosome sliding, nucleosome 
eviction, and histone modification (reviewed in Li et al., 2007; Petesch and Lis, 2012). 
Collectively, these factors and modifications to chromatin structure affect gene 
expression by modulating RNAPII transcriptions and overcome the effect of DNA 
sequence on nucleosome occupancy. 
 
ATP-dependent chromatin or nucleosome remodellers use ATP to translocate along 
DNA and can move nucleosomes by nucleosome sliding, evict entire nucleosomes, or 
evict/exchange histones (reviewed in Clapier et al., 2017). Together, these activities 
can therefore change the position of nucleosome, or change the composition of the 
nucleosome (for example, by eviction of a particular post-translationally modified 
histone) and in so doing make particular DNA sequences more or less accessible by 
the transcription machinery. There are four different families of chromatin remodeller 
conserved in eukaryotes: SWI/SNF, CHD, ISWI and INO80. Each family has a 
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conserved ATPase domain, but differ in the domains flanking it. Flanking the 
conserved ATPase domain, each family has ‘reader’ domains that bind to particular 
types of post-translationally modified histones. Within each family, there are several 
subcomplexes and each chromatin remodeller is present in complex with many other 
proteins (reviewed in Clapier et al., 2017).  
 
Histones have N-terminal tails that protrude from the core, making them easily 
accessible to be post-translationally modified in a number of different ways that affect 
higher-order chromatin structure and therefore RNAPII transcription. Different types 
of protein modify and interact with histone N-terminal tails: ‘writers’ that modify 
histones (histone methyltransferases, histone acetyltransferases, kinases), ‘readers’ 
that bind to the histone modification (bromodomain, chromodomain and Tudor 
domain proteins) and ‘erasers’ (demethylases, histone deacetylases, phosphatases) that 
remove the modification (reviewed in Nicholson et al., 2015). These writers, readers 
and erasers can be recruited with the transcription machinery by associating with 
transcription factors bound to specific DNA sequences, directly by binding to histone 
modifications, or indirectly via readers bound to histone modifications (reviewed in 
Zhang et al., 2015). Most recently, it was found that some histone modifiers bind to 
nascent RNAPII transcripts (Battaglia et al., 2017; Luciano et al., 2017; Sayou et al., 
2017). Histone modifications include: acetylation, phosphorylation, methylation, 
ubiquitination, sumoylation and ADP-ribosylation (reviewed in Bannister and 
Kouzarides, 2011). Some histone modifications affect chromatin structure by 
changing the charge of the amino acid and therefore alter contacts between histones 
and DNA, and other modifications rely on ‘reader’ proteins to mediate the effect. 
Importantly, histone modifications are reversible, which enables dynamic regulation 
of chromatin structure and gene expression. There are a vast number of histone 
modifications, and the combinatorial effect of these modifications gives rise to great 
complexity in the regulation of gene expression (reviewed in Zhang et al., 2015).  
 
Modification of histones can affect chromatin compaction by changing the charge of 
the modified amino acid. For example, acetylation of histone lysine residues by histone 
acetyltransferases, and phosphorylation of serines, threonines and lysines by kinases 
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neutralises the positive charge of the residues modified, disrupting the electrostatic 
interaction between the histone and DNA and making chromatin less compact and a 
more favourable and accessible environment for transcription factor binding and 
transcription (reviewed in Bannister and Kouzarides, 2011). The less compact 
chromatin structure upon acetylation is highlighted by the fact that acetylated 
chromatin is more sensitive to DNase (Hebbes et al., 1994). Histone acetylation is 
found from yeast to humans on many different H3 and H4 lysine residues, and these 
modifications are enriched at promoter regions, which facilitates access by 
transcription factors and therefore stimulates RNAPII transcription (reviewed in 
Kurdistani and Grunstein, 2003; Bannister and Kouzarides, 2011). Histone 
phosphorylation is also conserved from yeast to humans and correlates with (but is 
much less common than) histone acetylation. Histone phosphorylation is associated 
both with activating and repressive roles in transcription regulation and chromatin 
compaction during mitosis (reviewed in Rossetto et al., 2012).  
 
In contrast, some histone modifications are small and do not directly affect chromatin 
compaction but indirectly, by providing a binding site for other ‘reader’ proteins that 
modify chromatin to make it more or less compact (depending on their activity) and 
in this way affect transcription. An example of this is histone methylation (of lysines 
or arginines) by histone methyltransferases, a chromatin mark conserved from yeast 
to humans. There are numerous characterised histone methylation events that occur 
most commonly on histones H3 and H4, though is also found on histones H2A and 
H2B. Histone methylation is a neutral modification that does not alter the charge of 
the amino acid on which it is deposited but provides a binding site for other chromatin 
modifiers with appropriate domains that can act to make chromatin more or less 
compact (reviewed in Hyun et al., 2017). There are three possible histone methylation 
states conserved from yeast to humans: mono- (me1), di-(me2) and tri-methylation 
(me3), and the degree of methylation determines the effect of the modification, giving 
an added layer of complexity to this histone modification. The effects of histone 
methylation are context-dependent – could be activating or repressive - which, as 
methylation is a neutral mark, are determined by proteins that bind to the mark. For 
example, in higher eukaryotes chromatin remodeller Chd1 binds to trimethylated 
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histone H3 lysine 4 (H3K4me3) (deposited by Set1 methyltransferase from yeast to 
humans), and, via interactions with RNAPII, histone chaperone complex FACT, and 
DSIF, is thought to positively influence transcription elongation (Simic et al., 2003). 
In S. cerevisiae, Chd1 lacks the binding domain for H3K4me3 (Sims et al., 2005) and 
instead, H3K4me3 is a binding site for Yng1, which stabilises recruitment of the 
histone acetyltransferase NuA3, that acetylates H4K14 thereby activating transcription 
(Taverna et al., 2006). While H3K4me3 correlates with active transcription, the 
function of H3K4me3 in transcription is unclear, with bothww repressive and 
activating functions reported (Howe et al., 2017) and discussed in more detail in 
chapter 4. From yeast to humans, H3K36me3 is deposited by Set2 methyltransferase 
and found throughout actively transcribed protein-coding genes. H3K36me3 recruits 
the histone deacetylase complex Rpd3S, which prevents aberrant intragenic 
transcription (Carrozza et al., 2005).  
 
Ubiquitination is a bulky modification of lysine residues of histones H2A and H2B, 
which can be mono or polyubiquitinated. Some types of ubiquitination have repressive 
or activating effects on transcription by recruitment of repressive or activating 
complexes. For example, in higher eukaryotes, H2A ubiquitination at lysine 119 
recruits repressive complex PRC2 (reviewed in Weake and Workman, 2008). On the 
other hand, conserved from lower to higher eukaryotes, histone H2B ubiquitination on 
lysine 123 (H2BK123) promotes histone H3 lysine 4 di- and trimethylation (H3K4me2 
and H3K4me3) by acting as a bridge for the Set1 methyltransferase. H3K4me2 and 
H3K4me3 are chromatin marks associated with active transcription elongation, and by 
helping to recruit the FACT histone chaperone complex (Xiao et al., 2005; Pavri et 
al., 2006; Lee et al., 2007; Kim et al., 2009; Nakanishi et al., 2009).  
 
In addition to modification of histone N-terminal tails, the globular domains of 
histones can be post-translationally modified and new histone modifications are still 
being discovered, revealing further complexity of the roles of histone modifications in 





1.4 Transcription initiation 
 
RNAPII is recruited to promoters of genes by interaction with general transcription 
factors, which bind to a specific consensus sequence (TATA) within the promoter 
called the ‘TATA box’. Though some eukaryotic promoters contain the consensus 
TATA box, genome-wide studies have shown the majority of eukaryotic promoters 
from yeast to humans lack this consensus sequence and rely on sequence elements 
downstream of promoters which are bound by other proteins that help to align RNAPII 
at the promoter. There are therefore two general classes of promoter in eukaryotes: 
TATA-less and TATA-containing (reviewed in Danino et al., 2015).  
 
The complex of RNAPII, DNA and general transcription factors is called the pre-
initiation complex (PIC) (reviewed in Luse, 2014). General transcription factors 
collectively comprise: TFIIB, TFIID, TFIIE, TFIIF and TFIIH. Firstly, the TATA box-
binding protein (TBP) subunit of TFIID binds either directly to the TATA box (at 
TATA box promoters), or TBP-associated factors (TAF’s) bind to sequences 
downstream of the promoter and help to align TBP at the promoter (reviewed in 
Shandilya and Roberts, 2012; Grünberg and Hahn, 2013). The binding of TBP induces 
a bend in the DNA at promoters and facilitates DNA melting. This complex is 
stabilised by binding of TFIIB and TFIIA. RNAPII bound to TFIIF then joins, 
followed by TFIIE and TFIIH which forms the PIC. TFIIH has an ATP-dependent 
RNA helicase subunit (Xpb) which unwinds approximately 10 base pairs of promoter 
DNA and enables placement of single-stranded DNA in the active site of RNAPII 
forming the ‘transcription bubble’ (reviewed in Shandilya and Roberts, 2012; 
Grünberg and Hahn, 2013). The initial synthesis of RNA by RNAPII is known as 
abortive transcription, where several short segments of RNA are transcribed and 
released. The PIC undergoes conformational changes – the contacts between RNAPII 
and general transcription factors are broken, and the kinase subunit of TFIIH 
phosphorylates residues of the largest subunit of RNAPII - until eventually a segment 
of RNA 9-11 base pairs in length is synthesised and RNAPII clears the general 
transcription factors and the promoter and starts transcription elongation with new 
proteins recruited to facilitate this (reviewed in Shandilya and Roberts, 2012; 
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Grünberg and Hahn, 2013). The general transcription factors are released to recruit a 
new RNAPII molecule for another round of transcription.  
 
1.5 Transcription elongation 
 
During transcription elongation, RNAPII associates with a number of different 
transcription elongation factors to form the transcription elongation complex that 
facilitates elongation and prevents RNAPII stalling or dissociation before the end of 
the gene. Upon promoter clearance, RNAPII in theory can begin transcribing along 
the gene in a 5’ to 3’ direction. However, in metazoans, 20-120 nucleotides 
downstream of the transcription start site RNAPII pauses in a phenomenon known as 
‘promoter-proximal pausing’. Promoter-proximal pausing is important as a quality 
control checkpoint for 5’ capping of the nascent transcript and is also important for the 
regulation of developmental genes. During promoter-proximal pausing, pausing 
factors DSIF (Spt4/5 in S. cerevisiae) and NELF (unknown in S. cerevisiae, possibly 
IswI (Morillon et al., 2003)) cause RNAPII to pause in a stable manner, and serine 5 
of the CTD is hyperphosphorylated by TFIIH. To transition RNAPII to a productive 
elongation state, positive transcription elongation factor (P-TEFb) (Bur1/2 and the Ctk 
complex (Ctk1/2/3) in S. cerevisiae) (Wood and Shilatifard, 2006)) phosphorylates 
DSIF, causing NELF to be released, and activating DSIF as a positive elongation 
factor. At this time, serine 5 of the CTD is dephosphorylated, and P-TEFb 
phosphorylates serine 2, converting RNAPII into an active elongation state (Adelman 
and Lis, 2012). As S. cerevisiae lacks NELF, it is thought that promoter-proximal 
pausing does not occur, however NET-SEQ studies in S. cerevisiae have shown that 
RNAPII accumulates at the 5’ ends of genes near transcription start sites (Churchman 
and Weissman, 2011; Milligan et al., 2016).  
 
After promoter clearance and release of promoter-proximal pausing, the rate of 
RNAPII transcription elongation is not uniform across the gene, or between genes. 
The RNAPII elongation rate can differ between genes up to 3-fold (Jonkers et al., 
2014; Veloso et al., 2014; Fuchs et al., 2014). RNAPII has been shown to slow down 
over exons (due to increased nucleosome density) and to pause for co-transcriptional 
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RNA processing (5’ capping, pre-mRNA splicing, cleavage and polyadenylation). 
Differences in RNAPII elongation rates can be explained by differences in nucleosome 
occupancy, histone modifications, chromatin remodellers and association of 
transcription elongation factors – none of which are mutually-exclusive.  
 
Unlike RNAPI and RNAPIII, RNAPII has a large unstructured ‘carboxy-terminal 
domain’ or ‘CTD’ in the largest subunit (Rpb1) that protrudes from the catalytic core. 
The CTD is conserved from yeast to humans and comprises heptapeptide repeats with 
the consensus amino acid sequence YSPTSPS (reviewed in Eick and Geyer, 2013). 
While the CTD is conserved in presence and consensus sequence, the number of 
heptapeptide repeats varies seemingly by complexity of the organism – there are 26 
heptapeptide repeats in S. cerevisiae that are almost identical, whereas the human CTD 
has 52 heptapeptide repeats that diverge from the consensus sequence more often 
(reviewed in Eick and Geyer, 2013). The CTD is a low-complexity domain that has no 
enzymatic activity but is likened to a ‘landing pad’ for the recruitment of transcription 
elongation factors that regulate stages of RNAPII transcription and chromatin 
modifiers. Additionally, the CTD is important for the recruitment of RNA processing 
factors, and it is thought that, as the CTD is close to the exit channel on RNAPII, the 
RNA processing factors can readily transfer from the CTD to nascent pre-mRNA 
molecule (reviewed in Eick and Geyer, 2013). 
 
Eukaryotic life is possible without a CTD – for example, RNAPII of Trypanosoma 
brucei has no CTD, however at least parts of the CTD are essential for viability in the 
organisms in which it is found. Genetic experiments have shown that deletion of up to 
a half of the individual repeats of the CTD does not affect viability in yeast or 
mammals, however, deletion of half or more of the repeats impairs cell growth and 
viability (Bartolomei et al., 1988; West and Corden, 1995; Meininghaus et al., 2000). 
The ‘functional unit’ of the CTD was experimentally shown to consist of one heptad 
repeat followed by the first four residues of the next heptapeptide repeat (Stiller and 
Cook, 2004). At promoters, the CTD of RNAPII is unmodified (Lu et al., 1991), 
however individual residues within the heptad repeats of the CTD are subject to post-
translational modification that dynamically change during the transcription cycle, 
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enabling diverse regulation of co-transcriptional RNA processing and chromatin 
modification (reviewed in Eick and Geyer, 2013). Potentially each individual residue 
within the heptad repeats of the CTD is subject to post-translational modifications that 
dynamically change during the transcription cycle, enabling diverse regulation of co-
transcriptional RNA processing and chromatin modification (reviewed in Eick and 
Geyer, 2013). Examples of CTD post-translational modification include: 
phosphorylation (of serine, threonine and tyrosine), glycosylation (of serine and 
threonine), ubiquitination (of lysine and arginine) and methylation (of lysine and 
arginine). Additionally, the prolines can undergo cis-trans isomerisation. Considering 
the potential combinations of CTD post-translational modification, it was proposed 
that there is a CTD ‘code’ that marks the transcriptional progress of RNAPII, which 
can be read by other proteins and thereby facilitate their recruitment at the appropriate 
time during the transcription cycle (Buratowski, 2003).  
 
The best characterised form of CTD modification is phosphorylation. Five of the seven 
residues (tyrosine 1, serine 2, threonine 4, serine 5 and serine 7) of the CTD heptad 
repeats are reversibly phosphorylated according to the transcriptional progress of 
RNAPII along a gene, thereby facilitating the recruitment of RNA processing factors 
and chromatin modifying enzymes at the correct point in the transcription cycle 
(Figure 1.1A). Phosphorylation makes the CTD less compact and more extended in 
structure (reviewed in Meinhart et al., 2005). The importance of the dynamic nature 
of CTD phosphorylation is highlighted by genetic evidence that mutated 
phosphorylated resides of the CTD to alanine or glutamic acid. Using a partially 
truncated CTD (18 repeats), it was shown that mutation of serines 2, 5 or 7 to glutamic 
acid is lethal, and mutation of serines 2 and 5 to alanine is lethal in S. cerevisiae (West 
and Corden, 1995; Zhang et al., 2012). Mutation of serine 5 to alanine or to glutamic 
acid was lethal in S. pombe but tethering the capping enzymes to the CTD rescued this 
effect (Schwer and Shuman, 2011). Analysis of full-length CTD phosphorylation 
mutants later showed that mutation of serine 2 to alanine was not lethal but caused 
growth defects in both S. cerevisiae and S. pombe (Cassart et al., 2012). In theory, the 
number of possible combinations of phosphorylated residues within a single repeat is 
416 (reviewed in Eick and Geyer, 2013). Monoclonal antibodies specific to different 
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phosphorylated forms of the CTD were developed, which recognise different CTD 
phosphorylation, and have been instrumental in biochemical studies and genome-wide 
studies mapping the enrichment of the phosphorylation across the gene. However, 
results may differ depending on the antibody used, as epitope recognition by some 
CTD antibodies is masked by adjacent post-translationally modified residues (Table 
1). Further, the use of antibodies does not allow quantitation of the combinations or 
degree of phosphorylation per CTD repeat. Recently, quantitative mass spectrometry 
of a minimal CTD in S. cerevisiae and humans revealed, with conservation, that most 
CTD repeats are unphosphorylated, multiple phosphorylation events within a single 
CTD repeat are rare, with only the combination of phosphorylated serine 5 followed 
by phosphorylated serine 2 detected (Schüller et al., 2016; Suh et al., 2016). These 
two mass spectrometry studies agree that tyrosine 1, threonine 4 and serine 7 
phosphorylation are rare in comparison to serine 2 and serine 5 phosphorylation in 
yeast and humans. Together, these studies suggest that the CTD code is less complex 
than first thought.  However, mass spectrometry may miss functionally important low-
abundant or more transient populations of RNAPII enriched in these CTD 
phosphorylated residues. For example, serine 7 phosphorylation was shown to be 
important for snRNA gene expression in mammalian cells (Egloff et al., 2007). 
Furthermore, the CTD may form a complex structure where different repeats are 
placed in close-proximity and this may modulate protein binding. These mass 
spectrometry studies suggest there are factors that limit the degree of CTD 
phosphorylation, and this could include phosphorylated CTD residues inhibiting near-
by phosphorylation events by kinases.  
 
Though potentially limited by antibody recognition, ChIP experiments using different 
CTD antibodies have broadly determined the average phosphorylation profile of the 
CTD across protein-coding genes, and these patterns are generally conserved from 
yeast to humans. What is clear from these studies is that the pattern of CTD 
phosphorylation is intimately linked with proper recruitment of downstream proteins, 
such as RNA-processing factors. The most well-studied phosphorylation marks are 
serine 2 and serine 5 phosphorylation of the CTD, and the patterns of these marks are 
conserved from yeast to humans. Serine 5 is phosphorylated in yeast by Kin28 (Cdk7 
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in mammals) and is enriched near promoters and transcription start sites where it is 
important for the recruitment of mRNA capping enzymes (Cho et al., 1999; Schwer 
and Shuman, 2011), during early transcriptional elongation and is a hallmark of 
promoter-proximal RNAPII pausing and other types of RNAPII pausing (reviewed in 
Liu et al., 2015). In S. cerevisiae, serine 5 phosphorylation is thought to be important 
Figure 1.1 RNAPII CTD phosphorylation 
 
(A) “Average” ChIP profile of CTD phosphorylation in S. cerevisiae. The X-axis shows the 
position along a gene, and the transcription start site (TSS) and polyA site are indicated.  
(B) Table showing a list of the CTD kinases and phosphatases in mammals and S. cerevisiae. 





Table 1 List of CTD antibodies and epitope recognition 
 
Monoclonal antibody Recognition Epitope 
4F8 Unphosphorylated CTD Y1S2P3T4S5P6S7 
8WG16 Unphosphorylated Serine 2 Y1S2P3T4S5P6S7 
1C7 Unphosphorylated Serine 5 Y1S2P3T4S5P6S7 
3D12 Phosphorylated Tyrosine 1 Y1S2P3T4S5P6S7 
Y1S2P3T4S5P6S7 
3E10X Phosphorylated Serine 2 Y1S2P3T4S5P6S7 
Y1S2P3T4S5P6S7 
1G7 Phosphorylated Threonine 4 Y1S2P3T4S5P6S7 
6D7 Phosphorylated Threonine 4 Y1S2P3T4S5P6S7 
3E8X Phosphorylated Serine 5 Y1S2P3T4S5P6S7 
4H8 Phosphorylated Serine 5 Y1S2P3T4S5P6S7 
4E12X Phosphorylated Serine 7  Y1S2P3T4S5P6S7 
Y1S2P3T4S5P6S7 
H5 Phosphorylated Serine 2/5 Y1S2P3T4S5P6S7 
H14 Phosphorylated Serine 5/2 Y1S2P3T4S5P6S7 
Y1S2P3T4S5P6S7 
CMA601 
(Nojima et al., 2015) 
Unphosphorylated CTD 
Phosphorylated Serine 2 




(Nojima et al., 2015) 








(Nojima et al., 2015) 








Residues in bold: phosphorylated. Residues in red: if this residue is phosphorylated, antibody 
recognition is blocked. For the Nojima antibodies, no data on adjacent residues blocking 













for full levels of serine 2 phosphorylation by recruitment of serine 2 kinases (Qiu et 
al., 2009). Serine 5 phosphorylation declines toward the 3’ end of genes, and in yeast 
the phosphatase for serine 5 is Ssu72 (Scp1 in mammals). In contrast, serine 2 is 
phosphorylated by Ctk1 and Bur1 kinases in yeast (Cdk9 and Cdk12 in mammals) and 
is a mark of transcription elongation that is low at promoter regions and increases 
toward the 3’ end of genes (declining after the poly(A) site) where it is important for 
cleavage and recruitment of 3’ end processing factors from yeast to mammals (Skaar 
and Greenleaf, 2002; Ahn et al., 2004; Gu et al., 2013), and recruitment of pre-mRNA 
splicing factors and splicing in mammals (Gu et al., 2013). Fcp1 also dephosphorylates 
serine 2 of the CTD.  
 
Unlike serine 5 and serine 2 phosphorylation, the functions of serine 7, threonine 4 
and tyrosine 1 phosphorylation seem to be species-specific and their roles in gene 
expression less well understood (reviewed in Yurko and Manley, 2017). As with serine 
5 phosphorylation, serine 7 phosphorylation (by Kin28 in yeast, Cdk7 in mammals) is 
highest at promoter regions but, unlike serine 5 phosphorylation, serine 7 remains 
phosphorylated throughout gene bodies, until the 3’ end of the gene. The role of serine 
7 phosphorylation in transcription remains unclear, its mutation to alanine is tolerated 
and only snRNA gene expression is reduced in humans (Egloff et al., 2007). In S. 
pombe, serine 7 phosphorylation is required for capping, however the function of 
serine 7 phosphorylation in S. cerevisiae remains unclear (St. Amour et al., 2012). 
Threonine 4 phosphorylation (kinase unknown in S. cerevisiae, Plk3 in mammals) is 
present at relatively low levels throughout gene bodies, and mutation to valine did not 
significantly affect transcription in yeast (Hsin et al., 2011; Hintermair et al., 2012; 
Rosonina et al., 2014). However, in chicken DT40 cells threonine 4 phosphorylation 
is essential and required for 3’ end processing of non-polyadenylated transcripts (Hsin 
et al., 2011). This function of threonine 4 phosphorylation is not applicable to yeast, 
and mutation of threonine 4 to alanine is not lethal in S. cerevisiae (Schwer and 
Shuman, 2011), however mutation to glutamic acid is lethal in S. cerevisiae and S. 
pombe (Harlen et al., 2016; Kecman et al., 2018). Threonine 4 phosphorylation is 
important for chromatin remodelling in certain growth conditions and causes growth 
defects in these conditions in S. cerevisiae (Rosonina et al., 2014). Most recently, 
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threonine 4 phosphorylation was shown to be important for proper transcription 
termination and post-transcriptional splicing in S. cerevisiae (Stiller et al., 2000; 
Harlen et al., 2016). Tyrosine 1 phosphorylation (by Slt2 in S. cerevisiae (Yurko et 
al., 2017) and c-Abl in mammals (Baskaran et al., 1997)), resembles but is not 
identical to the pattern of serine 2 phosphorylation. Tyrosine 1 phosphorylation 
increases after the transcription start site and remains high throughout the gene body 
until just before the poly(A) site (Mayer et al., 2012). Tyrosine 1 phosphorylation is 
important for proper termination, and its mutation to alanine is lethal in yeast (Schwer 
and Shuman, 2011). In vertebrates, tyrosine 1 phosphorylation is essential and 
important for stability of the CTD (Hsin et al., 2014), in addition to being important 
in regulating antisense transcription (Descostes et al., 2014). In S. cerevisiae, the role 
of tyrosine 1 phosphorylation is less clear. The phosphatase for tyrosine 1 has recently 
been identified as Glc7 in S. cerevisiae and is required for proper transcription 
termination of non-coding RNAs (not applicable to higher eukaryotes) (Schreieck et 
al., 2014) (Figure 1.1B). 
 
General transcription elongation factors associate with RNAPII during transcription 
and facilitate transcription through the chromatin barrier. In yeast, these factors have 
been demonstrated to be recruited to gene bodies and associate with RNAPII from 
promoter regions to cleavage and polyadenylation sites (Mayer et al., 2010). Major 
transcription elongation factors in yeast include Spt4/5 (DSIF in humans), Paf1 and 
the CTD kinases Ctk1 and Bur1 (reviewed in Shilatifard, 2004; Perales and Bentley, 
2009). It is not entirely clear how these elongation factors are recruited to RNAPII 
during transcription, but it is known that Spt5 interacts with the body of the RNAPII 
elongation complex, Bur1 with the CTD, and Paf1 with Spt5 (Liu et al., 2009; Qiu et 
al., 2009; Qiu et al., 2012; Wier et al., 2013; Xu et al., 2017). Recent photoactivatable 
ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) studies 
have shown that each of these proteins interacts with nascent RNA, and it is suggested 
that this facilitates the chromatin association of these factors and assembly of the 




Spt5 is a highly conserved and essential elongation factor from yeast to humans that 
forms a complex with the non-essential zinc finger protein Spt4 (reviewed in Hartzog 
and Fu, 2013). Spt5 is not associated with RNAPII at promoters, but tightly associates 
with RNAPII during transcription elongation until transcription termination and acts 
as a docking site for numerous protein complexes that influence RNAPII processivity, 
RNA processing and histone modifications (reviewed in Hartzog and Fu, 2013). It is 
thought that Spt5 enhances RNAPII processivity by stabilising interaction between the 
clamp of RNAPII and DNA (Hirtreiter et al., 2010; Klein et al., 2011; Martinez-
Rucobo et al., 2011). Depletion of Spt5 in S. pombe caused genome-wide defects in 
transcription elongation (Shetty et al., 2017). In mammals, Spt5 depletion did not 
cause such genome-wide defects in transcription, instead it seems Spt5 is important 
for elongation only on long genes (Fitz et al., 2018). Spt5 has a conserved C-terminal 
region (CTR) that is comparable to the CTD of RNAPII as it is differentially 
phosphorylated during the course of transcription. In S. cerevisiae, the CTR of Spt5 
contains 133 residues consisting of 15 hexapeptide repeats with the consensus 
S[T/A]WGG[Q/A], of which the serine and threonine residues are phosphorylated 
(Zhou et al., 2009). The CTR of Spt5 is important for RNAPII elongation and histone 
modification (Zhou et al., 2009). In S. cerevisiae, the Bur1/2 complex phosphorylates 
the CTR of Spt5 upon recruitment by the serine 5 phosphorylated CTD (Qiu et al., 
2009). As previously discussed, in metazoans, DSIF (Spt4/5 in S. cerevisiae) and 
NELF cause RNAPII to pause in a stable manner downstream of transcription start 
sites during promoter-proximal pausing (reviewed in Adelman and Lis, 2012). In 
mammals and S. cerevisiae the CTR of Spt5 is non-essential, but its deletion confers 
sensitivity to 6-azauracil, suggesting that it promotes RNAPII elongation (Zhou et al., 
2009). 
 
The phosphorylation of the CTR of Spt5 by the Bur1/2 complex is important for Paf 
complex recruitment to elongating RNAPII (Laribee et al., 2005; Liu et al., 2009). The 
Paf complex is associated with RNAPII throughout actively transcribed genes where 
it serves as a ‘platform’ that co-ordinates the association of RNAPII with transcription 
factors and chromatin-modifying enzymes, thereby facilitating transcription 
elongation. The Paf complex on its own does not exhibit enzymatic activity. The Paf1 
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complex is composed of 5 subunits in S. cerevisiae (Paf1, Leo1, Ctr9, Rtf1, Cdc73), 
of which Paf1 and Ctr9 are the most important components for complex integrity (Betz 
et al., 2002). Rtf1, Paf1 and Ctr9 subunits are required for Rad6/Bre1-dependent 
histone H2BK123 mono-ubiquitination, which in turn is required for H3K4 di- and 
trimethylation (Wood et al., 2003; Krogan et al., 2003; Ng et al., 2003a; Xiao et al., 
2005). The Paf1 complex also affects H3K36 trimethylation; deletion of Paf1 complex 
subunits Paf1 and Ctr9 abolishes H3K36 trimethylation in S. cerevisiae (Chu et al., 
2007). The influence of Paf1 on H3K36me3 is likely indirect, since the Paf1 complex 
is required for full levels of serine 2 phosphorylation of the CTD of RNAPII which is 
required for the recruitment of Set2, the methyltransferase responsible for H3K36 
trimethylation, a mark of active transcription (Mueller et al., 2004; Nordick et al., 
2008). The Paf1 complex was shown to be a regulator of promoter-proximal pausing 
in mammalian cells in two quite conflicting studies (Chen et al., 2015; Yu et al., 2015).  
 
1.6 Transcription termination 
 
Eventually, RNAPII transcribes the 3’ untranslated region (3’UTR) of protein coding 
genes which is a sequence that serves as a signal for binding of cleavage and 
polyadenylation factor and cleavage factors. After endonucleolytic cleavage of the 
transcript at the poly(A) site, a poly(A) tail is added by the poly(A) polymerase (Pap1). 
RNAPII continues transcribing after the poly(A) site, and the 5’ ends of downstream 
transcripts produced following cleavage are targeted for 5’-3’ degradation by an 
exonuclease (Rat1 in yeast, Xrn2 in humans) as they do not have a 5’ cap. The precise 
mechanism of RNAPII transcription termination is not fully understood. There are two 
prevailing models to explain termination of RNAPII after transcript cleavage, both are 
applicable from yeast to humans. The allosteric model states that the loss of 
transcription elongation factors and conformational changes in RNAPII after the 
poly(A) site makes it unstable. The torpedo model states that the 5’-3’ exonuclease 
Rat1 catches up with transcribing RNAPII and causes dissociation (reviewed in Porrua 
and Libri, 2015; Porrua et al., 2016). The proper termination of RNAPII is important 




1.7 Pre-mRNA splicing  
 
Pre-mRNA splicing was first discovered in 1977 in two studies that used the DNA 
virus human adenovirus 2 (Ad2) as a model system (Chow et al., 1977; Bergett et al., 
1977). In both studies, mRNA of Ad2 was hybridised to Ad2 genomic DNA, and 
electron microscopy showed regions of DNA that formed loop structures that did not 
hybridise to mRNA. These DNA loops were introns, and this showed that genes were 
‘split’ into exons and introns, and that introns were removed or ‘spliced’ out. This 
discovery explained the previously puzzling finding that nuclear and cytoplasmic 
transcripts were different in size but had the same 5’ and 3’ sequences. It was later 
shown that pre-mRNA splicing is a widespread phenomenon among eukaryotes – from 
yeast to humans - and almost every gene of multi-cellular organisms is spliced.  
 
In higher eukaryotes, pre-mRNA splicing is not only essential for the production of 
one protein from one gene, but for the production of multiple proteins from a single 
gene in a process called alternative pre-mRNA splicing. For example, in humans the 
average number of introns per gene is 10, and at least 95% of transcripts are 
alternatively spliced (Pan et al., 2008). The importance of alternative pre-mRNA 
splicing is highlighted by the diversity and complexity it can generate. For example, 
nematodes and humans have approximately the same number of protein-coding genes 
in their genomes – in the human genome, there are approximately 20,000 protein-
coding genes and in the C. elegans genome there are approximately 19,000 protein-
coding genes (Ezkurdia et al., 2014). In C. elegans, approximately 4% of genes are 
alternatively spliced, and in contrast approximately 95% of human genes are 
alternatively spliced, giving approximately 200,000 expressed proteins resulting in the 
obvious differences in complexity between nematodes and humans (reviewed in 
Hodgkin, 2001; Pan et al., 2008). There are multiple forms of alternative splicing, 
including: exon skipping, intron retention, use of alternative 5’ or 3’ splice sites and 
mutual exclusivity of exons. As introns are generally removed during splicing, they 
may be considered as a waste of energy and relatively unimportant, however it is 
hypothesised that the presence of introns drives the generation of new proteins (by 




Pre-mRNA splicing is also particularly important in disease. The correct regulation of 
splicing is important for the proper functioning of individual cells and whole 
organisms - failures may lead to the production of defective proteins and, 
subsequently, disease or inability to sustain life (reviewed in Wang and Cooper, 2007). 
Indeed, more than one third of single nucleotide polymorphisms that are disease-
causing have the potential to disrupt splicing (Singh and Cooper, 2012). Further, 
approximately 25% of mutations in the beta-globin gene that cause the disease β-
thalassemia in humans result from mutations in splice sites and subsequent defects in 
pre-mRNA splicing (Treisman et al., 1983) 
 
The mechanism of pre-mRNA splicing is conserved from lower eukaryotes such as 
the budding yeast S. cerevisiae to higher eukaryotes such as humans. However, there 
are some key differences between splicing in S. cerevisiae to splicing in other 
eukaryotes, and in general S. cerevisiae exhibits a less complex gene architecture in 
terms of exon and intron densities. In fission yeast, 45% of genes contain an intron, 
many genes have two or more introns, and it is estimated that the transcripts of 2-3% 
of genes are alternatively spliced (Käufer and Potashkin, 2000; Bitton et al., 2015; 
Stepankiw et al., 2015).  In humans, approximately 95% of transcripts are alternatively 
spliced, and a minority of genes are intronless. In contrast, the majority of genes in S. 
cerevisiae are intronless, with 5% (of the 6000 genes total) intron-containing. In S. 
cerevisiae, the majority of splicing is constitutive, with only few known examples of 
genes containing more than one intron and a few cases of alternative splicing (Davis 
et al., 2000; Juneau et al., 2009; Volanakis et al., 2013; Kawashima et al., 2014). Still, 
splicing is an extremely important and essential process in S. cerevisiae, as many of 
the 5% of genes that are spliced are essential, and the spliced transcripts are highly 
expressed (largely ribosomal protein transcripts) and contribute to approximately 27% 
of total mRNA levels (reviewed in Ares et al., 1999). Furthermore, on average intron-
containing genes are expressed approximately 3.9 times more than intronless genes in 
S. cerevisiae (Juneau et al., 2006). These observations that introns stimulate 
transcriptional output is conserved from S. cerevisiae to mammals (Brinster et al., 




The importance of introns in S. cerevisiae and reason for so few introns in comparison 
to other species remains controversial – some propose that introns are relatively new 
to S. cerevisiae, and some propose they are in the process of being lost (reviewed in 
Ares et al., 1999; Bon et al., 2003). Under growth in optimal laboratory growth 
conditions deletion of many S. cerevisiae introns resulted in no substantial growth 
defects, however under conditions of stress, deletion of introns did result in growth 
defects with removal of introns decreasing RNA and protein levels (Juneau et al., 
2006; Parenteau et al., 2008). While deletion of three introns did cause severe growth 
defects, these defects were rescued by expression of the intronless mRNA and were 
not due to loss of splicing (Parenteau et al., 2008). 
 
Though there are key differences between S. cerevisiae and other eukaryotes, the 
fundamental biochemistry of pre-mRNA splicing is conserved from yeast to humans, 
and important advances in our knowledge of pre-mRNA splicing were gained from 
experiments using S. cerevisiae. For example, core components of the spliceosome 
(pre-mRNA processing (Prp) proteins) were first identified in temperature-sensitive 
mutant screens for defects in total RNA synthesis and extracts from these temperature-
sensitive mutants were used to determine basic mechanisms of splicing catalysis 
(Lustig et al., 1986; Vijayraghavan et al., 1989; reviewed in Hossain and Johnson, 
2014).  
 
1.8 Pre-mRNA splicing is a two-step process catalysed by the spliceosome 
 
Pre-mRNA splicing is dependent on a combination of trans-acting factors and short 
conserved sequences within introns. In total, the intron sequence is not conserved, 
however there are conserved sequences that define an intron, including: the 5’ splice 
site (5’SS), the 3’ splice site (3’SS) and the branch point (BP). In yeast, the consensus 
sequence of the 5’SS is GUAUGU, the consensus sequence of the BP is UACUAAC 
and the consensus sequence of the 3’SS is YAG. In contrast, splice sites of more 
complex organisms like humans are less well conserved, but have the consensus GU 
at the 5’SS and AG at the 3’SS. The BP of mammalian introns is less well conserved 
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(apart from the underlined adenosine), and mammalian introns contain a uridine and 
cytosine rich polypyrimidine tract (10 to 15 nucleotides in length) between the BP and 
3’SS sequences that is thought to compensate for lack of conservation of the 
branchpoint sequence, and is particularly important when the BP is a long distance 
from the 3’SS (Reed, 1989). S. cerevisiae introns do not contain a polypyrimidine tract, 
however some introns have a uridine-rich poly-U tract upstream of the 3’SS, which 
enhances splice site usage and may be important for longer introns that require 
additional splicing factors to bring splice site together (Patterson and Guthrie, 1991; 
Spingola et al., 1999; Ma and Xia, 2011). Conserved across eukaryotes, the 5’SS GU, 
3’SS AG and the underlined adenosine of the BP are essential for splicing catalysis as 
mutation of these residues reduces splicing efficiency or completely abolishes splicing 
(Langford et al., 1984; Chanfreau and Jacquier, 1993; Chanfreau et al., 1994). An 
exception to these conserved residues are the U12-type introns which are flanked by 
AT at the 5’SS and AC at the 3’SS. U12-type introns are not common and have a 
specialised minor U12 dependent spliceosome (Tarn and Steitz, 1996; Hall and 
Padgett, 1996; Burge et al., 1998). Consensus splice sites are important for the 
biochemical splicing reaction and the recruitment of splicing factors – the spliceosome 
must recognise these three sequences of the pre-mRNA, and therefore it is not 
surprising that they are conserved sequences. Pre-mRNA splicing occurs by two 
sequential transesterification reactions that remove the intron and join the exons 
(Figure 1.2A). In the first transesterification step of splicing (‘branching’), the 2’OH 
of the branchpoint adenosine carries out a nucleophilic attack on the phosphate group 
of the guanosine of the 5’SS, which cuts the RNA at the 5’SS. The cut 5’ end of the 
intron then forms a 2’-5’ bond with the branchpoint adenosine, generating the intron-
lariat intermediate. In the second transesterification step of splicing (‘exon ligation’), 
the 3’OH from the 5’ exon attacks the 3’SS, resulting in the ligation of the 5’ and 3’ 
exons forming a spliced transcript and release of the intron-lariat. The splicing 
reactions are catalysed by RNA and in vitro require metal ions (Mg2+), in addition to 
ATP (although the afore-mentioned transesterification reactions are not dependent on 
ATP hydrolysis) (Hardy et al., 1984; Hernandez and Keller, 1983; Fica et al., 2013). 
Two Mg2+ ions present in the active site of the spliceosome mediate the two 
transesterification reactions and splicing catalysis by RNA (Fica et al., 2013). 
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The two pre-mRNA splicing reactions are biochemically relatively simple, but are 
catalysed by a large (multi-megadalton) and highly dynamic RNA and protein  
 
Figure 1.2. Pre-mRNA splicing cycle 
(A) Splicing is a two-step transesterification reaction. In the first step, the 5’ss undergoes 
cleavage via a nucleophilic attack from the 2’OH group of the branchpoint (BP) adenine. The 
5’ splice site (SS) ligates to the BP, forming the lariat intermediate. In the second step, the 
3’OH from the 5’ exon attacks the 3’SS, resulting in the ligation of the 5’ and 3’ exons forming 
a mature RNA transcript (mRNA), and the release of the intron. 
(B) The spliceosome cycle. The 5 snRNPs that constitute the spliceosome are thought to 
assemble on the pre-mRNA transcript in a step-wise manner. First, the U1 snRNP binds to 
the 5’SS (forming the E complex), followed by the U2 snRNP which binds to the BP (forming 
the A complex). The U4/U6•U5 tri-snRNP then joins forming the pre-catalytically active 
spliceosome (B complex). The spliceosome undergoes substantial re-arrangements between 
RNA and protein interactions to produce the active spliceosome (B* complex) that catalyses 
both steps of splicing to generate a mature RNA transcript. In addition to snRNP particles, 
numerous ATP-dependent DExH/D-box RNA ATPases/helicases are crucial for the fidelity of 
splicing and are vital in the dynamic RNA-protein rearrangements that occur in spliceosome 
assembly and splicing. Figure adapted from Will and Lührmann, 2011 
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(ribonucleoprotein) complex called the spliceosome. The spliceosome is composed of 
five small, nuclear RNAs (snRNAs), U1, U2, U4, U5 and U6 that specify where 
splicing occurs and perform catalysis. snRNAs are short RNAs that complex with at 
least seven other proteins to form small nuclear ribonucleoprotein particles (snRNPs) 
(U1, U2, U4, U5 and U6). Though the splicing reaction is RNA catalysed, there are 
numerous proteins that comprise the spliceosome, and these trans-acting factors help 
to position the pre-mRNA for correct splicing (reviewed in Will and Lührmann, 2011). 
In the spliceosome, there are approximately 90 distinct core proteins conserved from 
yeast to humans, although the human spliceosome has approximately twice as many 
distinct proteins due to the complexity of alternative splicing (Fabrizio et al., 2009). 
While the two-step splicing reaction is not ATP-dependent, the substantial structural 
rearrangements that occur are ATP-dependent. There are eight ATP-dependent 
DExD/H-box RNA helicases evolutionarily conserved in eukaryotes that are required 
for pre-mRNA splicing – either for structural rearrangements or spliceosome 
dissociation. 
In vitro and in vivo evidence has shown that the five snRNPs assemble de novo in a 
step-wise manner on the pre-mRNA substrate to form the spliceosome, and that the 
spliceosome depends on the 5’SS, BP and 3’SS sequences for assembly (Figure 1.2B). 
Firstly, the U1 snRNP base pairs via the U1 snRNA to the 5’SS, and Mud2 and Msl5 
(branch point binding protein) bind to the BP sequence and form a bridge with the U1 
snRNP at the 5’SS. The interaction with the U1 snRNP and the 5’SS is necessary for 
subsequent stages of spliceosome assembly. Together, these proteins form the 
commitment complex, or E complex, as it commits the pre-mRNA to splicing. The U2 
snRNP then binds to the BP sequence, and together, the U1 and the U2 define the 
intron and form the pre-spliceosome or A complex. The binding of the U2 snRNP to 
the BP sequence causes the BP adenosine to bulge out, making the 2’OH available for 
nucleophilic attack on the 5’SS during the first catalytic step of splicing. The pre-
assembled 1.5 MDa tri-snRNP (U4, U5 and U6), comprised of over 30 proteins 
(Gottschalk et al., 1999), then joins the A complex to form the pre-catalytically 
activated spliceosome or B complex, which is the only stage of spliceosome assembly 
that contains all five snRNPs assembled on the pre-mRNA substrate. The U4 and U6 
snRNAs within the tri-snRNP are complementary base paired to each another, and 
 
 38 
during substantial structural re-arrangements, these base pairs are disrupted by the 
ATP-dependent RNA helicase activity of Brr2. The base pairs between the U1 snRNA 
and the 5’SS are also disrupted by the ATP-dependent RNA helicase Prp28, and in 
this way the U1 and U4 snRNPs leave the splicing process and the U6 snRNA base 
pairs with the 5’SS of the intron and the U2 snRNA. The U2:U6 duplex forms the 
catalytically active centre the spliceosome (Madhani et al., 1992; Fica et al., 2013).  
After dissociation of the U4 snRNP, the non-snRNP nineteen complex (NTC) then 
associates, forming the catalytically activated spliceosome (Bact complex). The NTC 
comprises up to 16 proteins and promotes snRNA/pre-mRNA interactions important 
for the catalytic core of the spliceosome by stabilising the interaction of U5 and U6 
snRNAs with the pre-mRNA substrate before the first step of splicing (Chan et al., 
2003; Chan and Cheng, 2005). Recent cryo-electron microscopy (Cryo-EM) studies 
in S. pombe have shown that the NTC extends throughout the spliceosome (Yan et al., 
2015).  
The Bact complex is not sufficiently mature to catalyse the first step of splicing– the 
spliceosome is activated in an ATP-dependent manner by the RNA helicase Prp2, 
which releases components of the U2 snRNP SF3A and SF3B, which generates the B* 
complex that can catalyse the first step of splicing – branching (Warkocki et al., 2009; 
Lardelli et al., 2010). The release of these components of the U2 snRNP is thought to 
uncover the branch point adenosine to enable the first catalytic step of splicing. Before 
the first step of splicing, core U5 snRNP protein Prp8, which is dubbed the ‘heart’ of 
the spliceosome as it is the largest and most conserved protein present, interacts with 
the 5’SS and helps to position it for the first step of splicing (reviewed in Grainger and 
Beggs, 2005). Prp8 was shown by Cryo-EM to interact with the U2, U4, U6 snRNAs 
and the intron to form a cavity that generates the catalytic centre of the spliceosome 
(Yan et al., 2015).  
The first step of splicing generates the C-complex, which again undergoes substantial 
ATP-dependent structural rearrangements in which first step splicing factors leave and 
the activated C* complex is formed (Tseng et al., 2011). Prp16, recruited by 
interaction with Brr2, is an ATP-dependent RNA helicase that facilitates the release 
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of factors required for the first step of splicing (Yju2 and Cwc25), which is thought to 
allow binding of second step factors Slu7 and Prp18 (van Nues and Beggs, 2001; 
Tseng et al., 2011). These second step factors and Prp8 help to place the 3’SS in the 
catalytic core of the spliceosome and mediate the second step of splicing by aligning 
and stabilising the exons in close-proximity to one another in the catalytic centre of 
the spliceosome via interaction of loop 1 of the U5 snRNA with the exons – this 
ultimately places the 3’SS in close-proximity to the 5’SS (Newman  and Norman, 
1992; Schwer and Guthrie, 1992; Teigelkamp et al., 1995; Crotti et al., 2007). The 
second step of splicing involves ligation of the exons and release of the intron-lariat.  
After splicing catalysis is complete, the spliced mRNA is released by the action of the 
conserved ATP-dependent RNA helicase Prp22. The 3’ to 5’ RNA helicase activity of 
Prp22 disrupts the interactions between the U5 snRNA (and U5 snRNP (Prp8)) and 
the spliced RNA, thereby releasing the spliced exons from the post-spliceosome 
complex (Company et al., 1991; Wagner et al., 1998; Aronova et al., 2007; Fica et al., 
2017). Cross-linking studies found Prp22 binds 13-33 nucleotides downstream of the 
3’SS (Schwer, 2008). In recent structural Cryo-EM studies, Prp22 was found in the C* 
complex interacting with Prp8 which is at the core of the spliceosome (Fica et al., 
2017). Prp22 has also been shown to have an ATP-independent role in the second step 
of pre-mRNA splicing (acting after Prp16) (Schwer and Cross, 1998), and is thought 
to facilitate 3’SS selection and perform an ATP-dependent proof-reading function 
before the second step – discarding suboptimal substrates (Mayas et al., 2006).   
The ATP-dependent RNA helicase Prp43 (with Ntr1 and Ntr2) acts at the latest stage 
of the splicing cycle and is required to release the excised intron-lariat from the post-
spliceosome complex, thereby disassembling the post-spliceosome (Martin et al., 
2002; Tsai et al., 2005). In addition to disassembly of the post-spliceosome complex, 
Prp43 is required for release of stalled spliceosomes from earlier stages of the splicing 
cycle, and for pre-rRNA processing (Pandit et al., 2006; Leeds et al., 2006; Mayas et 
al., 2010). The snRNPs can then be recycled for future rounds of splicing, and the 
intron-lariat de-branched by the lariat debranching enzyme Dbr1 and degraded in the 
cytoplasm by exonucleases Xrn1 (5’-3’) and Ski2 (3’-5’) (reviewed in Hesselberth, 
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2013). The disassembly of the spliceosome is necessary for the efficiency of future 
rounds of splicing, so that spliceosomes do not become limiting.  
It has been shown in vitro that pre-mRNA splicing is reversible. Using a mutant of 
Prp22 that failed to release the mRNA after splicing catalysis, post-catalytic 
spliceosomes were purified and under certain conditions pre-mRNA was the abundant 
species associated (not mRNA which is normally associated with post-catalytic 
spliceosomes). This means that both steps of splicing can be reversed in vitro (Tseng 
and Cheng, 2008). Reversibility of splicing catalysis has not been demonstrated in 
vivo, however the ordered assembly of spliceosomes was shown to be reversible by 
incorporating fluorescent markers in pre-mRNA and core components of the 
spliceosome and performing colocalization single-molecule spectroscopy and 
measuring association and dissociation kinetics (Hoskins et al., 2011).  
An extremely important aspect of pre-mRNA splicing is the fidelity – as discussed 
earlier, errors in splicing can be detrimental to cells and so it is vital that errors are 
supressed. Despite the complexity and dynamics of splicing in human cells, splicing 
is an inherently high-fidelity reaction, with an approximate error rate as low as 1 in 
every 100,000 splicing events (Fox-Walsh and Hertel, 2009). The high fidelity of 
splicing comes from the action of ATP-dependent RNA helicases that are not only key 
to mediating structural rearrangements in the spliceosome but also splicing fidelity. 
These ATPases act to supress sub-optimal splicing events, as well as promoting 
optimal splicing events (reviewed in Semlow and Staley, 2012). ATPases implicated 
in splicing fidelity include Prp5, Prp28, Prp16, Prp22 and Prp43, and they are 
collectively thought to proof-read both the first and second steps of splicing catalysis; 
rejecting suboptimal substrates via their RNA unwinding activity (Burgess and 
Guthrie, 1993; Mayas et al., 2006; Xu et al., 2007). As the spliceosome assembles in 
a step-wise manner on pre-mRNA substrates, the ATPase activity of Prp5, Prp28, 
Prp16, Prp22 and Prp43 can reject sub-optimal splicing events throughout the splicing 
cycle and prevent later stages of splicing. Prp5 acts before the first step of splicing, 
and Prp5 mutants with no ATPase activity are able to suppress effects of BP mutations 
in vivo, and it is suggested that Prp5 proof-reads the BP sequence by competing with 
the interaction of the U2 snRNA and BP, disrupting these interactions if suboptimal 
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(Xu and Query, 2007). Prp28 also acts before the first step of splicing, and it was 
shown that mutants of Prp28 enhance splicing of transcripts with suboptimal 5’SS, 
meaning Prp28 normally functions to reject transcripts with a suboptimal 5’SS (Yang 
et al., 2013). ATPase mutants of Prp16 were shown to allow splicing of transcripts 
with mutant BP sequences in vitro, meaning that normally Prp16 regulates BP usage 
(Burgess and Guthrie, 1993). Further, Prp16 was shown in vivo to suppress cleavage 
of the 5’SS of sub-optimal substrates at the first step of pre-mRNA splicing catalysis 
in vitro, and pre-mRNAs, lariat intermediates and spliceosomes were disassembled by 
Prp43 and eventually discarded (Mayas et al., 2010). In the absence of the ATPase 
activity of Prp22, it was shown in vitro that mutant 3’ splice sites were used more 
frequently, indicating Prp22 suppresses the use of aberrant splice sites prior to exon 
ligation (Mayas et al., 2006). It was proposed that these ATPases act to proof-read 
splicing catalysis by pulling the pre-mRNA within the spliceosome from a distance, 
as truncating the 3’ exon downstream of the BP and 3’SS prevented the activity of 
Prp16 and Prp22 (Semlow et al., 2016). Recent cryo-EM structures support this, 
finding Prp22 and Prp16 at the periphery of the C* complex in humans and in yeast 
(Bertram et al., 2017; Fica et al., 2017).  
There are two non-mutually exclusive kinetic models to explain the action of ATPases 
in splicing fidelity, the timer and sensor models (reviewed in Semlow and Staley, 
2012). In the timer model, there is a finite amount of time for substrates to be rejected. 
ATPases compete with the speed of splicing catalysis – if splicing catalysis occurs 
faster than the ATP hydrolysis activity, the transcript will be spliced at the expense of 
proof-reading and vice-versa. In the sensor model, sub-optimal substrates are rejected 
at a faster rate compared to optimal substrates. This could be explained by differences 
in the stability of the interaction between the spliceosome and pre-mRNA substrate, 
or by regulation of the ATPase activity of the helicase.    
Proteomics studies show that many spliceosomal proteins are post-translationally 
modified, including phosphorylation, ubiquitination, acetylation and glycosylation. 
Post-translational modification of splicing factors provide an obvious way to regulate 
key aspects of the splicing cycle including: structural rearrangements via protein-
protein interactions and protein-RNA interactions, the timings of these 
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rearrangements, splicing fidelity and splicing factor activities (reviewed in Mckay and 
Johnson, 2010). The mammalian spliceosome is extensively phosphorylated and to 
highlight its importance, phosphorylation of proteins in the tri-snRNP is vital for tri-
snRNP formation and B complex formation (Matthew et al., 2008).  Compared with 
the human spliceosome, the spliceosome of S. cerevisiae is less extensively modified, 
owing to the different complexities of alternative splicing in comparison to constitutive 
splicing.  
1.9 Links between splicing and transcription 
Upon discovery of pre-mRNA splicing, it was surmised that “The three short segments 
forming the 5’ tail of hexon mRNA are probably spliced to the body of this mRNA 
during post-transcriptional processing” (Berget et al., 1977). The suggestion that pre-
mRNA splicing occurs post-transcriptionally was supported by the finding that pre-
mRNA splicing could occur in vitro in splicing extracts and required an RNA 
substrate, ATP and Mg2+ (Hernandez and Keller, 1983; Padgett et al., 1983; Hardy et 
al., 1984). Though post-transcriptional splicing can occur, there is increasing evidence 
from yeast to humans that splicing occurs mainly co-transcriptionally, that is as 
RNAPII is still transcribing along the gene, before transcription termination (Figure 
1.3) (Görnemann et al., 2005; Kotovic et al., 2003; Lacadie and Rosbash, 2005; 
Listerman et al., 2006; Carillo Oesterreich et al., 2010, 2016; Ameur et al., 2011; 












Figure 1.3. Splicing occurs mainly co-transcriptionally 
 
During co-transcriptional splicing, the spliceosome assembles on the nascent pre-mRNA 
substrate. In this way, splicing, transcription and chromatin are in close-proximity and 
influence each other. 
 















Co-transcriptional splicing was first observed in 1981 in electron microscopy 
experiments – where lariats formed on nascent pre-mRNA transcripts associated with 
RNAPII were visualised (Beyer et al., 1981). Later, co-transcriptional spliceosome 
assembly was visualised by EM - where spliceosomes were found associated with 
splice junctions of nascent pre-mRNA transcripts in Drosophila embryos (Osheim et 
al., 1985). Co-transcriptional spliceosome assembly in budding yeast and metazoans 
was elegantly demonstrated by chromatin immunoprecipitation (ChIP) experiments, 
which took advantage of the close proximity of the spliceosome to chromatin during 
co-transcriptional splicing to show the step-wise assembly of the spliceosome in vivo, 
which validated the ground-breaking in vitro studies that found step-wise spliceosome 
assembly (Kotovic et al., 2003; Görnemann et al., 2005; Lacadie et al., 2010; 
Listerman et al., 2006).  
 
The extent of co-transcriptional splicing was first shown in S. cerevisiae by purifying 
chromatin-associated nascent RNA and using high-density tiling microarrays to 
analyse the amount of splicing that occurred before transcription was complete (Carillo 
Oesterreich et al., 2010). This indicated that more than 80% of pre-mRNA was spliced 
before transcription termination and that it was suggested that RNAPII pauses in 
terminal exons to allow sufficient time for co-transcriptional splicing to occur 
(splicing-dependent RNAPII pausing is discussed below). Furthermore, it was shown 
using a different approach in S. cerevisiae that the transcripts of a yeast reporter gene 
are co-transcriptionally spliced (Alexander et al., 2010a). Similar co-transcriptional 
splicing frequencies have since been demonstrated in higher eukaryotes (Ameur et al., 
2011; Khodor et al., 2011; Tilgner et al., 2012; Brugiolo et al., 2013). The first step of 
splicing requires the 5’SS and BP but does not require the 3’SS. Therefore, in theory, 
the first step of co-transcriptional splicing could occur when the BP but not 3’SS is 
available upon transcription by RNAPII (Rymond and Rosbash, 1985; Liu and Cheng, 
2012). Most recently single-molecule intron tracking (SMIT) experiments in S. 
cerevisiae have shown that splicing occurs in close-proximity to the exit channel of 
RNAPII, and it was concluded that co-transcriptional splicing catalysis occurs, on 
average, 26–129 nucleotides downstream of 3’SS (Carillo Oesterreich et al., 2016). 
This study suggests that as soon as the substrates are transcribed by RNAPII and 
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available to be bound by the spliceosome, splicing catalysis can occur, and therefore 
co-transcriptional splicing is an extremely well-timed and efficient process. 
Interestingly, high-throughput techniques have shown that not all transcripts that are 
spliced co-transcriptionally are spliced at the same rate – in S. cerevisiae, ribosomal 
protein transcripts are transcribed faster, more co-transcriptionally and with more 
fidelity than non-ribosomal protein genes. Additionally, it appears some transcripts are 
spliced post-transcriptionally. What governs these observations is still unknown but 
could be explained by a number of different factors, including: promoter elements, 
intron length, splice site strength, RNA secondary structure and transcription rate 
(Aslanzadeh et al., 2018; Wallace and Beggs, 2017).  
 
By definition, co-transcriptional splicing and transcription are connected in time and 
space, and this raises the possibility that these processes are functionally coupled such 
that they influence one another. There are two non-mutually-exclusive possibilities as 
to how transcription and splicing are functionally coupled (i) by speed of RNAPII 
(termed the ‘kinetic’ model) and/or (ii) by interactions between RNAPII and/or 
transcription elongation machinery and splicing machinery (termed the ‘recruitment’ 
model) (reviewed in Perales and Bentley, 2009; Bentley, 2014). Together, the speed 
of RNAPII and its co-transcriptional recruitment of splicing factors are important in 
regulating co-transcriptional splicing. 
 
The ‘kinetic model’ states that the rate of RNAPII transcription elongation affects 
splicing outcome by modulating the availability of splice sites and co-transcriptional 
spliceosome assembly (Buratowski, 2003; Bentley, 2005). There is a ‘window of 
opportunity’ for splice site recognition before the appearance of competing 
downstream splice sites, and a ‘fast’ elongation rate results in less time for splice site 
recognition compared to a ‘slow’ elongation rate. There are now multiple bodies of 
evidence that elongation rate of RNAPII affects splicing outcome, in particular the 
pattern of alternative splicing in both yeast and mammalian cells (de la Mata et al., 
2003; Howe et al., 2003; Dujardin et al., 2014; Fong et al., 2014). The importance of 
optimal co-transcriptional spliceosome assembly for splicing outcome was highlighted 
by the use of fast and slow RNAPII speed mutants – in either mutant splicing fidelity 
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is greatly reduced and the fast mutant indicates that post-transcriptional splicing cannot 
compensate for lack of co-transcriptional splicing as co-transcriptional splicing and 
overall efficiency are greatly reduced (Braberg et al., 2013; Aslandazeh et al., 2017).  
 
The ‘recruitment model’ states that physical interactions between RNAPII and/or 
factors associated with RNAPII facilitate co-transcriptional spliceosome assembly and 
splicing. Most evidence for the recruitment model surrounds the CTD of RNAPII, 
which is thought to function as a ‘landing pad’ with a ‘code’ that sequentially recruits 
RNA-processing factors during the transcription cycle (reviewed in Buratowski, 2003; 
Bentley, 2005). There are several links between the CTD of RNAPII and splicing. 
Immunoprecipitation experiments have demonstrated that the CTD of RNAPII 
interacts with splicing factors (Mortillaro et al., 1996; Yuryev et al., 1996; David et 
al., 2011). Genetic experiments in which the CTD was truncated or mutated at residues 
subject to phosphorylation resulted in reduced splicing efficiency in vitro and in vivo 
(McCracken et al., 1997; Hirose et al., 1999; Fong and Bentley, 2001). Furthermore, 
in vitro transcription experiments showed that the CTD stimulates pre-mRNA splicing 
in comparison to T7 RNA polymerase with no CTD (Hirose et al., 1999; Ghosh et al., 
2000; Das et al., 2006). As the CTD is close to the exit-channel of RNAPII, it is 
proposed that this facilitates the transfer of RNA processing factors to their pre-mRNA 
substrates (reviewed in Neugebauer 2002; Merkhofer et al., 2014).  
 
A CTD mutant, where serine 5 is mutated to alanine, results in intron retention in S. 
cerevisiae (Harlen et al., 2016). In mammalian cells, serine 2 phosphorylation of the 
CTD is required for recruitment of the U2 snRNP (shown by fluorescence in situ 
hybridization (FISH)) and proper pre-mRNA splicing (Gu et al., 2013). Additionally, 
inhibition of splicing using splicing inhibitor drugs and antisense oligonucleotides 
against snRNAs was shown to reduce the levels of serine 2 phosphorylation of the 
CTD in human cells (Koga et al., 2015), indicating a reciprocal relationship. 
 
Serine 2 and serine 5 phosphorylation of the CTD of RNAPII are also linked to 
splicing-dependent RNAPII pausing, whereby RNAPII pauses near splice sites. Using 
an inducible reporter gene, it was shown in S. cerevisiae that RNAPII accumulates 
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periodically (the pause comes and goes – representing waves of transcription) in the 
vicinity of the 3’SS, at which point the CTD of RNAPII becomes transiently 
hyperphosphorylated at serine 5 (a mark not normally found in gene bodies and a 
hallmark of paused RNAPII) followed by hyperphosphorylation at serine 2 (a mark of 
productive transcription elongation). Through genetic suppression of a splicing 
mutation, this pausing was demonstrated to be splicing-dependent (Alexander et al., 
2010b). Further, if pre-spliceosome formation is blocked, RNAPII 
hyperphosphorylated at serine 5 of the CTD accumulates over introns (Chathoth et al., 
2014). It was proposed that this represents a splicing-dependent transcriptional 
checkpoint that is dependent on pre-spliceosome formation, where a signal causes 
RNAPII to pause to allow sufficient time for spliceosome assembly and quality control 
to occur, thereby enhancing both splicing efficiency and fidelity. 
 
ChIP-sequencing showed that RNAPII was enriched in exons over introns in human 
cells, and so did PRO-SEQ in Drosophila (Brodsky et al., 2005; Schwartz et al., 2009; 
Kwak et al., 2013). NET-SEQ has revealed genome-wide RNAPII pausing near splice 
sites in both mammalian cells and S. cerevisiae, providing strong evidence that 
RNAPII pausing near splice sites is highly conserved from lower to higher eukaryotes 
(Mayer et al., 2015; Nojima et al., 2015; Harlen et al., 2016). Using mammalian NET-
SEQ, it was shown that RNAPII has higher density over the 5’ and 3’ ends of 
constitutive exons, indicating RNAPII pausing at these boundaries, and that on exons 
that are skipped RNAPII is lower in occupancy compared to exons retained in 
alternative splicing (Mayer et al., 2015). Nojima et al., (2015) found by mammalian 
NET-SEQ, using antibodies that detect serine 5 phosphorylation of the CTD, that 
RNAPII was associated with splicing intermediates and enriched over spliced exons. 
Importantly, this enrichment was demonstrated to be splicing-dependent by use of 
splicing inhibitor drugs. In S. cerevisiae, Harlen et al., (2016) also showed by NET-
SEQ that RNAPII pauses over intron-exon junctions. Harlen et al., (2016) also 
demonstrated using ChIP-nexus (He et al., 2015) that serine 5 phosphorylated RNAPII 
peaks downstream of the 3’SS and is associated with recruitment of the U1 snRNP, 
and by mass spectrometry that the splicing factors (U1 – NTC) are associated with 
serine 5 phosphorylated RNAPII. In mCRAC, tagged RNAPII is cross-linked in vivo 
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to its associated RNAs, followed by a second purification step using antibodies against 
different phosphorylated states of the CTD of RNAPII. Associated RNAs are then 
isolated, fragmented and sequenced (Milligan et al., 2016). Using mCRAC, Milligan 
et al., (2016) showed differences in CTD phosphorylation state between intronless and 
intron-containing genes, and that these were associated with splice sites. Overall, these 
studies demonstrate genome-wide causative and correlative links between different 
phosphorylated states of the CTD, RNAPII transcription and splicing. Many of these 
observations may be explained by higher nucleosome densities in exons compared to 
introns, and different histone modifications (as previously discussed).  
 
Recently, it was shown in S. cerevisiae that ubiquitination of a particular lysine residue 
in the catalytic subunit of RNAPII is linked to splicing-dependent RNAPII pausing 
and co-transcriptional splicing (Milligan et al., 2017). Deletion of Bre5, which is part 
of a complex that de-ubiquitinates the RNAPII, led to RNAPII elongation defects and 
reduced splicing efficiency on a reporter gene. Mutation of the ubiquitinated residue 
of RNAPII to a ubiquitin-resistant residue led to defects in co-transcriptional pre-
mRNA splicing genome-wide. A model was proposed whereby RNAPII is 
ubiquitinated in response to splicing in which RNAPII pauses, splicing occurs, and 
then de-ubiquitination occurs and RNAPII is released to continue elongation (Milligan 
et al., 2017).  
 
In addition to RNAPII and its CTD affecting co-transcriptional spliceosome assembly 
and co-transcriptional splicing, it is possible that core members of the transcription 
elongation machinery play an important role in co-transcriptional splicing, and indeed 
there are some links between the transcription elongation machinery and splicing that 
are discussed in detail in Chapter 3.  
 
1.10 Links between splicing and chromatin 
 
By definition, splicing that occurs co-transcriptionally occurs not only in close-
proximity to the transcription machinery but also to the chromatin template beneath 
(Figure 1.3). There is mounting causative and correlative evidence that chromatin can 
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influence splicing and vice-versa from S. cerevisiae to mammals. It is thought that 
chromatin can affect splicing in two non-mutually exclusive ways (i) by modulating 
the elongation rate of RNAPII (splicing is extremely sensitive to transcription speed, 
and nucleosomes act as a barrier to RNAPII transcription) and (ii) by interacting with 
splicing factors, providing a platform for their co-transcriptional recruitment 
(reviewed in Haque and Oberdoerffer, 2014; reviewed in Fiszbein et al., 2017). 
 
Most evidence suggests that nucleosome occupancy and histone modification can 
influence splicing outcome. There is correlative evidence that nucleosome positioning 
and histone modifications are differentially enriched on exons compared with introns. 
Genome-wide studies from worms to humans found that nucleosome occupancy is 
significantly higher and more ordered in exons compared to introns, and in 
constitutively spliced exons compared to alternatively spliced exons (Schwartz et al., 
2009; Spies et al., 2009; Amit et al., 2012; Tilgner et al., 2012). It was also found that 
nucleosome occupancy inversely correlates with the strength of the splice site, so that 
exons flanked by weak splice sites are enriched in nucleosomes in worms and humans 
(Tilgner et al., 2009, Spies et al., 2009). In addition, genome-wide mapping has found 
histone modifications enriched in exons relative to introns from worms to humans, 
including H3K36me3, H3K4me3 and H2BK123ub, even when considering 
differential nucleosome density in exons and introns (Andersson et al., 2009; 
Kolasinska-Zwierz et al., 2009; Schwartz et al., 2009; Spies et al., 2009; Dhami et al., 
2010; Huff et al., 2010; Shieh et al., 2011).  In the case of H3K36me3, this mark is 
enriched in constitutively spliced exons compared to alternatively spliced exons 
(Andersson et al., 2009; Kolasinska-Zwierz et al., 2009), and this mark is lower on 
intronless genes compared to intron-containing genes (Kim et al., 2011). Together, 
nucleosome positioning and chromatin modifications present within exons can present 
a barrier to RNAPII that slows RNAPII and consequently this is supposed to affect 
pre-mRNA splicing by modulating splice site availability and/or by modulating co-
transcriptional recruitment of splicing factors (Haque and Oberdoerffer, 2014).  
Evidence for this includes the fact that RNAPII was shown to accumulate over spliced 
exons and its elongation rate was shown to slow over exons (Brodsky et al., 2005; 
Chodavarapu et al., 2010; Wilhelm et al., 2011; Kwak et al., 2013; Veloso et al., 2014; 
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Mayer et al., 2015). Given the average length of an exon in mammals (145 bp) is 
similar to the amount of DNA win a nucleosome, it was suggested that this facilitates 
exon definition (Schwartz et al., 2009; Tilgner et al., 2009; Carrillo Oesterreich et al., 
2011).  
 
Though these genome-wide studies suggest links between splicing and chromatin, they 
are correlative. The first causative evidence that chromatin affects splicing came from 
the finding that treatment of mammalian cells with histone deacetylase inhibitor, 
trichostatin A, resulted in inhibition of fibronectin EDI exon inclusion (Nogués et al., 
2002). It was later shown that the same inhibition of histone deacetylase activity causes 
exon skipping of the neural cell adhesion molecule (Schor et al., 2009).  Further 
evidence that suggested chromatin affects splicing came from a study in mammalian 
cells that used a series of alternatively spliced reporter genes that were identical in 
gene sequence but differed in the response of their promoters to different steroid 
hormones (some were responsive, some were not). This study found that patterns of 
alternative splicing were altered in the reporter genes with steroid-responsive 
promoters, and not with the non-responsive promoters. Importantly, RNAPII 
occupancy was unaffected, indicating that the changes observed in alternative splicing 
were due to differences in factors recruited to promoters (chromatin modifiers) 
(Aubroeuf et al., 2002). In S. cerevisiae, the histone acetyltransferase of the SAGA 
complex, Gcn5, was shown to genetically interact with components of the U2 snRNP 
(Msl1 and Lea1) and specifically affect their co-transcriptional recruitment to genes 
and pre-mRNA splicing (Gunderson and Johnson, 2009). The same group later showed 
that mutation of the histone H3 residues modified by Gcn5 results in pre-mRNA 
accumulation, and deletion of histone deacetylases results in changes in co-
transcriptional spliceosome assembly and splicing defects, meaning that the level of 
histone acetylation is important for splicing outcome (Gunderson et al., 2011). In S. 
cerevisiae, deletion of Set2, which methylates H3K36, reduced co-transcriptional 
recruitment of the U2 and U5 snRNPs, and caused pre-mRNA splicing defects 
(Sorenson et al., 2016). These effects on co-transcriptional spliceosome assembly and 
splicing were independent of RNAPII occupancy, suggesting that chromatin structure 
can facilitate recruitment of splicing factors co-transcriptionally. 
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There is mounting evidence that splicing factors interact with chromatin modifiers and 
thereby affect splicing outcome, in addition to evidence that the presence of chromatin 
modifiers can affect splicing outcome. For example, SWI/SNF chromatin remodellers 
were also shown to interact with the U2 and U5 snRNPs and affect alternative splicing 
in Drosophila and humans (Batsché et al., 2006; Tyagi et al., 2009). In mammalian 
cells, regulators of alternative splicing PTB and hnRNP proteins associate with histone 
H3 lysine 9 trimethylation (H3K9me3) (Vermeulen et al., 2010). H3K36me3 was also 
shown to recruit PTB and affect alternative splicing via MRG15 which binds to 
H3K36me3 in mammalian cells (Luco et al., 2010). In mammalian cells, H3K4me3 
was also found interact with the U2 snRNP and to be important for pre-mRNA splicing 
outcome (Sims et al., 2007; Luco et al., 2010; Vermeulen et al., 2010) and the links 
between H3K4me3 and splicing are discussed in detail in Chapter 4. Further, it was 
shown that deletion of Bre1, the factor responsible for histone H2B 
monoubiquitination resulted in reduced pre-mRNA splicing efficiency of a subset of 
genes (~20) in S. cerevisiae (Moehle et al., 2012). Furthermore, histone variant H2A.Z 
was shown have genetic interactions with the U2 snRNP, and to be required for 
efficient co-transcriptional spliceosome rearrangements and pre-mRNA splicing of a 
subset of genes by reducing RNAPII elongation (Neves et al., 2017).  
 
As well as chromatin affecting both constitutive and alternative splicing, there is 
growing evidence in mammalian systems that splicing can in turn affect chromatin. 
For example, it was shown using a β-globin reporter gene that mutation of the 3’SS or 
treatment with splicing inhibitor drug spliceostatin A resulted in changes to 
H3K36me3 distribution without affecting transcription (Kim et al., 2011). 
Additionally, inhibition of splicing (using spliceostatin A or meayamycin splicing 
inhibitor drugs) was shown to impair recruitment of Set2 and reduce the level of 
H3K36me3 without affecting RNAPII occupancy (de Almeida et al., 2011).  It was 
further shown using a reporter gene that changes in alternative splicing patterns by 
altering splice site strengths, and treatment with splicing inhibitor drug meayamycin 
alters nucleosome (H3) positioning (Keren-Shaul et al., 2013). Further, binding of Hu 
proteins (which regulate exon inclusion or exclusion) to nascent pre-mRNA inhibits 
the activity of histone deacetylase 2 which increases exon exclusion possibly by 
 
 51 
increasing RNAPII elongation rate (via level of acetylation) (Zhou et al., 2011). It was 
also demonstrated in mammalian cells that splicing affects H34K4me3 (Bieberstein et 
al., 2012), and the links between H3K4me3 and splicing are discussed in detail in 
Chapter 4. Though these studies collectively clearly demonstrate that splicing affects 
chromatin modifications, it is not yet clear mechanistically how for the particular 
chromatin modifications studied. It is possible that splicing factors acting co-
transcriptionally modulate the association of chromatin modifiers with RNAPII during 
transcription.  
 
It is hypothesised that there is a ‘chromatin code’ for splicing that is established during 
the first rounds of co-transcriptional splicing that is maintained in subsequent rounds, 
and this chromatin code serves to influence processes such as transcription elongation 
and splicing factor recruitment, which ultimately combine to influence splicing 
outcome (Kim et al., 2011). Though the general conservation of the links between 
splicing and chromatin in lower and higher eukaryotes would suggest these links are 
important, the extent of conservation of particular phenomena is not yet clear, and 
some might be species-specific.  
 
1.11 S. cerevisiae as a model organism to study pre-mRNA splicing, and the links 
between splicing and transcription and links between splicing and chromatin 
 
The budding yeast S. cerevisiae is a simple eukaryote that shares many things in 
common with more complex organisms and is one of the most widely used model 
organisms to study conserved biological processes – from DNA replication to pre-
mRNA splicing. Whilst conserved from yeast to humans, biological processes are 
much less complex in S. cerevisiae, making it a simpler system to manipulate and learn 
from. There are many advantages to using S. cerevisiae as a model organism, including 
well-established methods of genetic manipulation, short generation time, and the 
relative affordability of maintenance.  
 
The core splicing machinery is conserved from S. cerevisiae to humans - 
approximately 90 distinct splicing factors are found in both species, although the 
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human spliceosome has approximately twice as many distinct proteins due to the 
complexity of alternative splicing (Fabrizio et al., 2009). The conservation of splicing 
machinery between yeast and humans was most recently highlighted by structural 
studies of the activated spliceosome (C-complex) – the core structure was found to be 
conserved from yeast to humans, with the major difference being 11 additional 
proteins in the human C-complex (Wan et al., 2016; Galej et al., 2016; et al., 2018). 
Further, the finding that splicing is mainly co-transcriptional is conserved from yeast 
to humans, and many of the links between splicing and transcription and splicing and 
chromatin are conserved from yeast to humans – indeed most of the core transcription 
machinery and chromatin modifications are conserved. For example, the rate of 
RNAPII affecting pre-mRNA splicing outcome, the phenomenon of splicing-
dependent RNAPII pausing, and splicing affecting transcription and chromatin 
modifications and vice-versa have all been demonstrated in human cells and S. 
cerevisiae. Due to the conservation of spliceosome structure and links between 
splicing and transcription and splicing and chromatin, S. cerevisiae is an ideal model 
to study some (but not all) aspects of splicing. The major caveat to working with S. 
cerevisiae is the lack of alternative splicing. 
 
In contrast to mammalian cells, where splicing inhibitor drugs (such as spliceostatin) 
are available for in vivo use, to date, there are no functional splicing inhibitor drugs 
that work in vivo in S. cerevisiae. Drugs that are available to inhibit pre-mRNA 
splicing in mammalian cells are not able to penetrate the thick cell wall of S. cerevisiae 
and splicing studies in S. cerevisiae have traditionally relied on the use of in vitro 
techniques, mutants and temperature-sensitive mutants as many splicing factors are 
essential and therefore classical gene deletion is not an option. To block specific stages 
of pre-mRNA splicing in vivo in S. cerevisiae, this study made use of the auxin-
inducible degron (AID) system, which is a powerful approach derived from plants to 
deplete proteins-of-interest in a reversible manner in response to the plant hormone 
auxin (Figure 1.4) (Nishimura et al., 2009). The system is now established from S. 
cerevisiae to mammalian cells. By targeting proteins for degradation, the AID system 
bypasses traditional problems with genetic techniques such as protein stability and 




Auxin is a plant hormone that regulates gene expression by interacting with the F-box 
transport inhibitor response I (Tir1) protein, which results in the interaction of the E3 
ubiquitin ligase SCF (SkpI, Cullin and F- box protein)-TIR1 complex with the 
AUX/IAA transcriptional repressors. Upon this interaction, the E2 ubiquitin-
conjugating enzyme is recruited that polyubiquitylates the AUX/IAA proteins, 
resulting in subsequent degradation by the proteasome. The SCF pathway is conserved 
from lower to higher eukaryotes, however TIR1 and AUX/IAA proteins are only 
present in plant species. The AID system takes advantage of this conservation, such 
that expression of TIRI and a protein-of-interest fused to an AUX/IAA recognition 
motif in another eukaryotic organism can result in the depletion of the protein-of-
interest in an auxin-dependent manner.  
 
The application of the AID system is not limited to splicing factors. The present work 
also made use of the AID system to conditionally deplete non-essential and essential 
transcription elongation factors. As with splicing factors, most studies have made use 
of mutants, and previous adaptation or compensatory mutations may have occurred in 
these strains, and therefore phenotypes observed may be indirect. The AID system 
therefore provides a novel approach to study in vivo direct consequences of loss of 





















Figure 1.4 The AID system 
 
In the present work, the AID system was used to conditionally deplete proteins-of-interest. The 
AID-degron system is derived from plants, in which auxin is a member of a family of hormones 
that regulate gene expression by interacting with the F-box transport inhibitor response I 
(TIR1) protein, which results in the interaction of the E3 ubiquitin ligase SCF (SkpI, Cullin and 
F-box protein)-TIR1 with the AUX/IAA transcriptional repressors. Upon this interaction, the E2 
ubiquitin-conjugating enzyme is recruited that polyubiquitylates (ub) the AUX/IAA proteins, 
resulting in subsequent degradation by the proteasome. The SCF pathway is conserved from 
lower to higher eukaryotes, however TIR1 and AUX/IAA are only present in plant species. The 
AID-degron system takes advantage of this conservation, such that expression of TIRI and a 
protein-of-interest fused to an AUX/IAA recognition motif (AID) in another eukaryotic organism 
can result in the depletion of the protein-of-interest in an auxin- dependent manner. Figure 




























1.12 Aims of the present work 
 
The present work used S. cerevisiae as a model organism to study the links between 
splicing and transcription and links between splicing and chromatin. There were two 
major aims of the present work: 
 
• To identify novel links between splicing and transcription by using the 
AID system to conditionally deplete essential transcription elongation 
factors and analysing any effects on co-transcriptional spliceosome 
assembly and splicing (presented in Chapter 3) 
 
• To decipher which stage of the splicing cycle, if any, affects the 
chromatin mark H3K4me3 in S. cerevisiae by using the AID system to 





























Chapter 2. Materials and methods 
 
2.1 General yeast maintenance 
Yeast cultures were maintained in Yeast Peptone Dextrose Adenine (YPDA) (1% 
yeast extract, 2% Bacto-peptone, 2% glucose, 0.003% adenine sulphate) or Yeast 
Minimal Media (YMM) (0.67% Yeast Nitrogen Base without amino acids 
(Formedium #CYN0401), 2% glucose) supplemented with Kaiser synthetic complete 
drop out powder (Formedium) according to the manufacturer’s instructions.  
For experiments, single colonies were picked from YPDA/YMM selective agar plates 
no older than 2 weeks. Cells were grown at 30℃, 180 rpm in the appropriate selective 
media. 
Glycerol stocks were prepared by adding a 1:1 volume of 30% (w/v) sterile glycerol 
to an overnight culture. Glycerol stocks were stored at -80℃.  
A list of strains used in this study can be found in Appendix 1.  
2.2 Time course experiments 
For all auxin depletion time courses, cells were diluted from an overnight culture to an 
OD600 of 0.2 in YPDA and grown to an OD600 of 0.7. At an OD600 of 0.7, cells were 
treated with 0.75 mM Indole-3-acetic acid (IAA) (auxin) (Acros organics 
#122160100) dissolved in DMSO for the appropriate amount of time. 
To induce TIR1 using the β-estradiol system, cells were diluted from an overnight 
culture to an OD600 of 0.2 in -LEU YMM media. At an OD600 of 0.7, cells were treated 
with 10 µM β-estradiol (dissolved in 100% ethanol) (Sigma-Aldrich #E8875) and 0.75 
mM IAA for 40 minutes.  
To induce wild-type and mutant Prp22 expression using the β-estradiol system and 
deplete AID-tagged endogenous Prp22 at the same time, the appropriate volume of 
cells were diluted from an overnight culture to an OD600 of 0.2 in -LEU YMM media. 
At an OD600 of 0.6, cells were treated with 10 µM β-estradiol (dissolved in 100% 
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ethanol) for 30 minutes, followed by 0.75 mM IAA for 60 minutes.  
Cells were harvested for chromatin immunoprecipitation (ChIP), RNA extraction and 
protein extraction as described below. Each time course was performed in biological 
triplicate. 
2.3 PCR  
To tag endogenous genes of interest, the Phusion high fidelity enzyme (NEB 
#MO530L) was used according to manufacturer’s instructions in a final volume of 100 
µl. PCR products were ethanol precipitated in 2.5 volumes of 100% ethanol at -20℃ 
for at least 30 minutes. DNA was pelleted by centrifugation at 20,000 x g for 20 
minutes and washed twice in 70% ethanol. The supernatant was discarded and the 
pellet air dried and dissolved in 50 µl ddH2O. A list of primers and plasmids used in 
this study can be found in Appendix 2 and Appendix 3, respectively. 
2.4 Yeast transformation 
Yeast were transformed using the TRAFO LiAc/PEG method (Gietz and Schiestl, 
2007). 50 ml cells were grown to an OD600 of 0.7 in the appropriate selective media. 
Cells were harvested by centrifugation at 1000 x g for 2 minutes, washed twice in 
ddH2O, once with 100 mM LiAc and resuspended in 400 µl 100 mM LiAc. 100 µl of 
cells were used per transformation, and the following transformation mix was added: 
240 µl 50% PEG4000, 36 µl 1 M LiAc, 50 µl 10 mg/ml ssDNA (Roche 
#11467140001) (boiled before use) and 10 µg of PCR product or 100 ng plasmid DNA. 
A negative control with no PCR/plasmid DNA was always included. The mix was 
incubated at 42℃ for 40 minutes and spun briefly at 1000 x g. The cells were 
resuspended in 500 µl media and incubated at 30℃ rotating for 2 hours to recover. 
After the recovery period, cells were harvested by centrifugation at 1000 x g for 2 
minutes and re-suspended in 100 µl ddH2O. Cells were plated on the appropriate 
selective media and incubated at 30℃ for 2-3 days, or until single colonies were 
visible. If overgrown, cells were replica plated on appropriate selective media and 




2.5 DNA preparation and PCR  
To check for positive yeast transformants, genomic DNA was extracted from an 
overnight culture of a single colony grown in 3 ml selective media. Cells were 
harvested by centrifugation at 1000 x g for 2 minutes. The pellet was re-suspended in 
200 µl ddH2O, 200 µl phenol:chloroform (1:1) pH 5.2, 200 µl DNA extraction buffer 
(2% Triton-x100, 1% SDS, 100 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 
8.0) and 200 µl 0.5 mm zirconia beads (Thistle scientific #11079105z). The mixture 
was vortexed for 2 minutes followed by centrifugation at 18,000 x g for 5 minutes. 
The aqueous phase was transferred to 2.5 volume 100% ethanol and DNA precipitated 
at -20℃ for 30 minutes. The sample was centrifuged at 18,000 x g for 10 minutes, 
washed twice in 70% ethanol and the DNA pellet re-suspended in 200 µl ddH2O.  
Each strain was verified by PCR using TAQ DNA polymerase (Invitrogen #10342020) 
according to the manufacturer’s instructions using oligonucleotides listed in Appendix 
2.  
2.6 Bacteria growth 
The Escherichia coli (E. coli) strain NEB-5-alpha (NEB #C2987H), was used to 
propagate plasmid DNA. Standard techniques were used for growing and transforming 
E. coli. 
2.7 Plasmids and cloning  
Plasmid DNA was extracted using the Qiagen QIAprep Spin Miniprep Kit (#27104) 
according to the manufacturer’s instructions. For restriction enzyme analysis, NEB 
restriction enzymes were used according to the manufacturer’s instructions. For 
ligation reactions, T4 DNA ligase (NEB #MO202) was used according to the 
recommended protocol. For gel extractions, the Qiagen Gel Extraction Kit (#28704) 
and protocol was used to purify DNA. All plasmids used in this study are listed in 
Appendix 3. 
Gibson assembly was used to generate the plasmids pZL-PRP22WT-V5, pZL-
PRP22T757A-V5 and pZL-PRP22I764A-V5. The backbone of these plasmids is 
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derived from pZTRL and the inserts derived from p360-PRP22-V5, p360-T757A-V5 
and p360-I764A-V5. 5 µg of pZTRL was digested with SfiI (NEB), the DNA 
fragments separated by agarose gel electrophoresis and the backbone segment 
extracted and purified using the Qiagen Gel Extraction Kit (#28704) according to the 
manufacturer’s instructions. The insert segments of Prp22 were amplified by PCR 
using NEB Phusion enzyme using primers listed in Appendix 2 according to 
manufacturer’s instructions. 5 µg of the insert PCR products were digested with SfiI 
and cleaned-up using the MinElute PCR clean-up kit (Qiagen #28006). The NEB 
Gibson assembly kit (#E2611) was used to generate pZL-PRP22WT-V5, pZL-
PRP22T757A-V5 and pZL-PRP22I764A-V5 according to the manufacturer’s 
instructions. 
2.8 DNA sequencing  
DNA was sequenced using the Sanger protocol at the Sequencing Facility at the 
University of Dundee (https://www.dnaseq.co.uk). 
2.9 Protein sample preparation and western blotting  
10 ml of cells at an OD600 of 0.8 were fixed in 5 ml of 100% methanol on dry ice and 
harvested by centrifugation at 1000 x g. Protein samples were prepared using a 
modified NaOH lysis and trichloroacetic acid (TCA) precipitation protocol (Volland 
et al., 1994). Cells were re-suspended in 830 μl ddH2O and 217 μl of 1 M NaOH, 
mixed and incubated on ice for 10 minutes. 58 μl 100% TCA was added and samples 
mixed and incubated on ice for 15 minutes. Samples were centrifuged at 20,000 x g 
for 5 minutes, the supernatant discarded, and the pellet resuspended in 77.8 μl of 
dissociation buffer (0.1M Tris-HCl pH6.8, 4mM EDTA pH8, 4% (w/v) SDS, 2% (v/v) 
2-mercaptoethanol, Orange G) and 35 μl 1 M Tris base. Protein samples were 
incubated at 96℃ for 10 minutes, centrifuged at 18,000 x g for 4 minutes and the 
supernatant retained for western blotting. Protein concentration was measured using 
the Bradford assay (Bio-rad #5000006).  
For western blotting, 25 μg of protein were run on a NuPAGE 4-12% gel Bis-Tris 
(Invitrogen #NP0323BOX) at 180 V in 1 X MOPS-SDS buffer (Invitrogen #1862491). 
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Proteins were transferred to a Bio-rad nitrocellulose membrane (0.2 µm, #LC2009) 
using a semi-wet transfer unit (Bio-rad) at 100 V for 1 hour at 4℃ in Tris-Glycine 
transfer buffer (200 mM Tris, 1.5 M glycine) with 10% methanol. The membrane was 
blocked in PBS and 5% (w/v) milk powder for 1 hour with gentle rocking. Primary 
antibodies were diluted in PBS with 0.2% TWEEN-20 and 5% milk powder and 
incubated for 1 hour at room temperature or overnight. The membrane was washed 3 
times for minutes each in PBS and 0.2% TWEEN-20. The membrane was incubated 
with the appropriate secondary antibodies diluted in PBS, 5% (w/v) milk powder and 
0.2% TWEEN-20 for 1 hour, rocking at room temperature. The membrane was washed 
3 times for 10 minutes each in PBS and 0.2% TWEEN-20, followed by a final wash 
in 1 X PBS. 
The Odyssey infrared imaging system (LI-COR Bioscience) was used to visualise 
proteins of interest after transfer. To quantitate, the median method of the Odyssey 
software was used. Unless otherwise stated, data were normalised against the 3-
Phosphoglycerate Kinase (Pgk1) loading control. Student’s t-tests were performed to 
determine the P-values for differences observed between wild-type and 
depletion/induction conditions. Primary and secondary antibodies used are listed in 
Tables 2 and 3, respectively.  
Table 2. Primary antibodies used for western blotting in this study 
Antibody Concentration Conditions 
Rabbit anti-Prp40 (rabbit 11 Eurogentec 2014) 1:1000 Overnight 4℃ 
Rabbit anti-Prp8 (R1703 Final bleed Boon 
peptide 5/046) 
1:1000 Overnight 4℃ 
Rat anti-FLAG (Agilent #200474)  1:1000 Overnight 4℃ 
or RT 1 hour 
Mouse anti-histone H3 (Diagenode 
#C15210011)  
1:1000 Overnight 4℃ 
or RT 1 hour 
Rabbit anti-histone H3K4me3 (Active motif 
#39159)  
1:1000 Overnight 4℃ 
or RT 1 hour 
Rabbit anti-histone H3K4me2 (Active motif 
#39141)  
1:1000 Overnight 4℃ 
or RT 1 hour 
Rabbit anti-histone H3K4me1 (Active motif 
#39297)  
1:1000 Overnight 4℃ 
or RT 1 hour 
 
 61 
Mouse anti-Rpb1 (Diagenode #C15100055-100)  1:1000 Overnight 4℃ 
or RT 1 hour 
Mouse anti-Rpb3 (Biolegend #665004)  1:1000 Overnight 4℃ 
or RT 1 hour 
Rat anti-S2P (Chromotek #3E10)  1:500 Overnight 4℃ 
Rat anti-S5P (Chromotek #3E8)  1:500 Overnight 4℃ 
Mouse anti-Pgk1 (Abcam #22C5D8) 1:5000 Overnight 4℃ 
or RT 1 hour 
Mouse anti-c-MYC (Santa Cruz #SC-40x) 1:1000 Overnight 4℃ 
or RT 1 hour 
Mouse anti-V5 (Invitrogen #MA5-15253) 1:1000 Overnight 4℃ 
or RT 1 hour 
Mouse anti-HA (Santa Cruz #F-7)  1:1000 Overnight 4℃ 
or RT 1 hour 
Rabbit anti-Spt5-P (#1761, kind gift from Steven 
Hahn) (Liu et al., 2009) 
1:1000 Overnight 4℃ 
Rabbit anti-Spt5 (kind gift from Grant Hartzog) 
(Hartzog et al., 1998) 
1:1000 Overnight 4℃ 
 
Table 3. Secondary antibodies used for western blotting in this study 
Antibody Concentration Conditions 
Goat anti-mouse IRDye680RD (LI-COR #926-
68070)  
1:10,000 RT 1 hour 
Goat anti-rabbit IRDye680RD (LI-COR #926-32223)  1:10,000 RT 1 hour 
Goat anti-rat IRDye800RD (LI-COR #926-32219)  1:10,000 RT 1 hour 
Goat anti-rabbit IRDye800RD (LI-COR #925-32211)  1:10,000 RT 1 hour 
 
2.10 Growth analysis  
An overnight culture from a single colony was diluted to an OD600 of 0.1 in 200 µl of 
the appropriate media in a sterile flat-bottomed 96 well plate. A Sunrise Absorbance 
Microplate Reader (Tecan Trading AG) was used to grow the cells at 30℃ 180 rpm. 
OD600 measurements were taken every 15 minutes for 18 hours. To test the auxin 
sensitivity of the AID-tagged strains, the cells were grown in the presence of 0.75 mM 




2.11 Total RNA preparation and RT-qPCR  
10 ml of cells at an OD600 of 0.8 were fixed in 5 ml methanol on dry ice and harvested 
by centrifugation at 1000 x g. RNA was extracted using a modified GTC:Phenol 
method from Tollervey and Mattaj (1987). Cell pellets were re-suspended in 400 µl 
AE buffer (50mM NaOAc pH 5.3, 10mM EDTA, 0.5% SDS), 600 µl of phenol citrate 
pH 4.3 and 300 µl zirconia beads. Cells were lysed in using a Mini-Beadbeater-24 
(BioSpec Products) at 2000 rpm twice for 2 minutes followed by 2 minutes on ice. The 
sample was placed on dry-ice for 2 minutes. Cells were centrifuged at 20,000 x g for 
5 minutes and the upper phase was transferred to a new tube containing 500 µl 
phenol:chloroform (5:1) pH 4.3 (ThermoFisher Scientific, AM9720). The sample was 
vortexed and centrifuged at 20,000 x g for 5 minutes. The upper phase was transferred 
to a new tube containing 500 µl chloroform, vortexed and centrifuged at 18,000 x g 
for 5 minutes. The upper phase containing RNA was precipitated in 1/3rd volume 10 
M LiCl for 30 minutes at -20℃. The sample was centrifuged at 18,000 x g for 5 
minutes at 4℃ and washed twice in 70% EtOH. The pellet was re-suspended in 50 µl 
ddH2O, and RNA concentration measured using a Nanodrop. 
 
For reverse transcription, 5 μg of RNA were diluted in ddH2O to a total volume of 8 
µl. Residual DNA was removed by DNase treatment for 15 minutes at 37℃ (1 µl 10x 
DNase I buffer, 0.9 µl DNase I enzyme (Promega #M6101) and 0.1 µl RNase inhibitor 
(Promega #N2511)). The DNase I was inactivated at 75℃ for 10 minutes. 2.5 µl of a 
mix containing the desired reverse primers (3 µM each) was added to the DNase-
treated RNA and incubated at 72℃ for 5 minutes. The sample was split into two – one 
for the reverse transcription and a negative control with no reverse transcriptase added. 
5 µl of a reverse transcriptase master-mix was added to each tube: 2 µl 5 x reverse 
transcription buffer, 0.75 µl 10 mM dNTPs (Promega #U1515), 0.25 µl RNase 
inhibitor, 1.7 µl ddH2O and 0.3 µl reverse transcriptase (Roche #3531287001) (or 
water in the negative control). cDNA synthesis was performed at 55℃ for at least 2 
hours, and the cDNA diluted to a final volume of 200 µl in ddH2O.  
For qPCR analysis, 2.5 μl cDNA was mixed with 2 μl Brilliant III SYBR green qPCR 
mix (Agilent #60088251) and 0.5 μl primer mix (3 μM each). Each qPCR reaction was 
 
 63 
run in technical triplicate.  
The following cycling parameters were used: 5 minutes at 95℃, 40 cycles of 10 
seconds at 94℃, 10 seconds at 60℃ and 15 seconds at 72℃. The absolute 
quantification/second derivative maximum analysis in the Light Cycler 480 software 
1.5.0 (Roche) was used to quantitate the signal and data were normalised to the 
intronless gene ALG9 and/or time zero/wild-type conditions, or to SCR1 and/or time 
zero/wild-type conditions. A list of primers used for reverse transcription and RT-
qPCR can be found in Appendix 4. Student’s t-tests were performed to determine the 
P-values for differences observed between wild-type and depletion/induction 
conditions. 
2.12 Chromatin immunoprecipitation (ChIP)  
50 ml of culture at an OD600 of 0.8 was cross-linked linked in 1% (w/v) formaldehyde 
for 10 minutes shaking at room temperature. The reaction was stopped by incubating 
the cells for 5 minutes with 2.5 ml of 2.5 M glycine. Cells were harvested by 
centrifugation at 1000 x g and washed twice in ice-cold 1 X PBS. Cell pellets were re-
suspended in 350 μl FA1 buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1mM 
EDTA pH 8.0, 1% Triton X-100, 0.1% sodium deoxycholate, one complete EDTA-
free proteinase inhibitor tablet (Roche #11836145001), four PhosSTOP tablets (Sigma 
Aldrich #000000004906845001) and 350 μl zirconia beads. The cells were disrupted 
using the Mini-Beadbeater-24 (BioSpec Products) twice at 2000 rpm for 2 minutes 
with 2 minutes on ice in between. The sample was separated from the beads by 
centrifugation at 1000 x g for 2 minutes. The sample was centrifuged at 20,000 x g for 
15 minutes at 4℃. The pellet was re-suspended in 600 μl FA1 buffer, and the sample 
sonicated using a New Twin Biorupt sonicator (Diagenode) for 15 cycles 30 seconds 
on and 30 seconds off. The sample was centrifuged at 20,000 x g for 30 minutes at 4℃ 
and the supernatant containing solubilised chromatin was retained. Protein 
concentration was determined using the Bradford assay.  
For immunoprecipitation, the appropriate amount of chromatin was incubated in 20 μl 
Protein A/G Dynabeads (Life Technologies #10001D/10003D) conjugated to antibody 
on a rotating wheel overnight at 4℃. A list of the antibodies and amount of chromatin 
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used per IP can be found in Table 4.  
The beads were washed 3 times in FA1 buffer, twice in FA2 buffer (50 mM HEPES-
KOH pH 7.5, 0.5 M NaCl, 1mM EDTA pH 8.0, 1% Triton X-100, 0.1% sodium 
deoxycholate), twice in FA3 buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 1mM 
EDTA pH 8.0, 0.5% NP-40, 0.5% Na deoxycholate) and once in Tris-EDTA pH 8.0 
0.05% TWEEN-20. Crosslinking was reversed with 150 μl elution buffer (50 mM Tris-
Hcl, 10 mM EDTA, 1% SDS) and 3 μl Proteinase K (25 mg/ml) and incubated at 42℃ 
for 2 hours and 65℃ overnight, shaking. An input sample equal to 10% of the protein 
that was used for the immunoprecipitation was prepared and crosslinking was reversed 
as above. The QIAGEN mini column clean-up kit was used to purify DNA according 
to the manufacturer’s instructions, and DNA eluted in 400 μl of 10 mM Tris pH 8.0. 
Samples were analysed by qPCR as described above using primers listed in Appendix 
5. The positions of amplicons used for qPCR for each gene are shown to scale in 
appendix 6. The ChIP data was using the relative threshold cycle (Ct) values for each 
sample. ChIP data are presented as percentage of input normalised to the first amplicon 
of each gene, to Rpb1, to histone H3 or to another negative control region specified in 
the figure legend. Student’s t-tests were performed to determine the P-values for 
differences observed between wild-type and depletion/induction conditions.  
Table 4. List of antibodies and conditions used for ChIP in this study 
Chromatin 
(µg) 
Antibody and concentration Dynabeads 
A/G 
250 Rabbit anti-Prp40 (rabbit 11 Eurogentec 2014); 5 µl/IP Protein A 
250 Rabbit anti-Prp8 (R1703 Final bleed Boon peptide 5/046); 5 
µl/IP 
Protein A 
500 Rabbit anti-HA (Abcam #AB9110); 5 µl/IP Protein A 
250 Mouse anti-FLAG (Sigma M2 #F1804); 5 µl/IP Protein G 
250 Mouse anti-c-MYC (Santa Cruz #SC-40x); 5 µl/IP Protein G 
250 Rabbit anti-V5 (Abcam #AB9116); 5 µl/IP Protein A 
125 Mouse anti-histone H3 (Diagenode #C15210011); 1.5 µl/IP Protein G 
125 Rabbit anti-histone H3K4me3 (Active motif #39159); 3 µl/IP Protein A 
125 Rabbit anti-histone H3K4me2 (Active motif #39141); 3 µl/IP Protein A 
125 Rabbit anti-histone H3K4me1 (Active motif #39297); 3 µl/IP Protein A 
125 Mouse anti-Rpb1 (Diagenode #C15100055-100); 1.5 µl/IP Protein G 
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125 Mouse anti-Rpb3 (Biolegend #665004); 2 µl/IP Protein G 
125 Rat anti-S2P (Chromotek #3E10); 10 µl/IP Protein G 
125 Rat anti-S5P (Chromotek #3E8); 10 µl/IP Protein G 
 
2.13 Thiolabelling of nascent RNA 
The protocol used was developed by David Barrass (Barrass et al., 2015). Cells 
containing the plasmid pRS426–FUI1 that encodes the uracil permease Fui1 were 
grown in -URA YMM to an OD600 of 0.8. To label the nascent RNA, 100 µM 4-
thiouracil (Acros organics # 359930010) was added to the culture and 30 ml of culture 
snap frozen by immersion into 20 ml methanol on dry ice at the following time points 
post 4-thiouracil addition: 1 minutes, 2 minutes, 4 minutes and 8 minutes. Cells were 
harvested by centrifugation at 1000 x g and washed once in ice-cold ddH2O. 
RNA was extracted as described above and re-suspended in a final volume of 90 µl 
TE pH 7.0 in a 0.2 ml tube. RNA was biotinylated at 65℃ for 15 minutes by the 
addition of 1/10th volume HPDP-biotin solution (4mM in dimethyl formamide). RNA 
was purified from excess HPDP-biotin solution ThermoFisher Scientific #21341), in 
a 0.5ml Zeba desalting column (ThermoFisher Scientific #89882), using TE buffer and 
following the manufacturer’s instructions. RNA was precipitated at -20℃for 30 
minutes by the addition of 1/3rd volume 10 M LiCl. The sample was spun at 18,000 x 
g for 5 minutes at 4 ℃, and pellet washed twice in 80% EtOH rotating at RT. The RNA 
was pelleted at 20,000 x g for 5 minutes at 4℃ and re-suspended in 200 µl ddH2O at 
65 ℃. RNA concentration was measured using a Nanodrop, and the concentration 
across samples equalised to final volume of 250 µl ddH2O. Bead buffer (final 
concentration 1 mM Tris-HCl pH7.0, 20 mM NaCl, 2.5 mM MgCl2, 100 mM NaPi pH 
6.8, 0.1% SDS) was added to the RNA and the samples were well mixed, with care 
being taken to avoid precipitation by adding the NaPi and SDS separately from the 
other components, all at room temperature. 
Magnetic streptavidin beads (NEB #S1420S) were prepared by adding 50 µl beads to 
a 1.5 ml low-binding tube and washing them in 200 µl of bead buffer. The beads were 
blocked in 200 µl bead buffer supplemented with 2.5 µl of 5 mg/mL tRNA and 10 µl 
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of 20 mg/mL glycogen for 20 minutes in a rotating wheel at RT, followed by a final 
wash in 200 µl bead buffer. The RNA was added to the beads and incubated on a 
rotating wheel for 30 minutes at RT. The beads were washed four times in 200 µl of 
bead buffer and eluted in 40 µl of 0.7 M 2-mercaptoethanol (freshly prepared). RNA 
was precipitated at -20℃ for 1 hour by adding 2.5 volumes 100% EtOH, 1/10th volume 
3 M NaOAc pH 5.3 and 10 µg glycogen (Roche # 10901393001). RNA pellets were 
washed twice in 70% ethanol and re-suspended in 10 µl TE pH 7.0. RNA quality was 
analysed using an Agilent 2100 bioanalyser RNA Nano-Chip according to the 
manufacturer’s instructions. Reverse transcription followed by qPCR was performed 
as described in section 2.11. 
2.14 Co-immunoprecipitation 
250 ml of culture at an OD600 of 0.8 was harvested by centrifugation at 1000 x g and 
washed twice in ice-cold 1 X PBS. The cell pellet was re-suspended in 900 µl lysis 
buffer (50 mM Tris-HCl pH 7.5, 2 mM Mg2Cl2, 150 mM NaCl, 0.2% NP-40 and one 
complete EDTA-free proteinase inhibitor tablet (Roche #11836145001) and 400 µl 
zirconia beads. Cells were lysed using a Mini-Beadbeater-24 (BioSpec Products) twice 
at 2000 rpm for 2 minutes followed by 2 minutes on ice. The sample was centrifuged 
at 1000 x g for 2 minutes, the supernatant was collected and additionally centrifuged 
at 20,000 x g for 30 minutes at 4℃ and used for immunoprecipitation.  
The concentration of protein was measured using the Bradford assay, and 1 mg of 
protein used per IP. Prior to immunoprecipitation, extract was pre-cleared by adding 
½ volume unconjugated Protein A/G Dynabeads (Life Technologies 
##10001D/10003D). 50 µl Protein A/G Dynabeads conjugated to antibody were 
incubated with the appropriate volume of extract on a rotating wheel overnight at 4℃. 
The next day, beads were washed 8 times in lysis buffer (non-bound fraction kept for 
analysis). 20 µl of loading buffer was added to the beads, input and non-bound 
samples, which were boiled for 10 minutes before loading on a NuPAGE 4-12% Bis-
Tris gel Bis-Tris (Invitrogen) and western blotting was performed as described above. 
A list of antibodies used for co-immunoprecipitation can be found in table 5, and 
antibodies used for western blotting can be found in Tables 2 and 3. 
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Table 5. List of antibodies and conditions used in this study for co -
immunoprecipitation in this study 
 
Amount of extract 
(µg) 
Antibody and concentration Dynabeads 
A/G 
1000 Mouse anti-FLAG (Sigma M2 #F1804); 10 µl/IP Protein G 
1000 Mouse anti-c-KMYC (Santa Cruz #SC-40x); 10 µl/IP Protein G 
1000 Rabbit anti-Prp8 (R1703 Final bleed Boon peptide 
5/046) 10 µl/IP 
Protein A 
 
2.15 Native elongating transcript (NET) purification and RT-qPCR 
The NET protocol used was a modified version of the protocol developed by 
Churchman and Weissman (2001). One litre of cells at an OD600 of 0.8 were harvested 
by centrifugation at 4℃ for 2 minutes, washed in ice-cold PBS and the pellet snap 
frozen in liquid nitrogen. Cells were subjected to cryogenic lysis using a mixer mill 
(SPEX 6780) for 5 rounds at 10 cps, for 2 minutes with 2 minutes cooling in between.  
 
For each immunoprecipitation of TAP-tagged Rpb3, 1 g of ground cells was re-
suspended in 5 ml ice-cold lysis buffer (20 mM HEPES pH 7.4, 110 mM KOAc, 0.5% 
Triton X-100, 0.1% TWEEN-20, 10 mM MnCl2, one complete EDTA-free proteinase 
inhibitor tablet (Roche #11836145001), 50 U/ml SUPERas.In RNase inhibitor 
(ThermoFisher Scientific #AM2694)) and 500 µl RNase-free DNase I (Promega 
#M6101) and incubated at 4℃ for 20 minutes. The lysate was centrifuged at 20,000 x 
g at 4 ℃ for 10 minutes. An input sample (20 µl) was collected at this point for western 
blotting, and for a total RNA reference (100 µl). To immunoprecipitate Rpb3-TAP, 
the supernatant was added to 500 µl of Protein A sepherose beads and incubated at 4℃ 
for 1.5 hours on a rotating wheel. The beads were centrifuged at 3000 x g and a non-
bound fraction was collected for future western blotting.  
 
Beads were washed 4 times in 10 ml ice-cold wash buffer (20 mM HEPES pH 7.4, 
110 mM KOAc, 0.5% Triton X-100, 0.1% TWEEN-20, 10 mM MnCl2, one complete 
EDTA-free proteinase inhibitor tablet (Roche #118361ss45001), 50 U/ml SUPERas.In 
RNase inhibitor (ThermoFisher Scientific #AM2694), 1 mM EDTA) rotating at 4℃ 
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for 2 minutes followed by centrifugation at 1000 x g at 4℃. The beads were re-
suspended in 300 µl wash buffer and transferred to a 1.5 ml tube. A fraction of the 
beads was collected at this point for future Western blotting. Rpb3-TAP was eluted 
from the beads in 300 µl TEV cleavage buffer (1X AcTEV buffer, 50 U/ml 
SUPERas.In RNase inhibitor (ThermoFisher Scientific #AM2694), 1 mM DTT, 5 µl 
AcTEV protease (ThermoFisher Scientific #12575-015)) at 4℃ on a rotating wheel 
overnight. A fraction of the beads (20 µl) was collected at this point for future western 
blotting. The beads were passed through a Pierce spin column (ThermoFisher 
Scientific #69725) and the elution collected (a fraction was taken for future Western 
blotting). The beads left in the column were re-suspended in 300 µl of ddH2O and the 
column centrifuged at 1000 x g. The elutions were combined and RNA extracted using 
the Qiagen miRNeasy Mini Kit (#217004) and eluted in 30 µl of RNase‐free water 
according to the manufacturer’s instructions. Reverse transcription followed by qPCR 

































Major elongation factors in yeast include Spt5, Paf1 and the CTD kinases Ctk1 and 
Bur1 (reviewed in Shilatifard, 2004; Perales and Bentley, 2009). In addition to the 
CTD of RNAPII, it is possible that elongation factors that dynamically associate with 
and/or modify RNAPII to facilitate transcription through the nucleosome barrier 
influence co-transcriptional splicing (Figure 3.1). This could occur by elongation 
factors facilitating the initial recruitment of splicing factors to newly synthesised pre-
mRNA substrates, by providing a platform to stabilise their association once recruited, 









Figure 3.1. Splicing occurs in close-proximity to the transcription elongation 
machinery 
 
Splicing occurs in close-proximity to the transcription elongation machinery. RNAPII is 
recruited to promoters in an unphosphorylated state and without Spt5. The CTD of RNAPII is 
then hyperphosphorylated at serine 5 at the 5’ end of genes by the kinase Kin28 (budding 
yeast). The Bur1/2 serine 2 CTD kinase complex is recruited by serine 5 phosphorylation of 
the CTD at the 5’end of genes where it augments the function of major serine 2 kinase Ctk1 
and phosphorylates serine 2 of the CTD towards the 5’ end of genes. In addition to 
phosphorylating serine 2 of the CTD of RNAPII, Bur1/2 phosphorylates Spt5 transcription 
elongation factor. Phosphorylated Spt5 recruits the Paf1 complex (PafC) which facilitates 
RNAPII transcription elongation through chromatin. Ctk1 acts toward the 3’end of genes to 
phosphorylate serine 2 of the CTD of RNAPII. The spliceosome is recruited to pre-mRNA 
substrates co-transcriptionally and is by definition in close-proximity to RNAPII and factors 
associated with RNAPII. Additionally, the spliceosome is in close-proximity to chromatin. 
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Currently, there is little functional or mechanistic insight into the contribution of the 
core transcription elongation machinery to co-transcriptional spliceosome assembly 
and splicing (reviewed in Neugebauer, 2002; Merkhofer et al., 2014). There is some 
evidence that core members of the transcription elongation complex affect splicing 
outcome. For example, mutations in Spt4 and Spt5 result in splicing defects in S. 
cerevisiae (Lindstrom et al., 2003; Burckin et al., 2005; Xiao et al., 2005), and 
depletion of Spt4 in mammalian cells results in changes to alternative splicing patterns 
(Liu et al., 2012). Furthermore, depletion of Spt5 in mammalian cells causes pre-
mRNA accumulation on some genes (Diamant et al., 2012). Additionally, it was 
shown in yeast that Spt5 exhibits intron bias, and that Spt5 co-immunoprecipitates 
with Prp40, a core member of the U1 snRNP (Moore et al., 2006; Shetty et al., 2017). 
Most recently, depletion of Spt5 in S. pombe was shown by RNA sequencing to cause 
pre-mRNA accumulation (Shetty et al., 2017). Furthermore, in mammalian cells it was 
proposed that splicing influences the elongation rate of RNAPII via P-TEFb (Fong and 
Zhou, 2001; Lin et al., 2008).  In mammalian cells, P-TEFb was shown to interact with 
splicing factor SKIP (Prp45 in S. cerevisiae) (Bres et al., 2005). More recently, in 
Arabidopsis, ELF7 (homolog of Paf1) of the Paf1 complex has been shown to interact 
with splicing factor SKIP (Cao et al., 2015; Li et al., 2016; Yang et al., 2016). 
Recently, elongation factors Bur1, Bur2, Spt5 and Ctk1 were found to crosslink to 
introns in S. cerevisiae, suggesting that these factors may be recruited by binding to 
pre-mRNA (Battaglia et al., 2017).  
 
While these studies demonstrate that elongation factors are important for splicing 
outcome, there is no clear mechanistic insight into how this might be, and effects on 
co-transcriptional spliceosome assembly or co-transcriptional splicing have not been 
investigated. Most studies have made use of mutant or deletion systems that may have 
adapted over time, and therefore there may be gaps in our knowledge as to how co-
transcriptional spliceosome assembly is finely tuned. Furthermore, these studies have 
mainly analysed the effects on splicing in total RNA (not co-transcriptional splicing) 
and have not analysed the effects on co-transcriptional spliceosome assembly. This is 
surprising as any effects on splicing are likely due to changes in a particular stage of 
co-transcriptional spliceosome assembly. Currently, a systematic characterisation of 
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the physical contribution of the core transcription elongation machinery to co-
transcriptional spliceosome assembly and co-transcriptional splicing is lacking. The 
present work describes the use of the AID system to conditionally deplete essential 
and non-essential components of the transcription elongation machinery in S. 
cerevisiae in order to determine their role in co-transcriptional spliceosome assembly 
and splicing. The AID system has the benefit of enabling the direct determination of 
the physical contribution of these factors, without prior adaptation or secondary effects 
likely present in deletion/mutant systems. In the present work, Spt5, the Bur1/2 
complex, Ctk1 and Paf1 were each conditionally depleted using the AID system and 
subsequent effects on RNAPII occupancy, co-transcriptional spliceosome assembly, 
splicing and co-transcriptional splicing were determined. 
 
Effects on RNAPII occupancy and co-transcriptional spliceosome assembly were 
analysed by ChIP followed by qPCR across intron-containing genes. This was 
particularly important, as both the kinetic and recruitment models rely on it. For 
example, should depletion of a particular elongation factor reduce RNAPII occupancy, 
by proxy this would indirectly reduce co-transcriptional spliceosome assembly due to 
there being fewer pre-mRNA transcripts to bind to or due to loss of interactions 
between splicing machinery and RNAPII, and the conclusion that that elongation 
factor is required for co-transcriptional spliceosome assembly could be misinterpreted.  
 
As splicing factors assemble on pre-mRNA during co-transcriptional splicing, their 
close proximity to chromatin enables them to be crosslinked to DNA and analysed by 
ChIP. In this way, the co-transcriptional recruitment of splicing factors and 
spliceosome assembly can be monitored in vivo (Kotovic et al., 2003; Görnemann et 
al., 2005; Tardiff and Rosbash, 2006). In the present work, ChIP using antibodies 
against core members of the spliceosome was used to test if depletion of elongation 
factors by the AID system affects co-transcriptional spliceosome assembly. Effects on 
pre-mRNA splicing and transcription were determined using RT-qPCR on total 
(steady-state) RNA and, if interesting effects on co-transcriptional spliceosome 
assembly were observed by ChIP after depletion of a particular elongation factor, 
 
 72 
effects on co-transcriptional splicing and transcription were determined by NET-RT-
qPCR Churchmann and Weissman, 2001; Aslanzadeh et al., 2017). 
 
To enable depletion, each protein-of-interest was tagged at the C-terminus with the 
AID* cassette comprised of the AUX/IAA (AID*) recognition motif for auxin-
mediated depletion and a 6 X FLAG tag for immunodetection (Morawska and Ulrich, 
2013) (Figure 3.2). AID-mediated depletion of a protein-of-interest requires 
expression of Tir1, and tagging was performed in a W303 parental strain with Oryza 
sativa TIR1 (OsTIR1) either constitutively expressed under a weak ADH1 promoter 
(PADH1-396) (integrated at the his3-11,15 locus) (Santangelo and Tornow, 1990; 
Mendoza-Ochoa et al., 2018), or conditionally expressed from a β-estradiol-inducible 
promoter present on a centromeric plasmid (McIsaac et al., 2014; Mendoza-Ochoa et 
al., 2018). OsTIR1 expression is repressed in the absence of β-estradiol, and induced 
by the addition of β-estradiol, thereby enabling auxin-mediated degradation of an 
AID*-tagged target protein.  
 
In the present work, correct integration of the AID* cassette at each locus was 
confirmed by PCR, expression was confirmed by western blotting (data not shown). 



















Figure 3.2. Endogenously tagging proteins-of-interest to enable depletion using the AID 
system 
 
(A) In this study, endogenous genes were modified with an AID* (AUX/IAA recognition motif) 
sequence at the C-terminus in W303 yeast strains expressing OsTIR. PCR was used to 
amplify the AID* cassette, and each PCR product contained sequence homology within the C-
terminus of each gene (blue) and the 3’UTR (red) such that, upon transformation, 
recombination would occur at the regions indicated by the grey lines. In addition to the AID* 
sequence, the cassette contains a 6XFLAG tag for immunodetection and hygromycin 
resistance (HygR) gene for selection of positive transformants (driven by a TEF promoter 
(PTEF)). At the 3’ end, a CYC1 terminator (TCYC1) is present.  
(B) The tagging of each gene with the AID*-6FLAG cassette results in the production of a 
fusion protein with the AID* to allow auxin-mediated depletion of each protein and a 6 X FLAG 
tag for immunodetection. In addition, 2 linker regions of 18 amino acids (aa) and 13 aa flanked 























3.2 Use of the AID system to conditionally deplete Spt5 
 
To determine whether the physical presence of Spt5 affects co-transcriptional 
spliceosome assembly in vivo in S. cerevisiae, Spt5 was conditionally depleted using 
the AID system. Spt5 was C-terminally AID*-6FLAG tagged in a strain that allowed 
conditional induction of OsTIR1 using the β-estradiol system (described in section 3.1) 
(McIsaac et al., 2013; Mendoza-Ochoa et al., 2018). Experiments were performed 
with and without 40 minutes of β-estradiol and auxin treatment.  
 
The effect of the AID* tag on Spt5 function and auxin-sensitivity was assessed by 
growth analysis of the parental strain (W303) with no AID* tag, and the Spt5-AID* 
strain with or without auxin and β-estradiol treatment (Figure 3.3A). In the absence of 
auxin, the Spt5-AID* strain grew comparably to the parental strain, showing that the 
C-terminal AID* tag does not affect Spt5 function. After auxin and β-estradiol addition 
to deplete Spt5, the Spt5-AID* strain grew more slowly than the parental strain – 
which was expected as Spt5 is essential in S. cerevisiae.  
 
Western blotting showed that depletion of Spt5 for 40 minutes resulted on average in 
a significant reduction to 40% of the undepleted amount of Spt5 (student’s t-test, 
P<0.05) (Figure 3.3B). It is estimated that Spt5 is present at approximately 4632 
molecules/cell (Kulak et al., 2014), therefore after 40 minutes of depletion there are 
approximately 1853 molecules/cell of Spt5 left.  
 
ChIP-qPCR analyses showed that, in addition to being depleted in whole cell extracts, 
Spt5-AID* was significantly depleted across each the intron-containing genes 
analysed (Figure 3.3C). On average, relative to conditions prior to depletion, there was 







Figure 3.3. Use of the AID system to conditionally deplete Spt5 
 
(A) Growth of the control parental strain (W303; no AID*-tagged proteins; black) and Spt5-
AID* tagged strain (red) was measured over a period of 17 hours without (-) auxin or β-
estradiol or with (+) auxin and β-estradiol treatment. Mean of three biological replicates.  
(B) Western blot probed with anti-FLAG and anti-Pgk1 as a loading control. Samples were 
taken before (T0) and 40 minutes (T40) after addition of auxin and β-estradiol. Spt5-AID* 
depletion was quantified and shown as the percentage mean of 3 biological replicates after 40 
minutes of auxin and β-estradiol addition with respect to (W.R.T) time zero and normalised to 
the Pgk1 signal. Error bars = standard error of the mean.  
(C) Anti-FLAG ChIP followed by qPCR analysis of the intron-containing genes ACT1, RPS13, 
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(orange) addition to deplete Spt5-AID*-6FLAG. The X-axis shows the positions of amplicons 
used for ChIP qPCR analysis – the exons of each gene are in grey. The data are presented 
as the mean percentage of input with respect to (W.R.T.) the first amplicon of each gene. 
Mean of at least three biological replicates. Error bars = standard error of the mean.  
 
 
3.3 Characterisation of the effect of Spt5 depletion on RNAPII occupancy, serine 
2 and serine 5 phosphorylation of the CTD of RNAPII 
 
To determine whether the depletion of Spt5 in these conditions affects the occupancy 
or phosphorylation status of RNAPII, ChIP was performed using antibodies against 
RNAPII (Rpb1), serine 2 (S2P) or serine 5 (S5P) CTD phosphorylation states followed 
by qPCR across intron-containing genes ACT1, RPS13 and ECM33. Depletion of Spt5 
for 40 minutes did not significantly affect RNAPII occupancy across ACT1 or ECM33 
(student’s t-test, P>0.05), however on RPS13 there was a small but significant 
reduction in RNAPII occupancy on average to 81% and 84% at amplicons 2 and 3 
(exon 1 and intron) (student’s t-test, P<0.05) relative to conditions without depletion 
(Figure 3.4A).  
 
ChIP-qPCR using an antibody against serine 2 (S2P) phosphorylation of the CTD 
showed the correct profile of serine 2 phosphorylation – an increase in this mark was 
observed toward the 3’ end of the genes relative to RNAPII occupancy. Depletion of 
Spt5 resulted in increased S2P phosphorylation across the intron-containing genes 
tested, though only significantly at amplicon 6 of ACT1 (exon 2), amplicon 2 of RPS13 
(exon 1) and amplicons 3 to 5 of ECM33 (3’SS-exon 2) (student’s t-test, P<0.05) 
(Figure 3.4B).  
 
ChIP-qPCR using an antibody against serine 5 phosphorylation of the CTD (S5P) 
showed the correct profile – a decline in this mark toward the 3’end of the gene relative 
to RNAPII occupancy. Depletion of Spt5 did not significantly alter the amount of S5P 
at the 5’end to the middle of the genes, however, at the very 3’end of the gene there 
was a significant increase in S5P on RPS13 on average to 172% at amplicon 6 (exon 
2) and on ECM33 on average to 124% at amplicon 5 (exon 2) (student’s t-test, P<0.05) 







Figure 3.4. Characterisation of the effect of Spt5 depletion on RNAPII occupancy, 
serine 2 and serine 5 phosphorylation of the CTD of RNAPII 
 
(A) Anti-Rpb1 (RNAPII), (B) anti-serine 2 phosphorylation (S2P) and (C) anti-serine 5 
phosphorylation (S5P) ChIP and qPCR across intron-containing genes ACT1, RPS13 and 
ECM33 without auxin or β-estradiol (blue) and with 40 minutes of auxin and β-estradiol 
addition to deplete Spt5-AID* (orange). The X-axis shows the positions of amplicons used for 
ChIP qPCR analysis – the exons are in grey. The Rpb1 ChIP data are presented as the mean 
percentage of input with respect to (W.R.T.) the first amplicon of each gene. The S2P and S5P 
ChIP data are relative to Rpb1 occupancy. Mean of at least 3 biological replicates. Error bars 
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3.4 Depletion of Spt5 reduces the co-transcriptional recruitment of the U5 snRNP 
without affecting earlier stages of co-transcriptional spliceosome assembly 
 
To determine whether the physical presence of Spt5 affects co-transcriptional 
spliceosome assembly, ChIP-qPCR was performed across intron-containing genes 
ACT1, RPS13 and ECM33 with and without depletion of Spt5 for 40 minutes. 
Antibodies were used that detect core members of the spliceosome: the U1 snRNP 
(Prp40), U2 snRNP (Lea1-3HA) and U5 snRNP (Prp8), which allowed a detailed 
picture of which stage, if any, of co-transcriptional spliceosome assembly may be 
affected by depletion of Spt5.  
 
In conditions without auxin or β-estradiol, the ChIP profile of U1, U2 and U5 was as 
expected – the U1 and U2 snRNPs peak near the 3’SS, and the U5 snRNP peaks 
downstream (toward the 3’end of the gene). ChIP-qPCR showed that depletion of Spt5 
did not significantly or consistently affect U1 or U2 snRNP occupancies where they 
peak (student’s t-test, P>0.05) (Figures 3.5A and 3.5B), relative to conditions without 
depletion. In contrast, depletion of Spt5 resulted in a significant reduction in U5 
snRNP occupancy to on average 43% where the U5 snRNP peaks on ACT1 (amplicon 
5, exon 2) (student’s t-test, P<0.05), 42% where the U5 snRNP peaks on RPS13 
(amplicon 5, exon 2) (student’s t-test, P<0.05) and 39% and 41% where the U5 snRNP 
peaks on ECM33 (amplicons 4 and 5, exon 2) (student’s t-test, P<0.05) (Figure 3.5C), 
relative to conditions without depletion. As recruitment of the U1 and U2 snRNP’s 
was unaffected, this suggests that the physical presence of Spt5 is not required for pre-
spliceosome assembly but is required for either the co-transcriptional recruitment or 
stable association of the U5 snRNP to form a pre-catalytically activated spliceosome 
(B complex). 
 
The loss of U5 snRNP occupancy upon Spt5 depletion could be explained by a 
reduction in the total cellular level of the U5 snRNP. To test this, western blotting was 
performed with an antibody against the U5 snRNP (Prp8) using extracts with and 
without 40 minutes of Spt5 depletion. The average cellular level of Prp8 after depletion 
of Spt5 was 113% relative to conditions without depletion, and this difference was not 
statistically significant (student’s t-test, P>0.05) (Figure 3.5D). 
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Figure 3.5. Depletion of Spt5 reduces the co-transcriptional recruitment of the U5 
snRNP without affecting earlier stages of co-transcriptional spliceosome assembly 
   
(A) Anti-Prp40 (U1 snRNP), (B) Anti-Lea1-HA (U2 snRNP) and (C) Anti-Prp8 (U5 snRNP) 
ChIP and qPCR across intron-containing genes ACT1, RPS13 and ECM33 without auxin or 
β-estradiol (blue) and with 40 minutes of auxin and β-estradiol addition to deplete Spt5-AID* 
(orange). The X-axis shows the positions of amplicons used for ChIP qPCR analysis – the 
exons are in grey. The ChIP data are presented as the mean percentage of input with respect 
to (W.R.T.) the first amplicon of each gene. Mean of at least 3 biological replicates. Error bars 


































































































































Figure 3.5 (continued). Depletion of Spt5 reduces the co-transcriptional recruitment of 
the U5 snRNP without affecting earlier stages of co-transcriptional spliceosome 
assembly 
 
(D) Western blot probed with anti-Prp8 (U5 snRNP), anti-FLAG and anti-PGK1 as a loading 
control. Samples were taken before (T0) and 40 minutes (T40) after addition of auxin and β-
estradiol. Prp8 was quantified and shown as the percentage mean of 3 biological replicates 
after 40 minutes of auxin and β-estradiol addition with respect to (W.R.T) time zero and 
normalised to the PGK1 signal. Error bars = standard error of the mean. 
 
 
3.5 Depletion of Spt5 affects pre-mRNA splicing 
 
Having observed an effect on the co-transcriptional recruitment of the U5 snRNP upon 
Spt5 depletion, it was next determined whether splicing catalysis was affected in these 
conditions. Splicing RT-qPCR was performed for transcripts of the intron-containing 
genes analysed by ChIP (ACT1, RPS13 and ECM33). Primers were used that detected 
pre-mRNA (3’SS or the BP), lariat (excised intron lariat or lariat-exon 2) and mRNA.  
 
An increase in 3’SS and BP signals are indicative of pre-mRNA accumulation and a 
first step splicing defect. Accumulation of the 3’SS and lariat only is indicative of a 
second step splicing defect (lariat-exon 2). Accumulation of the 3’SS, BP and lariat is 
indicative of a mixture of a first and second step splicing defect. Accumulation of lariat 
only (no pre-mRNA accumulation) is indicative of the excised intron-lariat that may 
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as it is a particularly difficult species to design primers for. All primers used were 
designed by David Barrass (Beggs lab). This RT-qPCR assay was used to determine 
which stage of splicing catalysis, if any, was affected by depletion of Spt5 for 40 
minutes (Figure 3.6A). 
 
RT-qPCR on total (steady state) RNA showed that depletion of Spt5 resulted in a 
significant accumulation of pre-mRNA species of ACT1 (BP and 3’SS), and a 
significant reduction in lariat, indicating a first step splicing defect (student’s t-test, 
P<0.05) (Figure 3.6B). ECM33 also significantly accumulated pre-mRNA (5’SS) upon 
Spt5 depletion, showing a defect in splicing catalysis (student’s t-test, P<0.05) (Figure 
3.6B). For RPS13, significant increases in pre-mRNA species (5’SS and 3’SS) were 
detected after depletion of Spt5, showing a defect in splicing catalysis (student’s t-test, 
P<0.05) (Figure 3.6B). No significant changes were detected in exon 2 levels for any 
of the genes analysed, indicating no effect on transcription upon Spt5 depletion (Figure 
3.6B).  
 
Overall, the splicing RT-qPCR data fit with the ChIP analysis (Figure 3.5) that Spt5 
depletion affects co-transcriptional recruitment of the U5 snRNP and B complex 







Figure 3.6. Depletion of Spt5 affects pre-mRNA splicing 
 
(A) Splicing RT-qPCR cartoon showing the primers used for the splicing RT-qPCR assay for 
an average gene. Primers used detected pre-mRNA (5’SS or BP and 3’SS), lariat (excised 
intron or intron-exon 2), exon 2 (ex 2) and mRNA.  
(B) RT-qPCR analysis of the intron-containing genes ACT1, RPS13 and ECM33 after 
depletion of Spt5-AID*. Normalised to the SCR1 PolIII transcript and time zero (without auxin 
and β-estradiol addition). Mean of at least 3 biological replicates. Error bars = standard error 
of the mean. 
 
3.6 Spt5 interacts with core members of the spliceosome 
 
It was possible that the effect of Spt5 depletion on co-transcriptional recruitment of 
the U5 snRNP was due to a physical interaction between Spt5 and the spliceosome in 
wild-type conditions. To test this, co-immunoprecipitation experiments were 
performed in which Spt5-AID*-6FLAG was pulled down using a FLAG antibody, 
followed by Western blotting using antibodies against core members of the 
spliceosome: the U1 snRNP (Prp40), U2 snRNP (Lea1-3HA) and U5 snRNP (Prp8). 
Interaction between Spt5-AID*-6FLAG and the U5 snRNP was detected by western 
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addition of RNase did not affect the co-immunoprecipitation (Figures 3.7A and 3.7B). 
No pull down of Prp8 was detected using a control strain with untagged Spt5, meaning 
the co-immunoprecipitation was specific. No interaction was detected between Spt5-
AID*-6FLAG and the U1 snRNP (Figure 3.7B) or the U2 snRNP proteins (Figure 
3.7C).  
 
It was possible that the interactions detected between Prp8 and Spt5 was indirect, via 
RNAPII. To test this, co-immunoprecipitation experiments were performed in which 
the U1 snRNP (Prp40), U2 snRNP (Lea1-3HA) and U5 snRNP (Prp8) were each 
pulled down, and western blotting performed using a FLAG antibody to detect Spt5-
AID*-6FLAG, and an antibody against RNAPII (Rpb1). Under these conditions, the 
U1, U2 and U5 snRNPs each pulled-down Spt5-AID*-6FLAG (Figure 3.7D) but with 
different efficiencies – the U2 and U5 snRNPs pulled down more Spt5-AID*-6FLAG 
than the U1 snRNP. These differences are not explained by differences in protein 
abundance, since the predicted number of molecules/cell of each Prp40, Lea1 and Prp8 
were similar (372, 203 and 225 respectively (Kulak et al., 2014)) and each was well 
immunoprecipitated (Figures 3.7D-3.7F). In theory, this could be due to the different 
antibodies used or the different snRNP affinities for Spt5. 
 
An interaction between the U2 snRNP and Rpb1 was detected (Figure 3.7E). No 
interaction between the U1 snRNP or U5 snRNP with Rpb1 was detected (Figure 
3.7E). This indicates that the co-immunoprecipitation between the U2 snRNP and Spt5 
that was detected could be indirect, via RNAPII. As the U1 snRNP and U5 snRNP co- 
immunoprecipitate Spt5 without RNAPII, these interactions may be more specific. 
Overall, the most consistent (reciprocal) interaction was detected between the U5 
snRNP and Spt5, though I cannot rule out interactions with other splicing factors that 










Figure 3.7. Spt5 interacts with core members of the spliceosome  
 
(A) Western blots from a co-immunoprecipitation experiment in which Spt5-AID*-6FLAG was 
pulled down using a FLAG antibody with (lane 3) or without RNase (lane 5). Additionally, a 
strain with no flag-tagged Spt5 was used as a negative control (lane 8). Input (lanes 1, 6), non-
bound (lanes 2, 4, 7) and immunoprecipitation (IP) (lanes 3, 5, 8) samples were loaded. The 
blot was probed with an antibody against Prp8 (U5 snRNP). Prp8 is indicated by the blue 
asterisk.  
(B) The blot in (A) was re-probed with a FLAG antibody to show that Spt5-AID*-6FLAG was 
successfully pulled-down in this assay. Spt5-AID*-6FLAG is indicated by the red asterisk. The 
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Figure 3.7 (continued). Spt5 interacts with core members of the spliceosome  
 
(C) The blot was also re-probed with an antibody against HA (Lea1; U2 snRNP), indicated by 
the orange asterisk. 
(D) Western blot from co-immunoprecipitation experiments in which the U1 snRNP (Prp40) 
(lane 3), U2 snRNP (Lea1-HA) (lane 6) and U5 snRNP (Prp8) (lane 9) were each pulled down 
using the indicated antibodies in the Spt5-AID*-6FLAG strain. Additionally, a negative rabbit 
IgG control was included in which rabbit IgG was used for a pull-down in the Spt5-AID*-6FLAG 
strain (lane 12). Input (lanes 1, 4, 7, 10) non-bound (lanes 2, 5, 8, 11) and immunoprecipitation 
(IP) (lanes 3, 6, 9, 12) samples were loaded. The blot was probed with antibodies against Prp8 
(U5 snRNP) and FLAG (Spt5-AID*-6FLAG). Prp8 is indicated by the blue asterisk. Spt5-AID*-
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Figure 3.7 (continued). Spt5 interacts with core members of the spliceosome  
 
(E) The blot in (D) was washed and re-probed with antibodies against Rpb1 (RNAPII) and HA 
(Lea1). Rpb1 is indicated by the black asterisk. Lea1-HA is indicated by the orange asterisk.  
(F) The blot in (D) was re-probed with an antibody against Prp40 (U1 snRNP). Prp40 is 
indicated by the green Asterisk. 
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3.7 Use of the AID system to conditionally deplete the Bur1/2 complex 
 
The CTR of Spt5 is phosphorylated by the Bur1/2 complex in S. cerevisiae (Liu et al., 
2009). Bur1 is the essential cyclin-dependent kinase and Bur2 is its non-essential 
cyclin by homology to other cyclins - although its expression does not cycle (Yao et 
al., 2000). To determine whether the effect of loss of Spt5 is equivalent to loss of its 
phosphorylation, and whether Bur1/2 play a role in co-transcriptional spliceosome 
assembly, Bur1 and Bur2 were each C-terminally AID*-tagged in a strain that 
constitutively expressed Tir1 that allowed their conditional depletion in the presence 
of auxin (described in section 3.1). Both Bur1 and Bur2 were analysed to allow one to 
distinguish specifically whether it is the physical presence of Bur1 or its kinase activity 
that is important for any observations made.  Experiments were performed with or 
without 30 minutes of auxin treatment. 
 
The effect of the tag on function of Bur1 and Bur2, and auxin-sensitivity, was assessed 
by growth analyses of the parental strain (W303-OsTIR) with no AID* tag and the 
Bur1-AID* and Bur2-AID* strains with or without auxin addition (Figure 3.8A). In 
the absence of auxin, the Bur1-AID* and Bur2-AID* strains grew comparably to the 
parental strain, indicating that the AID* tag does not affect Bur1 or Bur2 function. 
After auxin addition, the Bur1-AID* and Bur2-AID* strains each grew slightly more 
slowly than the parental strain. The effect on growth observed upon Bur1 depletion 
was less severe than expected, as Bur1 is essential.  
 
Western blotting showed that 30 minutes of auxin treatment significantly reduced the 
level of Bur1 and Bur2 on average to 12% each relative to conditions prior to auxin 
treatment (student’s t-test, P<0.05) (Figure 3.8B). It is estimated that Bur1 is present 
at approximately 1056 molecules/cell, and Bur2 at approximately 682 molecules/cell, 
giving approximately 127 molecules/cell of Bur1 and 82 molecules/cell of Bur2 
remaining after auxin treatment (Kulak et al., 2014). 
 
ChIP-qPCR analyses showed that, in addition to being depleted in whole cell extracts, 
Bur1 and Bur2 were both well depleted across the intron-containing genes ACT1, 
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RPS13 and ECM33 in response to auxin (Figure 3.8C). Bur1 was significantly depleted 
on average to 66% across ACT1, 67% across RPS13 and 46% across ECM33 (student’s 
t-test, P<0.05). Bur2 was significantly depleted on average to 50% across each of 
ACT1 and RPS13 and 58% across ECM33, relative to conditions prior to depletion 
(student’s t-test, P<0.05). 
 
To test whether depletion of Bur2 affects either the protein level or the recruitment of 
Bur1 to genes, Bur1 was C-terminally V5 epitope tagged in the Bur2-AID* strain. 
Western blotting showed that depletion of Bur2 did not significantly affect the total 
cellular level of Bur1 (101% relative to conditions prior to Bur2 depletion) (student’s 
t-test, P>0.05) (Figure 3.8D). ChIP-qPCR showed that depletion of Bur2 did not 
significantly change Bur1-V5 occupancy across intron containing genes ACT1, RPS13 
and ECM33 (student’s t-test, P>0.05), relative to conditions prior to depletion (Figure 
3.8E). Depletion of Bur2 was therefore a suitable way to distinguish whether the 
physical presence of Bur1 or its kinase activity was responsible for any changes 




















Figure 3.8. Use of the AID system to conditionally the Bur1/2 complex 
 
(A) Growth (OD600) of the control parental strain (W303-OsTIR; no AID*-tagged proteins; 
black), Bur1-AID*-tagged strain (red) and Bur2-AID*-tagged (blue) strain was measured over 
a period of 17 hours without auxin (-) or with auxin (+). Mean of three biological replicates.  
(B) Western blot probed with anti-FLAG and anti-Pgk1 as a loading control. Samples were 
taken before (T0) and 30 minutes (T30) after addition of auxin. The depletion of Bur1-AID* 
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replicates after 30 minutes of addition with respect to (W.R.T) T0 and normalised to the PG1 
signal. Error bars = standard error of the mean. 
(C) Anti-FLAG ChIP followed by qPCR analysis of the intron-containing genes: ACT1, RPS13, 
ECM33 0 minutes (- auxin; blue) and 30 minutes (+ auxin; orange) after auxin addition to 
deplete Bur1-AID* or Bur2-AID*. The X-axis shows the positions of amplicons used for ChIP 
qPCR analysis – the exons are in grey. The data are presented as the mean percentage of 
input with respect to (W.R.T.) the first amplicon of each gene. Mean of at least three biological 




Figure 3.8 (continued). Use of the AID system to conditionally the Bur1/2 complex 
 
(D) Western blot probed with anti-V5 and anti-Pgk1 as a loading control. Samples were taken 
before (T0) and 30 minutes (T30) after addition of auxin to deplete Bur2-AID* in a strain in 
which Bur1 was V5 tagged. The amount of Bur1-V5 was quantified and shown as the 
percentage mean of 3 biological replicates at T0 with respect to (W.R.T) T0 and normalised 
to the Pgk1 signal. Error bars = standard error of the mean. 
(E) Anti-V5 ChIP followed by qPCR analysis of the intron-containing genes: ACT1, RPS13, 
ECM33 at T0 (- auxin; blue) and after 30 minutes (+ auxin; orange) of auxin treatment to 
deplete Bur2-AID*. The X-axis shows the positions of amplicons used for ChIP qPCR analysis 
– the exons are in grey. The data are presented as the mean percentage of input with respect 
to (W.R.T.) the first amplicon of each gene. Mean of at least three biological replicates. Error 
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3.8 Depletion of Bur1 and Bur2 reduces Spt5 phosphorylation, without reducing 
serine 2 or serine 5 phosphorylation of the CTD of RNAPII 
 
To determine whether depletion of Bur1 or Bur2 for 30 minutes was an appropriate 
amount of time to reduce Spt5 phosphorylation, western blotting was performed using 
an antibody specific to the phosphorylated form of Spt5 (gift from Prof. Steven Hahn 
(Liu et al., 2009)) and an antibody specific to the central region of Spt5 (kind gift from 
Prof. Grant Hartzog (Hartzog et al., 1998)). Additionally, western blotting was 
performed using antibodies against serine 2 (S2P) or serine 5 (S5P) phosphorylated 
forms of the CTD of RNAPII to determine any effects on these CTD phosphorylation 
states upon Bur1 or Bur2 depletion. The quantitation of the S2P or S5P phosphorylated 
forms of the CTD were normalised to Rpb3, a subunit of RNAPII, to account for 
potential differences in the amount of RNAPII upon depletion of Bur1 or Bur2. 
 
Western blotting showed that depletion of Bur1 or Bur2 for 30 minutes resulted in a 
significant reduction in Spt5 phosphorylation on average to 18% and 5% respectively, 
relative to conditions prior to auxin addition and to total Spt5 (student’s t-test, P<0.05) 
(Figure 3.9A). Western blotting showed that depletion of Bur1 or Bur2 for 30 minutes 
resulted in serine 2 phosphorylation levels increasing to, on average, 120% and 117% 
respectively, relative to conditions prior to auxin addition and to Rpb3 (Figure 3.9B). 
Only the increase after depletion of Bur1 was significant (student’s t-test, P<0.05) 
(Figure 3.9B). Serine 5 phosphorylation levels increased significantly to, on average, 
to 141% and 123% after depletion of Bur1 and Bur2 respectively relative to conditions 
prior to auxin addition and to Rpb3 (student’s t-test, P<0.05) (Figure 3.9C). Depletion 
of Bur1 and Bur2 for 30 minutes was therefore a suitable amount of time to reduce 










Figure 3.9. Depletion of Bur1 and Bur2 reduces Spt5 phosphorylation, without reducing 
serine 2 or serine 5 phosphorylation of the CTD of RNAPII 
 
(A) Western blot probed with antibodies against phosphorylated Spt5 (anti-Spt5-P), anti-Spt5, 
anti-FLAG and anti-Rpb3 (RNAPII; as a loading control). Samples were taken before (T0) and 
30 minutes (T30) after addition of auxin to deplete Bur1-AID* or Bur2-AID*. Spt5 
phosphorylation levels were quantified after depletion of Bur1-AID* (red) or Bur2-AID* (blue) 
and shown as the percentage mean of 3 biological replicates after 30 minutes of auxin 
treatment with respect to (W.R.T) time zero and normalised to Spt5 signal.  
(B) Western blot probed with anti-serine 2 phosphorylation (S2P) and anti-Rpb3 (RNAPII) as 
a loading control. Samples were taken before (T0) and 30 minutes (T30) after addition of auxin 
to deplete Bur1-AID* or Bur2-AID*. Serine 2 phosphorylation levels were quantified after 
depletion of Bur1-AID* (red) and Bur2-AID* (blue) and shown as the percentage mean of 3 
biological replicates after 30 minutes of auxin addition with respect to (W.R.T) time zero and 
normalised to Rpb3 signal.  
(C) Western blot probed with anti-serine 5 phosphorylation (S5P) and anti-Rpb3 (RNAPII) as 
a loading control. Samples were taken before (T0) and 30 minutes (T30) after addition of auxin 
to deplete Bur1-AID* or Bur2-AID*. Serine 5 phosphorylation levels were quantified after 
depletion of Bur1-AID* (red) and Bur2-AID* (blue) and shown as the percentage mean of 3 
biological replicates after 30 minutes of auxin addition with respect to (W.R.T) time zero and 
normalised to Rpb3 signal.  
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3.9 Characterisation of the effects of depletion of Bur1/2 on RNAPII occupancy, 
serine 2 and serine 5 phosphorylation of the CTD of RNAPII 
 
To determine whether the depletion of Bur1 or Bur2 in these conditions affects the 
occupancy or phosphorylation status of RNAPII, ChIP was performed using 
antibodies against total RNAPII (Rpb1), phosphorylated serine 2 (S2P) or 
phosphorylated serine 5 (S5P) of the CTD followed by qPCR across intron-containing 
genes ACT1, RPS13 and ECM33. Depletion of Bur1 for 30 minutes did not 
significantly affect RNAPII occupancy across ACT1, RPS13 or ECM33 (student’s t-
test, P>0.05), relative to conditions prior to depletion (Figure 3.10A). Depletion of 
Bur2 did not significantly affect RNAPII occupancy across ACT1 (student’s t-test, 
P>0.05), however there was a small but significant reduction in RNAPII occupancy 
after depletion of Bur2 on RPS13 on average to 63% and 68% at amplicons 2 and 3 
(exon 1 and intron) and on ECM33 on average to 78% and 90% at amplicons 2 and 3 
(exon 1 and exon 2) (student’s t-test, P<0.05), relative to conditions prior to depletion 
(Figure 3.10D).  
 
Neither depletion of Bur1 nor depletion of Bur2 significantly affected serine 2 (S2P) 
or serine 5 (S5P) phosphorylation of the CTD of RNAPII across the intron-containing 
genes ACT1, RPS13 or ECM33 (student’s t-test, P>0.05), relative to conditions prior 
to depletion (Figures 3.10B, 3.10C, 3.10E, 3.10F). The lack of reduction in serine 2 
phosphorylation of the CTD of RNAPII observed by western blotting (Figure 3.9) and 
ChIP upon depletion of Bur1 and Bur2 was surprising, as deletion of Bur2 and 
inhibition of Bur1 activity were reported to reduce the level of serine 2 
phosphorylation by western blotting and by ChIP (Liu et al., 2009; Qiu et al., 2009; 










Figure 3.10. Characterisation of the effects of depletion of Bur1/2 on RNAPII occupancy, 
serine 2 and serine 5 phosphorylation of the CTD of RNAPII 
 
(A, D) Anti-Rpb1 (RNAPII), (B, E) anti-serine 2 phosphorylation (S2P) and (C, F) anti-serine 5 
phosphorylation (S5P) ChIP and qPCR across intron-containing genes ACT1, RPS13 and 
ECM33 without auxin (T0; blue) and after 30 minutes of auxin treatment to deplete Bur1-AID* 
(T30; orange; A, B, C) and Bur2-AID* (T30; orange; D,E,F). The X-axis shows the positions of 
amplicons used for ChIP qPCR analysis – the exons are in grey. The Rpb1 ChIP data are 
presented as the mean percentage of input with respect to (W.R.T.) the first amplicon of each 
gene. The S2P and S5P ChIP data are relative to Rpb1 occupancy.  








































































































































Figure 3.10 (continued). Characterisation of the effects of depletion of Bur1/2 on RNAPII 
occupancy, serine 2 and serine 5 phosphorylation of the CTD of RNAPII 
 
(A, D) Anti-Rpb1 (RNAPII), (B, E) anti-serine 2 phosphorylation (S2P) and (C, F) anti-serine 5 
phosphorylation (S5P) ChIP and qPCR across intron-containing genes ACT1, RPS13 and 
ECM33 without auxin (T0; blue) and after 30 minutes of auxin treatment to deplete Bur1-AID* 
(T30; orange; A, B, C) and Bur2-AID* (T30; orange; D,E,F). The X-axis shows the positions of 
amplicons used for ChIP qPCR analysis – the exons are in grey. The Rpb1 ChIP data are 
presented as the mean percentage of input with respect to (W.R.T.) the first amplicon of each 
gene. The S2P and S5P ChIP data are relative to Rpb1 occupancy.  
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3.10 Depletion of Bur1 causes co-transcriptional accumulation of the U2 and U5 
snRNPs 
 
To determine whether depletion of Bur1 or Bur2 in these conditions affects co-
transcriptional spliceosome assembly, ChIP-qPCR was performed across intron-
containing genes ACT1, RPS13 and ECM33 with or without depletion of Bur1 or Bur2 
for 30 minutes. Antibodies were used that detect core members of the spliceosome: 
the U1 snRNP (Prp40), U2 snRNP (Lea1-3HA) and U5 snRNP (Prp8), which allowed 
a detailed picture of which stage, if any, of co-transcriptional may be affected by loss 
of Bur1 or Bur2. 
 
ChIP-qPCR analysis showed that depletion of Bur1 did not significantly affect U1 
snRNP occupancy across the intron-containing genes tested (student’s t-test, P>0.05) 
(Figure 3.11A). In contrast, the U2 snRNP significantly accumulated on average to 
190% and 124% on ACT1 (amplicons 3 and 4, 3’SS and exon 2) and 198% on ECM33 
(amplicon 3, 3’SS), relative to conditions prior to depletion (student’s t-test, P<0.05) 
(Figure 3.11B). Depletion of Bur1 also caused the U5 snRNP to significantly 
accumulate on average to 184% on ACT1 (amplicon 4, exon 2), 186% and 174% on 
RPS13 (amplicons 4 and 5, 3’SS and exon 2) and 190% on ECM33 (amplicon 4, exon 
2) (student’s t-test, P<0.05), relative to conditions prior to depletion (Figure 3.11C). 
 
Depletion of Bur2 did not significantly affect U1 snRNP occupancy across ACT1 or 
ECM33, however across RPS13 U1 snRNP occupancy was significantly reduced on 
average to 74.8%, relative to conditions prior to depletion (student’s t-test, P<0.05) 
(Figure 3.11D). Depletion of Bur2 resulted in a significant accumulation of the U2 
snRNP on ACT1 on average to 130% (amplicon 3, 3’SS) and on ECM33 to 130% 
(amplicon 3, 3’SS) (student’s t-test, P<0.05), relative to conditions prior to depletion 
(Figure 3.11E). In contrast, the U2 snRNP was significantly reduced on average to 
81.4% across RPS13 upon Bur2 depletion (student’s t-test, P<0.05), relative to 
conditions prior to depletion (Figure 3.11E). Depletion of Bur2 caused the U5 snRNP 
to significantly accumulate on average to 243% on ACT1 (amplicon 4, exon 2) and 
146% on ECM33 (amplicon 4, exon 2), relative to conditions prior to depletion 
(student’s t-test, P<0.05) (Figure 3.11F). Depletion of Bur2 did not significantly affect 
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the occupancy of the U5 snRNP across RPS13, relative to conditions prior to depletion 
(student’s t-test, P>0.05) (Figure 3.11F).  
 
In summary, a similar phenotype of U2 and U5 snRNP accumulation was observed at 
least on ACT1 and ECM33 upon Bur1 and Bur2 depletion. Not only did the U2 and 
U5 snRNPs accumulate on these genes, but they peaked earlier, indicating co-
transcriptional spliceosome assembly is faster in the absence of Bur1. As the U2 and 
U5 snRNPs accumulated on ACT1 and ECM33 and not RPS13 upon Bur2 depletion, 
this means the effect of Bur1/2 depletion on co-transcriptional spliceosome assembly 
is gene-specific. Further, as the effect of Bur2 depletion appears less severe than the 
effect of Bur1 depletion, it may that Bur1 has some residual kinase activity without 
Bur2 or have Bur2-independent substrates that are important for this phenotype. There 
is precedent for this as Bur1 is essential whereas Bur2 is non-essential (Yao et al., 
2000). 
 
The effects on co-transcriptional spliceosome assembly observed after depletion of 
Bur1 and Bur2 are very different to the effects of Spt5 depletion (Figure 3.5). 
Therefore, the loss of phosphorylation of the CTR of Spt5 is not responsible for the 





















Figure 3.11. Depletion of Bur1 causes co-transcriptional accumulation of the U2 and 
U5 snRNPs  
 
(A, D) Anti-Prp40 (U1 snRNP) (B, E) Anti-Lea1-HA (U2 snRNP) and (C, F) Anti-Prp8 (U5 
snRNP) ChIP followed by qPCR analysis of the intron-containing genes: ACT1, RPS13, 
ECM33 0 minutes (no auxin; blue) and after 30 minutes (orange) of auxin addition to deplete 
Bur1-AID* (A-C) and Bur2-AID* (D-F). The X-axis shows the positions of amplicons used for 
ChIP qPCR analysis – the exons are in grey. The data are presented as the mean percentage 
of input with respect to (W.R.T.) the first amplicon of each gene. 
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Figure 3.11 (continued). Depletion of Bur1 causes co-transcriptional accumulation of 
the U2 and U5 snRNPs  
 
(A, D) Anti-Prp40 (U1 snRNP) (B, E) Anti-Lea1-HA (U2 snRNP) and (C, F) Anti-Prp8 (U5 
snRNP) ChIP followed by qPCR analysis of the intron-containing genes: ACT1, RPS13, 
ECM33 0 minutes (no auxin; blue) and after 30 minutes (orange) of auxin addition to deplete 
Bur1-AID* (A-C) and Bur2-AID* (D-F). The X-axis shows the positions of amplicons used for 
ChIP qPCR analysis – the exons are in grey. The data are presented as the mean percentage 
of input with respect to (W.R.T.) the first amplicon of each gene. 
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3.11 Depletion of Bur1 increases co-transcriptional spicing efficiency 
 
The accumulation of the U2 and U5 snRNP’s at ACT1 and ECM33 after depletion of 
Bur1 or Bur2 could be explained in three ways. Firstly, as U1 snRNP occupancy is 
normal upon Bur1/2 depletion, that there is a block to the progression of co-
transcriptional spliceosome assembly at the formation of the catalytically activated 
spliceosome (Bact complex) onwards and that complexes get stuck at the gene. 
Secondly, Bact formation and later steps in the splicing cycle might occur faster and 
more efficiently in the absence of Bur1. Thirdly, RNAPII elongates more slowly 
(could be pausing more frequently or for longer periods of time) and so the snRNPs 
are detected better by ChIP.  If there was a block to progression of co-transcriptional 
spliceosome assembly, defects in splicing catalysis would be predicted and if the Bact 
complex forms more efficiently, perhaps splicing catalysis would be more efficient. 
To distinguish between these two possibilities, RT-qPCR was performed on total 
(steady-state) RNA (as described in section 3.5) upon depletion of Bur1 or Bur2. RT-
qPCR showed that Bur1 depletion significantly reduced the 3’SS and BP pre-mRNA 
species of ACT1, in addition to the lariat (student’s t-test, P<0.05), whilst the mRNA 
and exon 2 levels did not significantly change (student’s t-test, P>0.05) (Figure 
3.12A). For ECM33, Bur1 depletion significantly reduced the 3’SS (student’s t-test, 
P<0.05) and did not change the levels of the 5’SS, mRNA or exon 2 (student’s t-test, 
P>0.05) (Figure 3.12A). No significant change in pre-mRNA species were detected 
for RPS13 upon Bur1 depletion (student’s t-test, P>0.05), however the mRNA and 
exon 2 levels were significantly reduced (P<0.05) (Figure 3.12A). In contrast, no 
significant reduction in pre-mRNA levels were observed for ACT1, RPS13 or ECM33 
upon Bur2 depletion (student’s t-test, P>0.05) (Figure 3.12B). The only significant 
difference upon Bur2 depletion was an increase in exon 2 levels of ACT1 and the 5’SS 
of ECM33 (student’s t-test, P<0.05) (Figure 3.12B) indicating increased levels of gene 
transcription. 
 
Next, the effect of Bur1 depletion on co-transcriptional splicing was tested by NET-
RT-qPCR using the same primers described previously (section 3.5). NET-RT-qPCR 
showed a significant reduction in 3’SS, BP and lariat species associated with RNAPII 
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co-transcriptionally upon Bur1-AID* depletion for ACT1 (student’s t-test, P<0.05), 
whilst the exon 2 and mRNA signals did not significantly change (student’s t-test, 
P>0.05) (Figure 3.12C). For ECM33, Bur1-AID* depletion significantly reduced the 
amount of 3’SS associated with RNAPII (student’s t-test, P<0.05), significantly 
increase amount of mRNA associated with RNAPII (student’s t-test, P<0.05) and did 
not significantly change the levels of the 5’SS, mRNA or exon 2 associated with 
RNAPII (student’s t-test, P>0.05) (Figure 3.12C). No significant changes were 
detected in pre-mRNA, mRNA or exon 2 levels of RPS13 associated with RNAPII 
upon Bur1-AID* depletion (student’s t-test, P>0.05) (Figure 3.12C). As exon 2 levels 
did not significantly change, Bur1 depletion does not cause a transcription defect on 
ACT1, ECM33 or RPS13. 
 
Together, the total RNA RT-qPCR and NET-RT-qPCR experiments agree. A 
reduction in pre-mRNA (BP) and the products of the first step of splicing (3’SS and 
lariat) was observed for ACT1, without significant changes to mRNA or exon 2 levels, 
suggesting pre-mRNA is spliced faster. For ECM33, the 5’SS, exon 2 or mRNA 
species do not significantly change, however the 3’SS is significantly reduced, 
suggesting that the second step of pre-mRNA splicing may be faster. This indicates 
that different steps of splicing are more efficient upon Bur1 depletion for these genes. 
This effect is gene-specific, as it was not observed for RPS13, which fits with the ChIP-
qPCR data where the U2 snRNP did not accumulate on RPS13 (Figure 3.11). This is 
consistent with the idea that Bact complex formation and progression past it in the 
spliceosome cycle is more efficient, rather than a block to the progression of co-
transcriptional spliceosome assembly. As the exon 2 levels associated with RNAPII 
did not significantly change (by NET-RT-qPCR), this would suggest that RNAPII 
does not pause more upon Bur1 depletion. The splicing RT-qPCR analysis of total 
RNA upon Bur1 and Bur2 depletion did not agree, with only depletion of Bur1 
increasing co-transcriptional splicing efficiency. Again, these differences between 
Bur1 depletion and Bur2 depletion can be explained by the fact that when Bur2 is 
depleted, the co-transcriptional recruitment of Bur1 was unaffected, and Bur1 may 





Figure 3.12. Depletion of Bur1 increases co-transcriptional pre-mRNA spicing efficiency  
 
RT-qPCR analysis of total RNA from the intron-containing genes ACT1, RPS13 and ECM33 
after depletion of Bur1-AID* (A) or Bur2-AID* (B). Normalised to the SCR1 PolIII transcript and 
time zero (no auxin). 
(C) NET-RT-qPCR analysis of the intron-containing genes ACT1, RPS13 and ECM33 after 
depletion of Bur1-AID*. Normalised to the intronless ALG9 PolII transcript and time zero 
(before auxin addition).  
Primers used detected pre-mRNA (5’SS or BP and 3’SS), lariat (excised intron or intron-exon 
2), exon 2 (ex 2) and mRNA (see figure 3.6A for cartoon).  
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3.12 Loss of Spt5 phosphorylation resembles depletion of Bur1 and Bur2  
 
Bur1 phosphorylates the first serine of the hexapeptide repeats of the CTR of Spt5 (Liu 
et al., 2009). To test whether the effect of Bur1-AID* and Bur2-AID* depletion is due 
to the loss of the phosphorylation to the CTR of Spt5 (and not another Bur1 substrate), 
Spt5 phosphomimetic and phosphomutants were used (these strains were a kind gift 
from Prof. Alan Hinnebusch (Liu et al., 2009; Qiu et al., 2012)). In the 
phosphomimetic Spt5, the first serine of each hexapeptide was mutated to glutamic 
acid (E). In the phosphomutant of Spt5, the first serine of each hexapeptide 
(S[T/A]WGG[Q/A]) was mutated to alanine (A) (Liu et al., 2009; Qiu et al., 2012). 
 
ChIP using antibodies that detect core members of the spliceosome: U1 snRNP 
(Prp40), U2 snRNP (Lea1-V5) and U5 snRNP (Prp8) was performed in strains 
containing either wild-type Spt5 (WT), phosphomutant Spt5 (S->A) or 
phosphomimetic Spt5 (S->E). Additionally, ChIP was performed using an antibody 
against RNAPII (Rpb1) to test for any differences in RNAPII occupancy between the 
wild-type and mutant strains. 
 
ChIP-qPCR analysis across intron-containing genes ACT1, RPS13 and ECM33 
showed no significant change in RNAPII or U1 snRNP occupancy between WT, S-
>A or S->E Spt5 (student’s t-test, P>0.05) (Figures 3.13A and 3.13B). The U2 snRNP 
significantly accumulated on ACT1 to 176% at amplicon 4 (exon 2), ECM33 to 176% 
at amplicon set 3 (3’SS) and to 170% at amplicon 5 (exon 2) on RPS13, relative to WT 
(student’s t-test, P>0.05) (Figure 3.13C). 
 
The U5 snRNP showed a significant increase in occupancy on ACT1 in the Spt5 
phosphomutant (S->A) on average relative to WT to 157%, 165% and 127% at 
amplicons 3, 4 and 5 (3’SS-exon 2) (student’s t-test, P<0.05), respectively, whilst the 
Spt5 phosphomimetic (S->E) did not significantly change relative to WT (student’s t-
test, P>0.05) (Figure 3.13D). The U5 snRNP also increased significantly in occupancy 
in the Spt5 phosphomutant (S->A) on RPS13 at amplicon 4 (3’SS) on average to 164% 
relative to WT (student’s t-test, P<0.05), with no significant changes observed with 
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the phosphomimetic (S->E) relative to WT (student’s t-test, P>0.05) (Figure 3.13D). 
For ECM33, the U5 snRNP also increased significantly in occupancy in the Spt5 
phosphomutant (S->A) at amplicon 3 (3’SS) on average by 163% relative to WT 
(student’s t-test, P<0.05), with no significant changes observed with the 
phosphomimetic (S->E) relative to WT (student's t-test, P>0.05) (Figure 3.13D). 
 
Next, the effect of Spt5 phosphomimetic/phosphomutant mutations on splicing was 
tested by RT-qPCR on total (steady-state) RNA (as described in section 3.5) (Figure 
3.13E). RT-qPCR showed no significant changes between phosphomimetic or 
phosphomutant Spt5 relative to WT Spt5. Both Spt5 mutants showed significant 
increases in mRNA levels for ACT1 and RPS13 (student’s t-test, P<0.05) (not 
ECM33). There were no consistent changes in pre-mRNA species. No significant 
changes were observed in pre-mRNA species for each mutant relative to WT Spt5 
(student’s t-test, P>0.05), there was a significant reduction in the 5’SS species of 
RPS13 for both mutants relative to WT Spt5 (student’s t-test, P<0.05), and there was 
a significant increase in the 5’SS species of ECM33 for both mutants relative to WT 
Spt5 (student’s t-test, P<0.05) 
 
The accumulation of the U5 snRNP in the Spt5 S->A phosphomutant relative to wild-
type conditions resembles depletion of Bur1 and Bur2, which fits nicely, as Bur1 and 
Bur2 depletion abolish Spt5 phosphorylation (Figures 3.9 and 3.11). The effects of the 
Spt5 phosphomutant on co-transcriptional spliceosome assembly are milder than 
depletion of Bur1, which is analogous to the effects of depletion of Bur2 on co-
transcriptional spliceosome assembly being milder to depletion of Bur1. No consistent 
changes in pre-mRNA species were observed by RT-qPCR for the Spt5 
phosphomimetic/phosphomutant strains relative to the WT Spt5 strain, and relative to 
each other no significant differences – again, analogous to depletion of Bur2. The ChIP 
data further agrees with the idea that the loss of phosphorylation of the CTR of Spt5 
is not responsible for the loss of U5 snRNP recruitment observed upon Spt5 depletion 
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Figure 3.13. Loss of Spt5 phosphorylation resembles depletion of Bur1 and Bur2 
 
(A) Anti-Rpb1 (RNAPII), (B) Anti-Prp40 (U1 snRNP), (C) Anti-Lea1-HA (U2 snRNP) and (D) 
Anti-Prp8 (U5 snRNP) ChIP followed by qPCR analysis of the intron-containing genes: ACT1, 
RPS13, ECM33 in strains expressing either wild-type (WT, blue) Spt5, Spt5 phosphomutant 
(S->A, orange) or Spt5 phosphomimetic (S->E, grey). The X-axis shows the positions of 
amplicons used for ChIP qPCR analysis – the exons are in grey. The data are represented as 
the mean percentage of input with respect to (W.R.T.) the first amplicon of each gene. 
(E) Splicing RT-qPCR analysis of the intron-containing genes ACT1, RPS13 and ECM33 in 
strains expressing either Spt5 phosphomutant (S->A, orange) or Spt5 phosphomimetic (S->E, 
grey). Normalised to the SCR1 PolIII transcript and WT Spt5. Primers used detected pre-
mRNA (5’SS or BP and 3’SS), lariat (excised intron or intron-exon 2), exon 2 (ex 2) and mRNA 
(see figure 3.6A for cartoon). Mean of at least 3 biological replicates. Error bars = standard 
error of the mean. 
All data (A-E): mean of at least 3 biological replicates, error bars = standard error of the mean.  
  
21



















































5'SS mRNA 3'SS EXON 2
Spt5 S->A Spt5 S->E
mRNA   3’SS    BP    Lariat   Ex 2 5’ S     mRNA    ’       Ex 2 5’ S     mRNA    3’SS      Ex 2
Figure 3.13. Loss of Spt5 phosphorylation resembles depletion of Bur1 and Bur2
 
 107 
3.13 Use of the AID system to conditionally deplete Ctk1 
 
In S. cerevisiae, Ctk1 is the major yet non-essential serine 2 CTD kinase of RNAPII 
(Cho et al., 2001). In the present work, Ctk1 was C-terminally AID*-tagged to enable 
conditional depletion using the AID system in order to determine whether serine 2 
phosphorylation of the CTD plays an important role in co-transcriptional spliceosome 
assembly and splicing in vivo in S. cerevisiae (described in section 3.1). Additionally, 
as Bur1 is proposed to augment the phosphorylation of Ctk1 and phosphorylate serine 
2 of the CTD at the 5’ end of genes (Qiu et al., 2009), depletion of Ctk1 served as a 
control for the effects on co-transcriptional spliceosome assembly and splicing 
observed upon Bur1 depletion. 
 
The effect of the AID* tag on Ctk1 function and auxin-sensitivity were assessed by 
growth analyses of the parental strain (W303-OsTIR) with no AID* tag and the Ctk1-
AID* strain with or without auxin treatment (Figure 3.14A). In the absence of auxin, 
the Ctk1-AID* strain grew comparably to the parental strain, indicating that the AID* 
tag does not affect Ctk1 function. After auxin addition, the Ctk1-AID* strain grew 
more slowly than the parental strain. Though Ctk1 is non-essential, its deletion has 
multiple phenotypes, including decreased anaerobic growth (Samanfar et al., 2013). 
 
Western blotting showed that depletion of Ctk1-AID* for 30 minutes resulted on 
average in a significant reduction to 12% of Ctk1 left relative to cells with no depletion 
(student’s t-test, P<0.05) (Figure 3.14B). It is estimated that Ctk1 is present at 
approximately 471 molecules/cell (Kulak et al., 2014), and therefore there may be 
approximately 57 molecules/cell of Ctk1 left after 30 minutes of auxin treatment.  
 
ChIP-qPCR analyses showed that, in addition to being depleted in whole cell extracts, 
Ctk1-AID* was significantly depleted on average to 60% across ACT1, 68% across 
RPS13 and 59% across ECM33 after 30 minutes of auxin treatment relative to 





Figure 3.14. Use of the AID system to conditionally deplete Ctk1 
 
(A) Growth of the control parental strain (W303-OsTIR; no AID*-tagged proteins; black) and 
Ctk1-AID* tagged strain (red) was measured over a period of 15 hours without auxin (-) or with 
auxin (+). Mean of three biological replicates.  
(B) Western blot probed with anti-FLAG and anti-Pgk1 as a loading control. Samples were 
taken before (T0) and 30 minutes (T30) after addition of auxin. Ctk1-AID* depletion was 
quantified and shown as the percentage mean of 3 biological replicates after 30 minutes of 
auxin addition with respect to (W.R.T) time zero and normalised to the Pgk1 signal. Error bars 
= standard error of the mean. 
(C) Anti-FLAG ChIP followed by qPCR analysis of the intron-containing genes: ACT1, RPS13, 
ECM33 0 minutes (no auxin; blue) and after 30 minutes (+ auxin; orange) of auxin addition to 
deplete Ctk1-AID*. The X-axis shows the positions of amplicons used for ChIP qPCR analysis 
– the exons are in grey. The data are presented as the mean percentage of input normalised 
to a negative control region. Mean of at least three biological replicates. Error bars = standard 
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3.14 Depletion of Ctk1 reduces serine 2 phosphorylation of the CTD of RNAPII 
 
To determine whether depletion of Ctk1 for 30 minutes was a sufficient amount of 
time to reduce serine 2 phosphorylation of the CTD of RNAPII, western blotting was 
performed using antibodies against the serine 2 (S2P) or serine 5 (S5P) phosphorylated 
forms of the CTD of RNAPII. The quantitation of the S2P or S5P phosphorylated 
forms of the CTD were normalised to Rpb3, a subunit of RNAPII, to account for 
potential differences in the amount of RNAPII upon depletion of Ctk1. Additionally, 
western blotting was performed using antibodies specific to the phosphorylated and 
unphosphorylated forms of Spt5 (see section 3.8 for details). 
 
Western blotting showed that depletion of Ctk1 for 30 minutes resulted in no 
significant reduction in Spt5 phosphorylation relative to conditions prior to auxin 
addition and to total Spt5 (student’s t-test, P>0.05) (Figure 3.15A). Depletion of Ctk1 
for 30 minutes resulted in a significant reduction in the level of serine 2 
phosphorylation on average to 17% relative to conditions prior to auxin addition and 
to Rpb3 (student’s t-test, P<0.05) (Figure 3.15B). Serine 5 phosphorylation increased 
significantly on average to 146% after depletion of Ctk1, relative to conditions prior 
to auxin addition and to Rpb3 (student’s t-test, P<0.05) (Figure 3.15C).  
 
To determine whether Ctk1 depletion resulted in changes in RNAPII occupancy, 
serine 2 (S2P), and serine 5 (S5P) phosphorylation of the CTD of RNAPII on a gene-
by-gene basis, ChIP-qPCR was performed across intron-containing genes ACT1, 
RPS13 and ECM33 using antibodies against RNAPII (Rpb1), S2P and S5P CTD 
phosphorylation. ChIP-qPCR analyses showed that depletion of Ctk1 for 30 minutes 
did not significantly affect RNAPII occupancy across ACT1, RPS13 or ECM33 
relative to conditions prior to auxin addition (student’s t-test, P>0.05) (Figure 3.15D). 
Depletion of Ctk1 in these conditions significantly reduced serine 2 phosphorylation 
of the CTD relative to RNAPII occupancy. On ACT1, serine 2 phosphorylation was 
significantly reduced on average to 65%, 28%, 21% and 16% at amplicons 3 to 6 
(3’SS-exon2) respectively, relative to conditions prior to auxin addition (student’s t-
test, P<0.05) (Figure 3.15E). On RPS13, serine 2 phosphorylation was significantly 
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reduced on average to 50%, 40%, 26% and 42% at amplicons 3 to 6 (3’SS-exon 2) 
respectively, relative to conditions prior to auxin addition (student’s t-test, P<0.05) 
(Figure 3.15E). On ECM33, serine 2 phosphorylation was significantly reduced on 
average to 69%, 57%, 41%, 25% and 34% at amplicons 1 to 5 respectively, relative to 
conditions prior to auxin addition (student’s t-test, P<0.05) (Figure 3.15E). 
 
Serine 5 phosphorylation did not significantly change across RPS13 relative to 
RNAPII occupancy (student’s t-test, P>0.05) (Figure 3.15F). However, serine 5 
phosphorylation was significantly increased on average to 122% at amplicon 5 (exon 
2) for ACT1 (student’s t-test, P<0.05), and on average to 123% at amplicons 3-5 (3’SS-
exon 2) of ECM33 (student’s t-test, P<0.05), relative to conditions prior to auxin 
addition and to RNAPII occupancy (Figure 3.15F). 
 
Ctk1 depletion for 30 minutes was therefore an effective way to reduce serine 2 





















Figure 3.15. Depletion of Ctk1 reduces serine 2 phosphorylation of the CTD of RNAPII 
 
(A) Western blot probed with anti-Spt5 phosphorylation (Spt5-P), anti-Spt5, anti-FLAG and 
anti-Rpb3 (RNAPII) as a loading control. Samples were taken before (T0) and 30 minutes 
(T30) after addition of auxin to deplete Ctk1-AID*. Spt5 phosphorylation levels were quantified 
after depletion of Ctk1-AID* and shown as the percentage mean of 3 biological replicates after 
30 minutes of auxin treatment with respect to (W.R.T) time zero and normalised to Spt5 signal.  
(B) Western blot probed with anti-serine 2 phosphorylation (S2P) and anti-Rpb3 (RNAPII) as 
a loading control. Samples were taken before (T0) and 30 minutes (T30) after addition of auxin 
to deplete Ctk1-AID*. Serine 2 phosphorylation levels were quantified after depletion of Ctk1-
AID* and shown as the percentage mean of 3 biological replicates after 30 minutes of auxin 
addition with respect to (W.R.T) time zero and normalised to Rpb3 signal.  
(C) Western blot probed with anti-serine 5 phosphorylation (S5P) and anti-Rpb3 (RNAPII) as 
a loading control. Samples were taken before (T0) and 30 minutes (T30) after addition of auxin 
to deplete Ctk1-AID*. Serine 5 phosphorylation levels were quantified after depletion of Ctk1-
AID* and shown as the percentage mean of 3 biological replicates after 30 minutes of auxin 
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Figure 3.15 (continued). Depletion of Ctk1 reduces serine 2 phosphorylation of the 
CTD of RNAPII 
 
(D) Anti-Rpb1 (RNAPII), (E) anti-serine 2 phosphorylation (S2P) and (F) anti-serine 5 
phosphorylation (S5P) ChIP and qPCR across intron-containing genes ACT1, RPS13 and 
ECM33 without auxin (T0; blue) and with 30 minutes of auxin addition to deplete Ctk1-AID* 
(T30; orange). The X-axis shows the positions of amplicons used for ChIP qPCR analysis – 
the exons are in grey. The Rpb1 ChIP data are presented as the mean percentage of input 
with respect to (W.R.T.) the first amplicon of each gene. The S2P and S5P ChIP data are 
relative to Rpb1 occupancy.  
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3.15 Depletion of Ctk1 does not affect co-transcriptional spliceosome assembly 
in S. cerevisiae 
 
To test whether loss of serine 2 phosphorylation affected co-transcriptional 
spliceosome assembly, ChIP-qPCR was performed across intron-containing genes 
(ACT1, RPS13 and ECM33) with and without depletion of Ctk1 for 30 minutes. 
Antibodies were used that detect core members of the spliceosome: the U1 snRNP 
(Prp40), U2 snRNP (Lea1-13MYC) and U5 snRNP (Prp8). ChIP-qPCR analyses 
showed no significant change in the occupancy of U1, U2 or U5 snRNPs upon Ctk1 
depletion for 30 minutes, relative to conditions prior to auxin addition (student’s t-test, 
P>0.05) (Figures 3.16A-3.16C).  
 
Therefore, in these conditions, in vivo loss of Ctk1 and serine 2 phosphorylation does 
not affect co-transcriptional spliceosome assembly, which is in contrast to findings in 
mammalian cells that a mutation of serine 2 of the CTD to alanine reduced recruitment 
of the U2 snRNP to transcription sites (assayed by FISH), and caused defects in pre-





















Figure 3.16. Depletion of Ctk1 does not affect co-transcriptional spliceosome assembly 
in S. cerevisiae 
 
(A) Anti-Prp40 (U1 snRNP), (B) anti-Lea1-MYC (U2 snRNP) and (C) anti-Prp8 (U5 snRNP) 
ChIP followed by qPCR analysis of the intron-containing genes: ACT1, RPS13, ECM33 0 
minutes (no auxin; blue) and after 30 minutes (orange) of auxin addition to deplete Ctk1-AID*. 
The X-axis shows the positions of amplicons used for ChIP qPCR analysis – the exons are in 
grey. The data are presented as the mean percentage of input with respect to (W.R.T.) the 
first amplicon of each gene. Mean of at least three biological replicates. Error bars = standard 
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3.16 Depletion of Ctk1 does not affect pre-mRNA splicing in S. cerevisiae 
 
To test whether depletion of Ctk1 affected pre-mRNA splicing, RT-qPCR was 
performed on total (steady-state) RNA, as described in section 3.5. No significant 
accumulation of pre-mRNA species upon depletion of Ctk1 was observed for ACT1, 
RPS13 and ECM33 (student’s t-test, P>0.05) (Figure 3.17). Additionally, there was a 
significant reduction in pre-mRNA of RPS13 (5’SS and 3’SS) and ECM33 (5’SS), in 
addition to significant reductions in mRNA and exon 2 levels for both genes (student’s 
t-test, P<0.05) (Figure 3.17). This was not observed for ACT1. This indicates that on 
RPS13 and ECM33 there are transcription defects. 
 
Overall, depletion of Ctk1 does not result in pre-mRNA splicing defects, which fits 
with the ChIP-qPCR data which showed no effect on co-transcriptional spliceosome  
assembly upon Ctk1 depletion (Figure 3.16). 
 
Figure 3.17. Depletion of Ctk1 does not affect pre-mRNA splicing in S. cerevisiae 
 
RT-qPCR analysis of total RNA from the intron-containing genes ACT1, RPS13 and ECM33 
after 30 minutes of depletion of Ctk1-AID* (A). Normalised to the SCR1 PolIII transcript and 
time zero (no auxin). Primers used detected pre-mRNA (5’SS or BP and 3’SS), lariat (excised 
intron or intron-exon 2), exon 2 (ex 2) and mRNA (see figure 3.6A for cartoon). Mean of at 
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Figure 3.17. Depletion of Ctk1 does not affect pre-mRNA splicing 
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3.17 Use of the AID system to conditionally deplete Paf1 
 
Spt5 functions to promote transcription elongation through recruitment of downstream 
factors that modulate transcription and chromatin state. It has been demonstrated using 
Spt5 phosphomutants/phosphomimetics that the phosphorylation of the CTR of Spt5 
by the Bur1/2 complex is important for Paf1 complex recruitment to elongating 
RNAPII (Laribee et al., 2005; Liu et al., 2009). To test whether the effects on co-
transcriptional spliceosome assembly observed upon Spt5 and Bur1/2 depletion is due 
to loss of the physical presence of Paf1, non-essential Paf1 was C-terminally AID*-
tagged and depleted using the AID system (described in section 3.1). Experiments 
were performed with and without 30 minutes of auxin treatment.  
 
Both the effect of the tag on Paf1 function and auxin-sensitivity were assessed by 
growth analyses of the parental strain (W303-OsTIR) with no AID* tag and the Paf1-
AID* strain with or without auxin (Figure 3.18A). In the absence of auxin, the Paf1-
AID* strain grew comparably to the parental strain, and with auxin the Paf1-AID* 
grew more slowly than the parental strain. Though Paf1 is non-essential, its deletion 
has multiple phenotypes, including decreased anaerobic growth (Samanfar et al., 
2013). 
 
Western blotting showed that depletion of Paf1 for 30 minutes resulted in a significant 
reduction of Ctk1 on average to 8% relative to cells with no depletion (student’s t-test, 
P<0.05) (Figure 3.18B). Paf1 is present at approximately 2542 molecules/cell (Kulak 
et al., 2014), and therefore after 30 minutes of depletion there may be approximately 
203 molecules/cell of Paf1 remaining.  
 
ChIP-qPCR analyses showed that, in addition to being depleted in whole cell extracts, 
Paf1 was significantly depleted relative to conditions prior to auxin addition on 
average to 28% across ACT1, 60% across RPS13 and 55% across ECM33 after 30 





Figure 3.18. Use of the AID system to conditionally deplete Paf1 
 
(A) Growth of the control parental strain (W303-OsTIR; no AID*-tagged protein; black) and 
Paf1-AID* tagged strain (red) was measured over a period of 17 hours without auxin (-) or with 
auxin (+). Mean of three biological replicates.  
(B) Western blot probed with anti-FLAG and anti-Pgk1 as a loading control. Samples were 
taken before (T0) and 30 minutes (T30) after addition of auxin. Paf1-AID* depletion was 
quantified and shown as the percentage mean of 3 biological replicates after 30 minutes of 
auxin addition with respect to (W.R.T) time zero and normalised to the Pgk1 signal. Error bars 
= standard error of the mean. 
(C) Anti-FLAG ChIP followed by qPCR analysis of the intron-containing genes: ACT1, RPS13, 
ECM33 0 minutes (no auxin; blue) and 30 minutes (+ auxin; orange) after auxin addition to 
deplete Paf1-AID. The X-axis shows the positions of amplicons used for ChIP qPCR analysis 
– the exons are in grey. The data are presented as the mean percentage of input with respect 
to (W.R.T.) the first amplicon of each gene. Mean of at least three biological replicates. Error 
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3.18 Depletion of Paf1 causes accumulation of RNAPII in gene bodies 
 
To determine whether Paf1 depletion changed RNAPII occupancy, serine 2, or serine 
5 phosphorylation of the CTD of RNAPII on a gene-by-gene basis, ChIP-qPCR was 
performed across intron-containing genes ACT1, RPS13 and ECM33 using antibodies 
against RNAPII (Rpb1), serine 2 (S2P) or serine 5 (S5P) CTD phosphorylation.  
 
ChIP-qPCR analyses showed that depletion of Paf1 for 30 minutes significantly 
increased RNAPII occupancy across ACT1, RPS13 or ECM33 (Figure 3.19A). For 
ACT1, RNAPII occupancy was significantly increased on average to 139% and 156% 
at amplicons 4 and 5 (exon 2), relative to conditions prior to auxin addition (student’s 
t-test, P<0.05).  For RPS13 RNAPII occupancy was significantly increased on average 
to 230% and 200% at amplicons 3 and 4 (intron, 3’SS), relative to conditions prior to 
auxin addition (student’s t-test, P<0.05). For ECM33 RNAPII occupancy was 
significantly increased on average to 191% at amplicon 3 (3’SS), relative to conditions 
prior to auxin addition (student’s t-test, P<0.05). 
 
Depletion of Paf1 in these conditions significantly increased serine 2 phosphorylation 
of the CTD relative to RNAPII occupancy on ACT1, RPS13 and ECM33 (Figure 
3.19B). On ACT1, serine 2 phosphorylation was significantly increased on average to 
156% and 395% at amplicons 5 and 6 (exon 2 and 3’ end), relative to conditions prior 
to auxin addition (student’s t-test, P<0.05). On RPS13, serine 2 phosphorylation was 
significantly increased on average to 147% at amplicon set 6 (3’end), relative to 
conditions prior to auxin addition (student’s t-test, P<0.05). On ECM33, serine 2 
phosphorylation was significantly increased on average to 176%, 143%, 151% and 
155% at amplicons 2-5 (exon 1-exon 2) respectively, relative to conditions prior to 
auxin addition (student’s t-test, P<0.05). 
 
Serine 5 phosphorylation of the CTD was also significantly increased upon depletion 
of Paf1 relative to RNAPII occupancy on ACT1, RPS13 and ECM33 (Figure 3.19B). 
On ACT1, serine 5 phosphorylation was significantly increased on average to 255%, 
232%, 355%, 210% and 306% at amplicons 1, 2, 3, 4 and 6 respectively, relative to 
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conditions prior to auxin addition (student’s t-test, P<0.05). On RPS13, serine 5 
phosphorylation was significantly increased on average to 240% and 352% at 
amplicons 1 and 2 (5’end and exon1), relative to conditions prior to auxin addition 
(student’s t-test, P<0.05). On ECM33, serine 5 phosphorylation was significantly 
increased on average to 184%, 150% and 147% at amplicons sets 1-3 (5’end-exon 2), 
relative to conditions prior to auxin addition (student’s t-test, P<0.05). 
 
Overall, Paf1 depletion resulted in significant accumulation of RNAPII on ACT1, 
ECM33 and RPS13 from the intron or 3’SS to exon 2 within the gene body. Serine 5 
and serine 2 phosphorylation of the CTD were also increased at particular locations 
along the gene. The RNAPII that accumulated in the gene bodies was only 
hyperphosphorylated at serine 5 on ACT1 and ECM33, and at serine 2 on ECM33. This 
accumulation of RNAPII in gene bodies is similar to the increase in RNAPII 
occupancy observed by Chen et al (2015) upon Paf1 knockdown in mammalian cells. 
The increase in serine 2 phosphorylation observed by ChIP-qPCR was surprising as 
previous ChIP-qPCR studies showed that deletion of Paf1 reduced serine 2 
phosphorylation in S. cerevisiae (Mueller et al., 2004; Nordick et al., 2008). However, 
Chen et al (2015) also observe an increase in serine 2 phosphorylation after Paf1 
knockdown in mammalian cells (Chen et al., 2015). 
 
To test whether loss of the physical presence of Paf1 affected co-transcriptional 
spliceosome assembly, ChIP-qPCR was performed across intron-containing genes 
(ACT1, RPS13 and ECM33) with and without depletion of Ctk1 for 30 minutes. 
Antibodies were used that detect core members of the spliceosome: the U1 snRNP 
(Prp40), U2 snRNP (Lea1-3HA) and U5 snRNP (Prp8). ChIP-qPCR analyses showed 
no significant change in the occupancy of U1, U2 or U5 upon Paf1 depletion for 30 
minutes on ACT1 or ECM33, relative to conditions prior to auxin addition (student’s 
t-test, P>0.05) (Figures 3.19D-3.19F). For RPS13, depletion of Paf1 significantly 
increased U1 snRNP occupancy to 300%, 257% and 207% at amplicons 3-5 (intron-
exon2) (student’s t-test, P<0.05), without significantly affecting U2 or U5 snRNP 
occupancy (student’s t-test, P>0.05), relative to conditions prior to auxin addition 
(Figures 3.19D-3.19F). In agreement, ChIP-qPCR analyses of co-transcriptional 
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spliceosome assembly in a Paf1 deletion strain show no significant effect on co-
transcriptional spliceosome assembly across the same intron-containing genes (data 
not shown). 
 
In summary, gene-specific effects were observed for RPS13, where the U1 snRNP 
significantly accumulated. However, as no consistent effects on co-transcriptional 
spliceosome assembly were observed upon Paf1 depletion, the effects on co-
transcriptional spliceosome assembly observed upon Spt5 depletion, Bur1 or Bur2 


























Figure 3.19. Depletion of Paf1 causes accumulation of RNAPII in gene bodies 
 
(A) Anti-Rpb1 (RNAPII), (B) anti-serine 2 phosphorylation (S2P), (C) anti-serine 5 
phosphorylation (S5P), (D) anti-Prp40 (U1 snRNP), (E) anti-Lea1-HA and (F) anti-Prp8 (U5 
snRNP) ChIP and qPCR across intron-containing genes ACT1, RPS13 and ECM33 without 
auxin (blue) and with 30 minutes of auxin addition to deplete Paf1-AID* (orange). The X-axis 
shows the positions of amplicons used for ChIP qPCR analysis – the exons are in grey. The 
Rpb1, Prp40, Lea1-HA and Prp8 ChIP data are presented as the mean percentage of input 
with respect to (W.R.T.) the first amplicon of each gene. The S2P and S5P ChIP data are 
relative to Rpb1 occupancy. All data (A-F): mean of at least 3 biological replicates, error bars 
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Figure 3.19 (continued). Depletion of Paf1 causes accumulation of RNAPII in gene 
bodies 
 
(A) Anti-Rpb1 (RNAPII), (B) anti-serine 2 phosphorylation (S2P), (C) anti-serine 5 
phosphorylation (S5P), (D) anti-Prp40 (U1 snRNP), (E) anti-Lea1-HA and (F) anti-Prp8 (U5 
snRNP) ChIP and qPCR across intron-containing genes ACT1, RPS13 and ECM33 without 
auxin (blue) and with 30 minutes of auxin addition to deplete Paf1-AID* (orange). The X-axis 
shows the positions of amplicons used for ChIP qPCR analysis – the exons are in grey. The 
Rpb1, Prp40, Lea1-HA and Prp8 ChIP data are presented as the mean percentage of input 
with respect to (W.R.T.) the first amplicon of each gene. The S2P and S5P ChIP data are 
relative to Rpb1 occupancy. All data (A-F): mean of at least 3 biological replicates, error bars 
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3.19 Depletion of Paf1 does not affect pre-mRNA splicing 
 
RT-qPCR was performed on total (steady-state) RNA to determine whether Paf1-
AID* depletion affected pre-mRNA splicing, as described in section 3.5. No 
significant changes in the levels of pre-mRNA species, mRNA species or exon 2 levels 
were observed upon depletion of Paf1-AID* for ACT1, RPS13 and ECM33 relative to 
conditions prior to auxin addition (student’s t-test, P>0.05) (Figure 3.20).  
 
The splicing RT-qPCR analysis showing no defects in pre-mRNA splicing agrees with 
the ChIP-qPCR data that showed no consistent changes in co-transcriptional 
spliceosome assembly upon Paf1-AID* depletion (Figure 3.19).  
 
Figure 3.20. Depletion of Paf1 does not affect pre-mRNA splicing 
 
RT-qPCR analysis of total RNA from the intron-containing genes ACT1, RPS13 and ECM33 
after 30 minutes of depletion of Paf1-AID* (A). Normalised to the SCR1 PolIII transcript and 
time zero (no auxin). Primers used detected pre-mRNA (5’SS or BP and 3’SS), lariat (excised 
intron or intron-exon 2), exon 2 (ex 2) and mRNA (see figure 3.6A for cartoon). Mean of at 
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Despite mounting evidence for functional links between transcription and splicing, the 
majority of this evidence is not mechanistic. A ‘recruitment’ model for co-
transcriptional spliceosome assembly has been suggested, whereby interactions 
between RNAPII and/or transcription elongation factors and splicing factors during 
transcription facilitate co-transcriptional spliceosome assembly and therefore affect 
splicing outcome (reviewed in Buratowski, 2003; Bentley, 2005). Most evidence for 
the recruitment model is assumptive, and most studies do not directly demonstrate that 
RNAPII, the CTD of RNAPII (and its phosphorylated states) or transcription 
elongation factors are required for co-transcriptional spliceosome assembly. 
Therefore, the recruitment model of co-transcriptional splicing currently lacks 
mechanistic evidence. By using the AID system to conditionally deplete essential and 
non-essential transcription elongation factors (Spt5, Bur1, Bur2, Ctk1 and Paf1), the 
experiments described here aimed to provide mechanistic insights into the links 
between the transcription elongation machinery and splicing in S. cerevisiae. Previous 
studies have made use of mutants or deletions and in these strains or systems 
adaptation or compensatory mutations may have occurred, and therefore previous 
observations of the functional roles of these proteins may have been secondary to their 
primary role. For this reason, the AID system provided a novel approach not only to 
assess effects of the core transcription elongation factors on co-transcriptional 
spliceosome assembly and splicing, but also effects on RNAPII occupancy and 
phosphorylation status of the CTD of RNAPII.  
 
Here, evidence is provided for a two-part function for Spt5 in co-transcriptional 
spliceosome assembly. ChIP, as a well-established assay for co-transcriptional 
spliceosome assembly, showed that whilst the U1 and U2 snRNPs were recruited 
normally upon Spt5 depletion, the recruitment of the U5 snRNP was significantly 
reduced (Figure 3.5). As the U1 and U2 snRNPs exhibit normal co-transcriptional 
recruitment, at least the pre-spliceosome or A complex can form in the absence of 
Spt5. This supports step-wise spliceosome assembly. In the absence the U5 snRNP, 
one might expect the pre-spliceosome to be unstable. Here, the A complex probably 
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forms and dissociates in an equilibrium such that no changes were observed by ChIP 
upon Spt5 depletion compared to undepleted. There is precedent for this given that 
individual stages of step-wise spliceosome assembly were shown by single molecule 
imaging to be reversible in S. cerevisiae (Hoskins et al., 2011). It was also shown in 
vivo that in the absence of the U5 snRNP pre-spliceosomes can form (Tardiff and 
Rosbash, 2006). However, Price et al (2014) found that the U5 snRNP promotes 
spliceosome maturation events that occur before tri-snRNP recruitment. 
 
As the U5 snRNP is an integral component of the tri-snRNP, the loss of co-
transcriptional recruitment of the U5 snRNP upon Spt5 depletion observed in the 
present work indicates that B complex cannot form efficiently or stably in the absence 
of Spt5. These ChIP experiments cannot distinguish between Spt5 affecting the initial 
recruitment of the U5 snRNP, or Spt5 affecting the stable association of the U5 snRNP 
once recruited. In the absence of stable association of the tri-snRNP and B complex 
formation, the spliceosome cannot be activated, and no splicing catalysis can occur (at 
least co-transcriptionally). Splicing defects would be predicted in these conditions, and 
indeed RT-qPCR analyses showed that depletion of Spt5 resulted in pre-mRNA 
accumulation on the same genes tested by ChIP (Figure 3.6). This is consistent with 
previous studies which found that mutations in Spt5 caused splicing defects in S. 
cerevisiae, and that depletion of Spt5 results in pre-mRNA accumulation in S. pombe 
(Lindstrom et al., 2003; Burckin et al., 2005; Shetty et al., 2017). While these splicing 
defects may be modest, it is possible that post-transcriptional splicing could partially 
compensate for lack of co-transcriptional splicing. 
 
By nature, co-transcriptional splicing is highly sensitive to changes in RNAPII 
elongation rate and a possible explanation as to how depletion of Spt5 reduces U5 
snRNP occupancy is that it affects RNAPII elongation. The prevailing view is that 
Spt5 reduces pausing or premature termination of RNAPII during transcription 
elongation and thereby acts as a positive transcription elongation factor through the 
chromatin barrier (Morillon et al., 2003; Mason and Struhl, 2005; Quan and Hartzog, 
2010; Diamant et al., 2016; Shetty et al., 2017). Loss of Spt5 would therefore be 
predicted to cause a reduction in RNAPII elongation rate, and reduced RNAPII 
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elongation rate correlates with reduced RNAPII occupancy along genes (Mason and 
Struhl 2005; Malik et al., 2017). Loss of RNAPII occupancy would be predicted in 
turn to affect co-transcriptional spliceosome assembly and splicing by affecting pre-
mRNA substrate availability. I discard this as an explanation for reduced U5 snRNP 
recruitment for two reasons. Firstly, no consistent changes in RNAPII occupancy were 
observed in the present work upon Spt5 depletion (Figure 3.4) and there was no effect 
on RNA production (as determined by exon 2 levels) (Figure 3.6) for the genes 
analysed, indicating no transcription defect upon Spt5 depletion. This contrasts with a 
recent study in which Spt5 was depleted for 4.5 hours using the AID system in S. 
pombe, where Spt5 depletion caused reduced RNAPII occupancy 3’ ends of genes 
(indicating RNAPII struggles transcribing past a barrier) and reduced RNA synthesis 
genome-wide in S. pombe upon Spt5 depletion (Shetty et al., 2017). This long 
depletion reduced the cellular level Spt5 to 13% and may have had consequences for 
RNAPII occupancy (Shetty et al., 2017). Secondly, in the present work the loss of 
splicing factor recruitment upon Spt5 depletion was specific to the U5 snRNP; no loss 
of earlier-acting splicing factors was observed upon Spt5 depletion and one would 
predict that changes to RNAPII elongation rate and loss of RNAPII occupancy would 
affect all stages of co-transcriptional spliceosome assembly. In particular, one might 
expect the U1 snRNP to be particularly sensitive to changes in RNAPII elongation rate 
as U1 snRNP occupancy correlates with level of transcription (Harlen et al., 2016; 
Wallace and Beggs, 2017). A further possibility is that the elongation rate of RNAPII 
is faster upon Spt5 depletion. However, there is no evidence to suggest that loss of 
Spt5 increases elongation rate of RNAPII – in vitro and in vivo studies show that loss 
of Spt5 increases RNAPII pausing, so one would predict elongation rate to be slower 
in the absence of Spt5 (Morillon et al., 2003; Mason and Struhl, 2005; Quan and 
Hartzog, 2010; Diamant et al., 2016; Shetty et al., 2017). 
 
Co-immunoprecipitation experiments showed a reciprocal interaction between Spt5 
and Prp8 (U5 snRNP) that is not via RNAPII and not RNA-dependent (Figure 3.7). It 
was difficult to detect the U1 or U2 snRNPs upon pulldown of Spt5, but pulldown of 
the U1 snRNP and U2 snRNP detected Spt5. However, the U2 snRNP pulled down 
RNAPII too, indicating that this interaction could be indirect, via RNAPII. The finding 
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that, in these conditions, U2 interacts with RNAPII and not with U1 or U5 was in itself 
interesting. One study found that Prp40 (U1 snRNP) binds to the phosphorylated CTD 
of RNAPII (Morris and Greenleaf, 2000; Gasch et al., 2006), and another by mass 
spectrometry that the splicing factors (U1 – NTC) are associated with the serine 5 
phosphorylated CTD of RNAPII (Harlen et al., 2016). Another study found that 
splicing factor U2AF65 interacts directly with the serine 2 phosphorylated CTD of 
RNAPII (David et al., 2011; Gu et al., 2013). U2AF facilitates stable binding of the 
U2 snRNP to pre-mRNA, and therefore the finding in the present work that U2 
interacts with RNAPII fits with these previous observations. Though I cannot rule out 
interactions between Spt5 and other splicing factors, overall the strongest interaction 
detected between Spt5 and a splicing factor in the present work was that between Spt5 
and the U5 snRNP. An interaction between Prp40 and Spt5 was detected previously, 
and therefore the co-immunoprecipitation assay in the present work may have missed 
some interactions (Moore et al., 2006). Mass spectrometry would give a clearer 
indication of the breadth of Spt5-splicing factor interactions. Taken together, these 
data provide mechanistic insight into how Spt5 could affect splicing - by modulating 
co-transcriptional recruitment of the U5 snRNP to form the B complex, possibly by 
direct interaction, at least with the U5 snRNP.   
 
It was possible that the reduction in U5 snRNP recruitment caused by Spt5 depletion 
was due to loss of Spt5 CTR phosphorylation. The CTR of Spt5 is phosphorylated 
during transcription by the Bur1/2 complex in S. cerevisiae (Liu et al., 2009). In the 
present work, depletion of Bur1 and Bur2 significantly reduced Spt5 phosphorylation, 
as expected, however, no significant reduction in serine 2 phosphorylation was 
observed by western blotting (Figure 3.9) or by ChIP (Figure 3.10) upon depletion of 
Bur1 or Bur2, meaning in these conditions the kinase activity of Bur1 is not required 
for serine 2 phosphorylation of the CTD. This was unexpected, as deletion of Bur2 
and inhibition of Bur1 activity were reported to reduce the level of serine 2 
phosphorylation by western blotting and at the 5’ end of the ARG1 gene by ChIP (Liu 
et al., 2009; Qiu et al., 2009; Dronamraju and Strahl, 2014). While the loss of serine 
2 phosphorylation in whole cell extracts in these studies is clear, the ChIP-qPCR 
showing loss of serine 2 phosphorylation at the 5’ end of genes was performed on one 
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gene, the intronless gene ARG1, which is of course not representative of all genes. 
Differences in observations made could also be due to the difference in using a 
conditional system in comparison to a deletion system, or due to differences in 
antibodies used for detection of the phosphorylated CTD.  
 
Depletion of Bur1 and Bur2 did not result in loss of U5 snRNP recruitment to intron-
containing genes, and therefore, the effect observed upon Spt5 depletion was not 
simply due to loss of phosphorylated Spt5. This is consistent with the fact that the CTR 
of Spt5 is non-essential in S. cerevisiae (Yao et al., 2000; Ding et al., 2010), and agrees 
with the findings in S. pombe where deletion of the CTR of Spt5 did not cause 
significant splicing defects in comparison to depletion of Spt5 (Shetty et al., 2017). In 
contrast, Bur1 and Bur2 depletion resulted in a significant accumulation of the U2 and 
U5 snRNPs on ACT1 and ECM33 (Figure 3.11). Further, U2 and U5 snRNPs seemed 
to peak earlier along the genes, indicating that co-transcriptional spliceosome 
assembly is faster in the absence of Bur1. As U1 snRNP occupancy did not change, 
that means that U1 associates and dissociates normally and at least the Bact complex 
(and complex preceding it) forms normally upon Bur1 and Bur2 depletion. 
 
The observed accumulation of the U2 and U5 snRNPs could potentially be explained 
by changes in RNAPII elongation rate upon depletion of Bur1 or Bur2 - RNAPII could 
be pausing more frequently (or for longer periods of time) and accumulating at 
particular locations and, if this delays progression through the spliceosome cycle, it 
might explain better detection of the snRNPs by ChIP. However, depletion of Bur1 
did not significantly affect RNAPII occupancy, CTD phosphorylation or RNA 
production (exon 2 levels of nascent RNA and steady-state RNA) for the genes tested 
(Figures 3.10 and 3.12). Additionally, as discussed below, Paf1 depletion increases 
RNAPII occupancy on the intron-containing genes tested without causing 
accumulation of U2 or U5 snRNPs. Further, the occupancy of the U1 snRNP was 
unaffected in these conditions, and if the elongation rate of RNAPII was affected one 
would expect changes in occupancy of all the snRNPs, particularly the U1 snRNP (as 
discussed previously). Though mutations of Bur1 confer sensitivity to 6-azauracil and 
loss of RNAPII occupancy, which suggests a role for Bur1 in transcription elongation 
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and processivity (Keogh et al., 2003; Murray et al., 2001), other studies have not found 
such a role (Liu et al., 2009). The finding in the present work that depletion of Bur1 
does not significantly affect RNAPII occupancy agrees with the finding that inhibition 
of Bur1 kinase activity does not affect RNAPII occupancy or transcription (Liu et al., 
2009), and that deletion of Bur2 has no effect on RNAPII occupancy in S. cerevisiae 
(Qiu et al., 2009). However, it was recently shown in fission yeast using PRO-SEQ 
that inhibition of Bur1 kinase activity reduced RNAPII elongation rate (Booth et al., 
2018). In a similar way, PRO-SEQ could be used to test effects Bur1 depletion on 
RNAPII elongation rate.  
 
If not due to changes in RNAPII elongation rate, the increased ChIP signal for the U2 
or U5 snRNPs upon Bur1 depletion could be explained in two ways. Firstly, as U1 
snRNP occupancy is normal upon Bur1/2 depletion, there could be a block to the 
progression of co-transcriptional spliceosome assembly at some stage past the 
formation of the catalytically activated spliceosome (Bact complex) (i.e. subsequent 
to dissociation of U1 snRNP, which would otherwise accumulate) and that Bact or 
subsequent complexes get stuck at the gene. Alternatively, Bact complex formation 
and later steps in the splicing cycle might occur more faster and more efficiently in the 
absence of Bur1. If there was a block to co-transcriptional spliceosome progression, 
this would be predicted to prevent spliceosome recycling, which would lead to defects 
in co-transcriptional spliceosome assembly (as snRNPs would be limiting) and defects 
in splicing catalysis. In contrast, if the Bact complex forms more efficiently, one might 
predict splicing catalysis would be more efficient, as a result of more co-transcriptional 
splicing. Loss of Bur1 was found to enhance co-transcriptional splicing of ACT1 and 
ECM33 by NET-RT-qPCR, and because of this we favour the idea that loss of Bur1 
enhances co-transcriptional assembly of spliceosomes and that splicing occurs more 
efficiently in the absence of Bur1 (Figure 3.12). Further, as the U2 and U5 snRNPs 
peak earlier by ChIP upon Bur1 depletion, this indicates that co-transcriptional 
spliceosome assembly occurs not only more efficiently but faster, as well as showing 
that there are no spliceosome recycling defects. We also rule out the possibility of a 
post-splicing complex accumulating at the gene, as lariat does not accumulate (should 
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be detected by NET-RT-qPCR) and there were no defects observed in spliceosome 
recycling or splicing catalysis upon Bur1 depletion (Figure 3.12). 
 
The gene-specific effects of U2 and U5 snRNP accumulation could be explained by 
differences between non-ribosomal protein genes and ribosomal protein genes. ACT1 
and ECM33 are both non-ribosomal, whereas RPS13 is ribosomal. Ribosomal protein 
genes are spliced quickly and co-transcriptionally in comparison to non-ribosomal 
genes in S. cerevisiae, and perhaps as RPS13 is already spliced quickly and co-
transcriptionally the any effects are not apparent (Wallace and Beggs, 2017).  
 
As a kinase, Bur1 could potentially phosphorylate multiple targets, and it is possible 
that phosphorylation of proteins other than Spt5 was responsible for the effects on co-
transcriptional spliceosome assembly observed upon Bur1 and Bur2 depletion (Figure 
3.11). In contrast to depletion of Bur1, no significant changes in pre-mRNA splicing 
were observed upon depletion of Bur2, which fits with the less severe effects on co-
transcriptional spliceosome assembly observed upon Bur2 depletion (Figures 3.11 and 
3.12).  The less severe effects of Bur2 depletion could be explained by the fact that 
when Bur2 is depleted the level and co-transcriptional recruitment of Bur1 were 
unaffected, and Bur1 may have some residual kinase activity without Bur2 or have 
Bur2-independent substrates that are important for this phenotype. It has been 
suggested that Bur1 has targets independent of Bur2, or is regulated by other cyclins, 
as Bur1 is essential whereas Bur2 is non-essential (Yao et al., 2000). The finding here 
that loss of Bur1 kinase activity does not cause splicing defects but enhances co-
transcriptional splicing fits with the fact that Bur2 and the CTR are not essential in S. 
cerevisiae (Yao et al., 2000; Ding et al., 2010). The finding in the present work that a 
phosphomutant of Spt5 (equivalent to depletion of Bur1/2) showed the same 
accumulation of the U2 and U5 snRNPs (without significant changes in RNAPII 
occupancy) as a depletion of Bur1/2 cemented the idea that the phosphorylation status 
of Spt5 is important for this phenomenon, though the phenotype is milder than 
depletion of Bur1 and is more similar to depletion of Bur2 (Figures 3.13 and 3.11). 
Further, comparison of the WT and phosphomutant Spt5 showed no consistent 
changes in pre-mRNA splicing, which is also analogous to depletion of Bur2 (Figures 
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3.12 and 3.13). This milder phosphomutant phenotype could be explained by the fact 
that expression of the Spt5 WT/phosphomutant/phosphomimetic proteins was not 
inducible, and therefore the strains may have adapted so that changes to co-
transcriptional spliceosome assembly are harder to observe. Spt5 phosphorylation by 
Bur1 does appear to be Bur2-dependent (Figure 3.9A), and therefore another (Bur2-
independent) target of Bur1 may be involved that is important for the effects on co-
transcriptional spliceosome assembly observed upon Bur1 depletion. At this stage, it 
cannot be concluded that it is the phosphorylation of Spt5 by Bur1 alone that is 
responsible for the accumulation of U2 and U5 snRNPs. Bur2-independent targets of 
Bur1 could be assayed by comparative mass spectrometry after depletion of either 
Bur1 or Bur2. 
 
Spt5 phosphorylation is required for recruitment of the Paf complex, which facilitates 
transcription elongation by RNAPII (Laribee et al., 2005; Liu et al., 2009). It is 
possible that the effects observed upon depletion of Bur1/2 and with the Spt5 
phosphomutant were due to loss of Paf complex recruitment. However, depletion of 
Paf1, the core component of the Paf complex, did not cause accumulation of the U2 
and U5 snRNPs, meaning that this phenotype cannot be explained by loss of Paf1 
recruitment (Figure 3.19). Furthermore, no significant changes in pre-mRNA splicing 
were observed (Figure 3.20).  Interestingly, Paf1 depletion did result in RNAPII 
accumulation and an increase in serine 2 and serine 5 phosphorylation of the CTD of 
RNAPII (Figure 3.19). This accumulation of RNAPII in gene bodies is similar to the 
increase in RNAPII occupancy observed by Chen et al., (2015) upon Paf1 knockdown 
in mammalian cells. The increase in serine 2 phosphorylation observed by ChIP-qPCR 
was unexpected as previous ChIP-qPCR studies showed that deletion of Paf1 reduced 
serine 2 phosphorylation in S. cerevisiae (Mueller et al., 2004; Nordick et al., 2008). 
However, Chen et al (2015) also observe an increase in serine 2 phosphorylation after 
Paf1 knockdown in mammalian cells (Chen et al., 2015). In S. cerevisiae, NET-SEQ 
showed that deletion of Paf1 resulted in a shift of the 5’ peak of RNAPII toward the 
3’ end of genes (Fischl et al., 2017). These data also act as a control for the Bur1 
depletion data – depletion of Paf1 increases RNAPII occupancy without causing co-




How might loss of Bur1 kinase activity and Spt5 phosphorylation enhance co-
transcriptional formation of spliceosomes? In mammals, phosphorylation of the CTR 
of Spt5 has been shown to convert Spt5 from an inhibitor of transcription elongation 
to a promoter of transcription elongation. Though this two-part function for Spt5 has 
not been demonstrated in S. cerevisiae (Spt5 is thought to only act only as a positive 
regulator), an intriguing possibility is that loss of Spt5 phosphorylation causes 
transient pausing of RNAPII and this transient pause is sufficient to promote co-
transcriptional splicing. Indeed, RNAPII has been demonstrated to transiently pause 
in a splicing-dependent manner on an inducible reporter gene in S. cerevisiae, the 
mechanism for which is currently unknown (Alexander et al., 2010b). Further, 
RNAPII pausing was also demonstrated at intron-exon junctions in S. cerevisiae 
(Harlen et al., 2016). As pausing is highly transient, it would be difficult to detect 
using the methods described in the present work and use of an inducible reporter gene 
where transcription is synchronised or more high-throughput methods such as NET-
SEQ would be more informative. As previously discussed, the changes in pausing 
would still have to be transient enough not to be detected in the present work (no 
changes in RNAPII occupancy observed). A second non-mutually-exclusive model is 
that at least the unphosphorylated form of Spt5 and Bur1 kinase activity facilitates 
structural rearrangements or dynamics in the spliceosome, potentially via interaction 
with splicing factors acting at the B to Bact transition, such as Brr2 (Maeder et al., 
2009). This could be analogous to the interaction of Spt5 with the capping enzymes - 
the unphosphorylated CTR of Spt5 facilitates recruitment of capping enzymes, whilst 
phosphorylation by Bur1 releases the capping enzymes once capping is complete and 
releases paused RNAPII (Wen and Shatkin, 1999; Lidschreiber et al., 2013; 
Doamekpor et al., 2014, 2015). Both models for the role of unphosphorylated form of 
Spt5 in splicing would rely on exchange of phosphorylated Spt5, de novo recruitment 
of unphosphorylated Spt5 or the inhibition of Bur1 kinase activity and activity of a 
phosphatase. In S. pombe, Dis2 (PP1 in mammals, Glc7 in S. cerevisiae) was recently 
shown to be the phosphatase for Spt5 that functions in the absence of Bur1 kinase 




Proteins in the spliceosome could be regulated by Bur1 phosphorylation. There are 
multiple reversible phosphorylation events during spliceosome assembly that are 
thought to be important for structural rearrangements within the spliceosome 
(reviewed in Will and Luhrmann, 2011). In the present work, dephosphorylation of 
proteins acting at the B to Bact transition by loss of Bur1 could promote the B to Bact 
transition. Dephosphorylation of U1 and SR proteins is required for the first step of 
splicing in mammals (Tazi et al., 1993; Cao et al., 1997). In mammals, SF3b1 has been 
shown to be phosphorylated by kinase DYRK1A, which is important for splicing 
catalysis (Wang et al., 1998; de Graaf et al., 2006). Cyclin-dependent kinases have 
recently been shown to regulate the association of SF3b1 with chromatin (Murthy et 
al., 2018). However, many of the phosphorylated domains discussed above are missing 
in S. cerevisiae, and the kinases and phosphatases absent so the importance of 
phosphorylation of the spliceosome in S. cerevisiae is less clear than in mammals 
(reviewed in Will and Luhrmann, 2011). 
 
Together, experiments described here suggest a two-part function for Spt5 in co-
transcriptional spliceosome assembly in S. cerevisiae (Figure 3.21). Firstly, its 
physical presence is required for proper recruitment or stable association of the U5 
snRNP and formation of a pre-catalytically activated spliceosome (B complex) 
(possibly by direct/indirect interaction between Spt5 and at least the U5 snRNP). This 
phenomenon is not dependent on downstream recruitment of Paf1 or the 
phosphorylation status of Spt5. Secondly, the loss of Bur1 kinase activity and at least 








































Figure 3.21. A two-part role for Spt5 in co-transcriptional spliceosome assembly in S. 
cerevisiae 
 
(A) (i) In wild-type (WT) conditions (without Spt5 depletion), Spt5 facilitates proper recruitment 
or stable association of the U5 snRNP and therefore formation of a pre-catalytically activated 
spliceosome (B complex). This may be mediated, either directly or indirectly, by interaction 
between Spt5 and the U5 snRNP. (ii) Upon Spt5 depletion (indicated by the red cross), the U5 
snRNP is not properly recruited or stably associated, and the B complex cannot form (indicated 
by the red cross), leading to defects in splicing catalysis. 
(B) The loss of Bur1 kinase activity (indicated by the red cross) and at least the subsequent 
unphosphorylated CTR (indicated by the red cross) of Spt5 directly or indirectly promotes (++) 
co-transcriptional assembly of spliceosomes at the stage of Bact formation or later, and in this 




catalytically activated spliceosome (Bact complex onwards) and promotes co-
transcriptional splicing in an unknown mechanism.  
 
Whether this model would be applicable for higher eukaryotes remains to be seen. It 
is certainly possible, as Spt5 is highly conserved from yeast to humans (DSIF in 
humans), as is phosphorylation of its CTR by Bur1/2 (P-TEFb) and splicing occurs 
co-transcriptionally. There is evidence that Spt5 affects alternative splicing and 
constitutive splicing in mammalian cells (Diamant et al., 2012; Liu et al., 2012). 
Furthermore, there is some evidence that P-TEFb affects alternative splicing patterns 
in mammalian cells, by causing inclusion of an alternative exon (Barboric et al., 2009). 
However, this is via phosphorylation of the CTD of RNAPII which facilitates 
recruitment of SR splicing factor SF2/ASF, which is important for splice site 
recognition (Barboric et al., 2009). In mammalian cells, DSIF is converted to a positive 
elongation factor by interaction with elongation factor Tat-SF1 (Chen et al., 2009). 
Tat-SF1 and yeast homolog Cus2 interact with splicing factors, and it has been 
suggested that the phosphorylation of DSIF by P-TEFb and recruitment of Tat-SF1 
could facilitate co-transcriptional splicing (Yan et al., 1998; Fong and Zhou, 2001; 
Lenasi and Barboric, 2010). In mammalian cells, there is strong evidence that P-TEFb 
phosphorylates serine 2 of the CTD of RNAPII, and therefore this model is not 
applicable to S. cerevisiae (Wood and Shilatifard, 2006; Bartkowiak et al., 2011). 
While Spt5 and its phosphorylation by P-TEFb are conserved, the functions are likely 
divergent – this is exemplified by the fact that phosphorylation of the DSIF in 
mammalian systems is known to be important for release of RNAPII promoter-
proximal pausing, a function that has not been demonstrated in S. cerevisiae (Adelman 
and Lis, 2012). Furthermore, there are key differences in splicing and gene architecture 
between yeast and humans that complicate matters. The splicing machinery is 
expanded in human cells to accommodate alternative splicing - 95% of transcripts are 
alternatively spliced and only 3% of genes are intronless (Kornblihtt et al., 2013). This 
contrasts with S. cerevisiae where 5% of genes contain a single intron and there is very 




Depletion of Ctk1 was an effective way to reduce serine 2 phosphorylation at the 3’ 
ends of genes, without affecting RNAPII occupancy (Figure 3.15). The large decrease 
in serine 2 phosphorylation of the CTD upon Ctk1 depletion fits with the idea that 
Ctk1 is the major serine 2 CTD kinase in S. cerevisiae (Cho et al., 2001). In contrast, 
Bur1 depletion did reduce serine 2 phosphorylation of the CTD but significantly 
reduced Spt5 phosphorylation (in contrast, Ctk1 depletion did not significantly affect 
Spt5 phosphorylation) (Figures 3.9, 3.10 and 3.15). These data fit with the idea that 
the activity of P-TEFb is split between Bur1 and Ctk1 in S. cerevisiae (Keogh et al., 
2003; Wood and Shilatifard, 2006). It was surprising that loss of serine 2 
phosphorylation by Ctk1 depletion in these conditions did not affect co-transcriptional 
spliceosome assembly or splicing (Figures 3.16 and 3.17). The finding that loss of 
serine 2 phosphorylation does not affect splicing agrees with a study in S. cerevisiae 
that expressed truncated CTD mutants (8 repeats) in which the serine 2 residues were 
mutated to alanine (Harlen et al., 2016). These results contrast with findings in 
mammalian cells that a mutation of serine 2 of the CTD to alanine reduced recruitment 
of the U2 snRNA to transcription sites (assayed by FISH), and caused defects in pre-
mRNA splicing (Gu et al., 2013). Further, it was shown that splicing factor U2AF65 
interacts directly with the serine 2 phosphorylated CTD of RNAPII, suggesting a 
reciprocal relationship between serine 2 phosphorylation and splicing in mammalian 
cells (David et al., 2011). The observed differences may be explained by differences 
in the complexity of splicing between S. cerevisiae and mammals. The Ctk1 depletion 
act as a useful control for the Bur1 depletion experiments and shows that the effects 




















Of particular interest to the present work were the links between splicing and 
H3K4me3. There are several pieces of evidence that H3K4me3 affects splicing and 
vice-versa. In mammalian cells, RNAi knockdown of Ash2 (a subunit of the Set1 
complex specific for H3K4me3) and RNAi knockdown of Chd1 (a reader of 
H3K4me3 and chromatin remodeller) both result in reduction of the association of the 
U2 snRNP component SF3a with chromatin and reduced pre-mRNA splicing 
efficiency (Sims et al., 2007). This showed the first functional link between H3K4me3 
and pre-mRNA splicing. It was later shown that Ash2 overexpression affects patterns 
of alternative splicing in mammalian cells (Luco et al., 2010)). The authors also found 
that H3K4me3 is able to enrich for core members of the U2 snRNP, and that Chd1 
physically interacts with SF3a, providing a model whereby Chd1 binding to H3K4me3 
recruits the U2 snRNP and influences pre-mRNA splicing (Sims et al., 2007). The 
H3K4me3 reader Sgf29 has also been demonstrated to interact with U2 snRNP 
components (Vermeulen et al., 2010). 
 
Subsequently, examination of genome-wide ChIP-sequencing data sets in mammalian 
cells showed that the peak of H3K4me3 was enriched at the first 5’SS of intron-
containing genes but not at downstream splice sites, even when proximal to the 
transcription start site (Bieberstein et al., 2012). When the 5’SS was near a promoter, 
a single peak of H3K4me3 was observed but when the first exon was larger than 500 
nucleotides, two peaks of H3K4me3 were observed. Further, a reporter gene with a 
3’SS mutation that blocks pre-mRNA splicing, or an intronless version, exhibit 
reduced levels of H3K4me3 relative to the wild-type intron-containing reporter 
(Bieberstein et al., 2012). In addition, the use of splicing inhibitor drug spliceostatin 
reduced H3K4me3 levels (Bieberstein et al., 2012). In contrast, deletion of Set1 in S. 
cerevisiae did not affect co-transcriptional spliceosome assembly and microarray 
experiments showed reduced pre-mRNA splicing of only a subset of genes (Hérissant 
et al., 2014). Deletion of Chd1 in S. cerevisiae resulted in the strongest changes to 
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H3K4me3 on intron-containing genes, and lead to an increased pre-mRNA splicing 
efficiency (Lee et al., 2017). 
 
There are three possible histone methylation states of H3K4: mono- (me1), di-(me2) 
and tri-methylation (me3). The patterns of H3K4me3, H3K4me2 and H3K4me1 form 
a gradient, with the peak of H3K4me2 on a nucleosome downstream of H3K4me3, 
and the peak of H3K4me1 on a nucleosome downstream of H3K4me2 on actively 
transcribed genes (Howe et al., 2017). These different methylation states are thought 
to be brought about by a “time model”, which correlates the amount of time Set1 
spends at a particular genomic location to a higher level of H3K4 methylation (Ng et 
al., 2003b; Soares et al., 2017). The histone methyltransferases responsible for H3K4 
methylation are conserved from yeast to humans, and each contain the Set1 
methyltransferase, which contains within it a conserved SET histone methyltransferase 
domain. Metazoans have multiple complexes responsible for H3K4 methylation while 
in S. cerevisiae there is a single histone methyltransferase called Set1. Set1 is present 
in a complex called COMPASS (complex associated with Set1), and in S. cerevisiae, 
the COMPASS complex is composed of Set1 and seven other structural proteins: Bre2, 
Swd1, Spp1, Swd2, Swd3 and Sdc1 and Shg1. Set1, Swd1 and Swd3 are required for 
all three H3K4 methylation states, Sdc1, Swd2 and Bre2 are required for H3K4me2 
and H3K4me3, and Spp1 is specifically required for H3K4me3 in vivo (Cheng et al., 
2004; Dehé et al., 2006; Lee et al., 2007; Schneider et al., 2005) (Figure 4.1). In 
mammals, there are at least six histone methyltransferase complexes responsible for 
H3K4me3 (SET1A, SET1B, MLL1, MLL2, MLL3 and MLL4). The mammalian Set1-
containing complexes are most similar to the S. cerevisiae Set1 complex (reviewed in 
Shilatifard, 2012) (Figure 4.1). In mammals, the six Set1-containing complexes are 
not functionally redundant, as deletion of individual complex components is 
embryonic lethal (Glaser et al., 2006; Lee et al., 2008).  
 
Set1 is recruited during transcription to the CTD of transcribing RNAPII via the Paf 
complex, which interacts with the serine 5 phosphorylated CTD of RNAPII (Krogan 
et al., 2003; Ng et al., 2003b). Serine 5 phosphorylation is enriched at the 5’end of 
genes and could help to explain the enrichment of H3K4me3 there. It was also shown  
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Figure 4.1. The Set1 complex in S. cerevisiae, D. melanogaster and mammals 
 
Set1 complexes in S. cerevisiae, D. melanogaster and mammals. Subunits required for 
H3K4me3 are shown in yellow, subunits required for H3K4me2/3 are shown in orange, 
subunits required for H3K4me1/2/3 are shown in red. Species-specific subunits are shown in 
blue. Figure taken from (Howe et al., 2017). 
 
that the Swd2 subunit of the Set1 complex interacts with histone H2B ubiquitination 
(Lee et al., 2007). However, recent studies showed that the distribution of Set1 does 
not correlate with serine 5 phosphorylation (Sayou et al., 2017), and it was proposed 
that there must be alternative ways by which Set1 is recruited to chromatin. Set1 has 
two RNA recognition motifs (Schlichter and Cairns, 2005), and was recently shown 
by several groups to preferentially bind the 5’ends of nascent RNAPII transcripts, 
which has been proposed to explain the enrichment of H3K4me3 at the 5’ ends of 
genes – due to increased Set1 occupancy via RNA binding (Battaglia et al., 2017; 
Luciano et al., 2017; Sayou et al., 2017). Despite recent advances, the precise 
mechanism of Set1 recruitment is not yet fully characterised (Luciano et al., 2017).  
 
Genome-wide ChIP studies have shown a conserved peak of H3K4me3 from yeast to 
humans at the transcription start sites of actively transcribed genes, the level of which 
positively correlates with level of transcription (Benayoun et al., 2014; Chen et al., 
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2015; Howe et al., 2017). As H3K4me3 correlates with active transcription, it is 
generally thought of as an activating chromatin mark that stimulates RNAPII 
transcription. However, knockdown of H3K4me3 in S. cerevisiae and mammalian 
systems shows little effect on global steady-state gene expression, arguing against a 
global role of H3K4me3 as a transcription activator (Margaritis et al., 2012; Howe et 
al., 2017). In fact, several studies suggest a role for Set1 in gene silencing in yeast 
(Nislow et al., 1997; Briggs et al., 2001; Margaritis et al., 2012; Castelnuovo et al., 
2014). As knockdown of Set1 reduces all H3K4 methylation states, a strategy used to 
specifically study the function of H3K4me3 is to specifically deplete Spp1 (Cfp1 in 
mammals), which reduces H3K4me3 without affecting H3K4me1 or H3K4me2. In S. 
cerevisiae, neither Set1 nor Spp1 is an essential gene, and global loss of H3K4me3 
does not affect viability and does not result in significant changes to gene expression 
(Briggs et al., 2001; Miller et al., 2001). In mammalian cells, loss of H3K4me3 
prevents proper embryogenesis, although cultured embryonic stem cells are viable 
(Carlone and Skalnik, 2001; Carlone et al., 2005). Depletion of Cfp1 (Spp1) to reduce 
H3K4me3 in mammalian cells did not result in significant changes to gene expression 
(Clouaire et al., 2012). Therefore, the precise role for H3K4me3 in transcription from 
yeast to mammals currently remains unclear (Howe et al., 2017). The lack of effects 
on transcription upon loss of H3K4me3 suggests that low levels of H3K4me3 are 
sufficient for any effect on transcription it might have. In S. cerevisiae, H3K4me3 (and 
H3K4me2) was shown to be a highly stable chromatin mark, remaining at the GAL10 
gene for 5 hours after switching off expression of GAL10, which reduced transcription 
and Set1 recruitment within 1 hour (Ng et al., 2003b). This means that either the 
demethylase responsible for removal of H3K4 methylation is not very active, or that 
loss of H3K4 methylation normally relies on dilution of histones during DNA 
replication (Ng et al., 2003b; Radman-Livaja et al., 2010). It also infers that H3K4 
methylation is not an inherited mark through cell division, and its placement is de novo 
with each round of transcription (Ng et al., 2003b). 
 
The particular stage of the pre-mRNA splicing cycle that might affect H3K4me3 is 
unknown, and the precise molecular mechanisms involved remain unclear. Further, it 
is not known whether the link between H3K4me3 and splicing is conserved from 
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mammals to S. cerevisiae. The present work describes the application of the AID 
system to conditionally deplete essential splicing factors in S. cerevisiae to block 
different stages of spliceosome assembly and pre-mRNA splicing in order to determine 
any effects on H3K4me3 in vivo. Splicing factors were selected at different stages 
throughout the splicing cycle, in an attempt to pin-point which particular stage of 
splicing is important for any changes in H3K4me3 observed.  
 
In the present work, the AID system was used to conditionally deplete the following 
essential splicing factors: Prp39, Prp9, Slu7 and Prp22, which are all conserved from 
yeast to humans (Figure 4.2). Prp39, Prp9, Slu7 and Prp22 were each conditionally 
depleted using the AID system. Effects on pre-mRNA splicing were determined by 
RT-qPCR and subsequent in vivo effects on H3K4me3 determined by ChIP-qPCR. 
Prp39 is a core member of the U1 snRNP that is essential for splicing, functioning at 
the earliest stage of splicing (5’SS recognition) and required for the commitment of a 
pre-mRNA to the splicing pathway (Lockhart and Rymond, 1994; Gottschalk et al., 
1998). Prp9 is a core member of the U2 snRNP and is essential in forming the pre-
spliceosome and for pre-mRNA splicing (Hodges and Beggs, 1994; Wiest et al., 
1996). Prp22 is an essential DExH-box ATP-dependent 3’-5’ RNA helicase that 
disrupts the contacts between the U5 snRNP and mRNA after exon ligation to release 
the spliced mRNA (Company et al., 1991; Schwer and Cross, 1998; Wagner et al., 
1998). Prp22 has also been shown to be required for the second catalytic step (Schwer 
and Cross, 1998), and has been proposed to facilitate 3’SS selection and perform a 
proof-reading function prior to the second step – discarding suboptimal substrates 
(Mayas et al., 2006).  
 
At this point, I would like to gratefully acknowledge Dr. Emanuela Sani (Beggs lab) 
who generated and characterised the Slu7-AID* and Prp22-AID* strains used in this 
study, and who provided the H3K36me3 data. I would also like to gratefully 
acknowledge David Barrass (Beggs lab) who helped me perform 4-thiouracil labelling 





Figure 4.2. Choosing splicing factors throughout the splicing cycle to address which  
stage of splicing, if any, affects H3K4me3 
 
Classical splicing cycle showing where the essential splicing factors of interest to this work act 
in the splicing cycle: Prp39 (blue, U1 snRNP), Prp9 (black, U2 snRNP), Slu7 (purple) and 
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4.2 Use of the AID system to conditionally deplete essential splicing factors 
 
To enable analysis of the effects of depletion of essential splicing factors on H3K4me3 
in vivo, Prp39, Prp9, Slu7 and Prp22 were each C-terminally AID*-tagged in a strain 
that constitutively expressed Tir1, enabling their conditional depletion in the presence 
of auxin by the AID system. Experiments were performed with or without 30 minutes 
of auxin treatment. 
 
Firstly, the effect of the AID* tag on function of each splicing factor and auxin-
sensitivity was assessed by comparing the growth of the parental strain (W303-OsTIR) 
that has no AID* tag with the Prp39-AID* strain, the Prp9-AID* strain, the Slu7-AID* 
strain and the Prp22-AID* strain with or without auxin treatment (Figure 4.3A). In the 
absence of auxin, the AID*-tagged strains grew comparably to the parental strain, 
showing that the C-terminal AID* tag does not affect their function. After auxin 
addition to deplete the AID*-tagged proteins, each AID*-tagged strain grew more 
slowly and the parental strain was unaffected. The growth defect upon depletion of the 
AID*-tagged proteins was expected as these proteins are essential in S. cerevisiae. 
Figure 4.3. Use of the AID system to conditionally deplete essential splicing factors 
 
(A) Growth of the control parental strain (W303-OsTIR; no AID*-tagged proteins; red), Prp39-
AID* strain (red), Prp9-AID* strain (black), Slu7-AID* strain (purple) and Prp22-AID* strain 
(green) was measured over a period of 11 hours without (-) auxin or with (+) auxin treatment. 
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Western blotting showed that 30 minutes of auxin treatment significantly reduced the 
level of each of Prp39, Prp9, Slu7 and Prp22 on average to 16%, 16%, 19% and 45% 
relative to conditions without auxin (student’s t-test, P<0.05) (Figure 4.3B). It is 
estimated that Prp39 is present at approximately 177 molecules/cell, Prp9 at 
approximately 291 molecules/cell, Slu7 at approximately 425 molecules/cell and 
Prp22 at approximately 232 molecules/cell. Therefore, after auxin treatment for 30 
minutes, there were approximately 28 molecules/cell of Prp39, 47 molecules/cell of 
Prp9, 81 molecules/cell of Slu7 and 104 molecules/cell of Prp22 remaining (Kulak et 
al., 2014). It was interesting that Prp39, Prp9 and Slu7 were all better depleted than 
Prp22 in these experimental conditions. This is not explained by differences in protein 
copy number, as the estimates of protein copy number for Prp39, Prp9, Slu7 and Prp22 
are all very similar, and is probably explained by differing accessibility of the C-
terminal AID* tag for degradation by the AID system (Kulak et al., 2014). 
 
To test whether the chromatin-associated pool of each splicing factor was depleted, 
ChIP was performed using a FLAG antibody followed by qPCR analyses across 
intron-containing genes ACT1 and ECM33 (Figure 4.3C). Firstly, the ChIP profile 
across the intron-containing genes ACT1 and ECM33 was correct – the earlier acting 
splicing factors Prp39 and Prp9 peak earlier along the genes (towards the 5’end) than 
later acting factors Slu7 and Prp22 (peak toward the 3’end, at the end of exon 2). ChIP-
qPCR showed that, in addition to being depleted in whole cell extracts, each of the 
essential splicing factors was well depleted from chromatin (Figure 4.3C). Prp39 was 
significantly depleted on average to 44% at amplicons 3 and 4 (3’SS and exon 2) on 
ACT1, and 52% at amplicons 2 and 3 (exon 1 and 3’SS) on ECM33 (student’s t-test, 
P<0.05), relative to conditions without auxin (Figure 4.3C). Prp9 was significantly 
depleted on average to 51% at amplicons 3, 4 and 5 (3’SS-exon 2) on ACT1, and 47% 
at amplicons 3, 4 and 5 (3’SS-exon 2) on ECM33 (student’s t-test, P<0.05), relative to 
conditions without auxin (Figure 4.3C). Slu7 was significantly depleted on average to 
54% at amplicon 5 (exon 2) on ACT1, and 70% at amplicons 4 and 5 (exon 2) on 
ECM33 (student’s t-test, P<0.05), relative to conditions without auxin (Figure 4.3C). 
Prp22 was significantly depleted on average to 54% at amplicon 5 (exon 2) on ACT1, 
and 37% at amplicons 3 and 4 (3’SS and exon 2) on ECM33 (student’s t-test, P<0.05), 
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relative to conditions without auxin (Figure 4.3C). The finding that each factor was 
depleted co-transcriptionally was important, as it is the chromatin-associated pool that 
would most likely affect H3K4me3. 
 
Next, a splicing RT-qPCR assay was used to determine whether depletion of Prp39, 
Prp9, Slu7 and Prp22 in these conditions resulted in the expected splicing defects 
(Figures 4.3D and 4.3E). Prp39 and Prp9 are first step splicing factors, and their 
depletion would be expected to result in accumulation of pre-mRNA (5’SS, 3’SS and 
BP) species, and reduction in lariat (product of first step), which is exactly what was 
observed for the intron-containing genes ACT1 and RPL28 (Figure 4.3E). Depletion 
of Prp39 and Prp9 also caused pre-mRNA accumulation of intron-containing genes 
RPS13 (5’SS and 3’SS) and ECM33 (5’SS), where no lariat primer sets were available 
(Figure 4.3E. Depletion of Slu7 resulted in the accumulation of 3’SS, BP and lariat 
species of ACT1, 5’SS and lariat of RPL28, 5’SS and 3’SS of RPS13 and 5’SS of 
ECM33. The accumulation of lariat in addition to pre-mRNA (5’SS/BP) species 
indicates a mixture of a first and second step splicing defect upon Slu7 depletion 
(Figure 4.3E). Depletion of each of Prp39, Prp9 and Slu7 caused a significant 
reduction in mRNA and exon 2 levels for all genes tested. In contrast, Prp22 depletion 
resulted in no pre-mRNA accumulation on all genes tested, however for ACT1 and 
RPL28, the lariat species significantly accumulated (Figure 4.3E). As no significant 
accumulation of the 3’SS ACT1 was observed in these conditions, this means that the 
lariat accumulating must be excised intron-lariat, and under these conditions, depletion 
of Prp22 does not cause defects in splicing catalysis, but causes defects in spliceosome 
disassembly after the second step. No significant decrease in mRNA or exon 2 levels 
were observed for any of the genes tested upon Prp22 depletion in these conditions, 
giving further evidence for no defects in splicing catalysis in these conditions.  
 
In summary, the AID system worked well to deplete the essential splicing factors 
Prp39, Prp9, Slu7 and Prp22 from whole cell extracts and chromatin and in addition 
caused the expected defects in splicing catalysis. The loss of exon 2 and mRNA species 
upon depletion of Prp39, Prp9 and Slu7 could be explained by degradation of spliced 
RNA. As pre-mRNA species accumulate, it is not indicative of a transcription defect.  
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Figure 4.3 (continued). Use of the AID system to conditionally deplete essential 
splicing factors 
 
(B) Western blot probed with anti-FLAG and anti-Pgk1 as a loading control. Samples were 
taken before (0) and 30 minutes (30) after addition of auxin. Prp39-AID*, Prp9-AID*, Slu7-AID* 
and Prp22-AID* depletion was quantified and shown as the percentage mean of 3 biological 
replicates after 30 minutes of auxin addition with respect to (W.R.T) time zero and normalised 
to the Pgk1 signal. Error bars = standard error of the mean.  
(C) Anti-FLAG ChIP followed by qPCR analysis of the intron-containing genes ACT1 and 
ECM33 without (-) auxin (blue) or with (+) 30 minutes of auxin (orange) addition to deplete 
Prp39-AID*, Prp9-AID*, Slu7-AID* and Prp22-AID*. The X-axis shows the positions of 
amplicons used for ChIP qPCR analysis – the exons are of each gene in grey. The data is 
presented as the mean percentage of input normalised to a negative control amplicon. Mean 
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Mean of 3 biological replicates. Error bars = S.E.M.
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Figure 4.3 (continued). Use of the AID system to conditionally deplete essential 
splicing factors 
(D) Splicing RT-qPCR cartoon showing the primers used for the splicing RT-qPCR assay for 
an average gene. Primers used detected pre-mRNA (5’SS or BP and 3’SS), lariat (excised 
intron or intron-exon 2), exon 2 (ex 2) and mRNA. 
(E) RT-qPCR analysis of total RNA from the intron-containing genes ACT1, RPS13, ECM33 
and RPL28 after 30 minutes of depletion of Prp39-AID*, Prp9-AID*, Slu7-AID* and Prp22-
AID*. Normalised to ALG9 intronless transcript and time zero (without auxin addition). Mean 
of at least 3 biological replicates. Error bars = standard error of the mean. 
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4.3 Depletion of essential splicing factors that affect the first, or first and second, 
step of splicing reduces the level of H3K4me3 
 
To determine whether the level of h3K4me3 is altered by depletion of splicing factors 
that affect the first (Prp39, Prp9), or first and second (Slu7) steps in these, ChIP was 
performed using antibodies against H3K4me3 and histone H3 followed by qPCR 
across intron-containing genes ACT1, RPS13 and ECM33. H3K4me3 peaks towards 
the 5’ end of actively transcribed genes and declines toward the 3’end, and H3K4me3 
across ACT1, RPS13 and ECM33 showed this correct pattern. Depletion of Prp39 on 
average significantly reduced the level of H3K4me3 to 59% at amplicon 2 (exon 1) of 
ECM33 (student’s t-test, P<0.05), 66%, 68% and 71% at amplicons 1-3 (5’-3’SS) of 
ACT1 (student’s t-test, P<0.05), and to 54% at amplicon 2 (exon 1) of RPS13 (student’s 
t-test, P<0.05), relative to conditions without depletion (Figure 4.4A). Depletion of 
Prp9 on average significantly reduced the level of H3K4me3 to 67% and 75% at 
amplicons 1 and 2 (5’-exon 1) of ECM33 (student’s t-test, P<0.05), 75% at amplicon 
2 (exon 1) of ACT1 (P<0.05), and to 74% at amplicon 2 (exon 1) of RPS13 (student’s 
t-test, P<0.05), relative to conditions without depletion (Figure 4.4B). Depletion of 
Slu7 on average significantly reduced the level of H3K4me3 to 76% and 75% at 
amplicons 2 and 3 (exon 1 and 3’SS) of ECM33 (student’s t-test, P<0.05), 82%, 78% 
and 80% at amplicons 1-3 (5’-3’SS) of ACT1 (P<0.05), and to 71% at amplicon 2 
(exon 1) of RPS13 (student’s t-test, P<0.05), relative to conditions without depletion 
(Figure 4.4C). 
 
Overall, under these conditions depletion of splicing factors that affect the first (Prp39, 
Prp9), or first and second (Slu7) steps reduces the level of H3K4me3, which is 
consistent with previous findings in mammalian cells of a reduction in H3K4me3 upon 











Figure 4.4. Depletion of essential splicing factors that affect the first, or first and 
second, step of splicing reduces the level of H3K4me3 
 
Anti-H3K4me3 ChIP followed by qPCR analysis of the intron-containing genes ACT1, RPS13 
and ECM33 without (-) auxin (blue) or with (+) 30 minutes of auxin (orange) addition to deplete 
(A) Prp39-AID*, (B) Prp9-AID* and (C) Slu7-AID*. The X-axis shows the positions of amplicons 
used for ChIP qPCR analysis – the exons are in grey. The data is presented as the mean 
percentage of input with respect to (W.R.T.) total histone H3. Mean of at least three biological 















Figure 4.4. Depletion of essential splicing factors that affect the first, or first and second, 
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4.4 Prp22 is the latest-acting factor whose depletion causes a reduction in 
H3K4me3 without causing defects in splicing catalysis 
 
It was predicted from previous studies in mammalian cells that depletion of splicing 
factors that affect the first or second step of splicing would result in loss of H3K4me3. 
We next tested whether depletion of late-acting Prp22 for 30 minutes, which did not 
cause defects in splicing catalysis, reduced H3K4me3 levels. ChIP was performed 
using antibodies against H3K4me3 and histone H3 followed by qPCR across intron-
containing genes ACT1, RPS13 and ECM33. Depletion of Prp22 on average 
significantly reduced levels of H3K4me3 to 60% and 66% at amplicons 1 and 2 (5’ 
and exon 1) of ECM33 (student’s t-test, P<0.05), 65%, 64% and 70% at amplicons 1-
3 (5’-3’SS) of ACT1 (student’s t-test, P<0.05), and to 69% and 73% at amplicons 2 
and 3 (exon 1 and intron) of RPS13 (student’s t-test, P<0.05), relative to conditions 
without depletion (Figure 4.5A). 
Figure 4.5. Prp22 is the latest-acting factor whose depletion causes a reduction in 
H3K4me3 without causing defects in splicing catalysis 
 
(A) Anti-H3K4me3 ChIP followed by qPCR analysis of the intron-containing genes ACT1, 
RPS13 and ECM33 without (-) auxin (blue) or with (+) 30 minutes of auxin (orange) addition 
to deplete Prp22-AID*. The X-axis shows the positions of amplicons used for ChIP qPCR 
analysis – the exons are in grey. The data is presented as the mean percentage of input with 
respect to (W.R.T.) total histone H3. Mean of at least three biological replicates. Error bars = 
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The finding that Prp22 depletion caused a reduction in H3K4me3 without causing 
defects in splicing catalysis (after 30 minutes of depletion) was unexpected. To 
confirm this, a more thorough time course of Prp22 depletion was performed with 15, 
30, 45, 60 and 120 minutes of auxin treatment. Western blotting showed that Prp22 
was on average significantly depleted to 66%, 35%, 26%, 20% and 20% after 15, 30, 
45, 60 and 120 minutes of auxin treatment, respectively (student’s t-test, P<0.05) 
(Figure 4.5B). Splicing RT-qPCR showed that Prp22 depletion resulted in no 
significant accumulation of pre-mRNA species (3’SS and BP) (student’s t-test, 
P>0.05) of ACT1, but a significant accumulation of lariat after 15 and 30 minutes of 
auxin treatment (student’s t-test, P<0.05) (Figure 4.5C). After 45, 60 and 120 minutes 
of auxin treatment, pre-mRNA (3’SS and BP) and lariat species of ACT1 significantly 
accumulated (student’s t-test, P<0.05), indicating that there was a first and second step 
splicing defect at these later time points upon further Prp22 depletion (Figure 4.5C). 
Further, 4-thiouracil labelling and purification of newly synthesised RNA was 
performed (Barrass et al., 2015) (data generated in collaboration with David Barrass, 
whom I gratefully acknowledge). Prp22 was depleted on average to 40%, 20% and 9% 
relative to wild-type levels, and each Prp22-depleted culture was subjected to 4-
thiouracil labelling for 1, 2, 4, 6 and 8 minutes and newly synthesised RNA was 
purified, in addition to total RNA (Figure 4.5D). 4-thiouracil labelling agreed with 
earlier experiments – when there was on average 40% of Prp22 left, an accumulation 
of lariat was observed for ACT1, with little effect on pre-mRNA species (Figure 4.5E). 
When Prp22 was further depleted on average to 20% and 9%, the ACT1 lariat further 
accumulated with the 3’SS also increasing – indicating a defect in the second step of 
splicing (Figure 4.5E). The 4-thiouracil labelling further shows that the primary 
consequence of Prp22 depletion is the accumulation of the excised intron-lariat, 









Figure 4.5 (continued). Prp22 is the latest-acting factor whose depletion causes a 
reduction in H3K4me3 without causing defects in splicing catalysis 
 
(B) Western blot probed with anti-FLAG and anti-Pgk1 as a loading control. Samples were 
taken before (T0) and 15 (T15), 30 (T30), 45 (T45), 60 (T60) and 120 (T120) minutes after 
addition of auxin. Prp22-AID* depletion was quantified and shown as the percentage mean of 
3 biological replicates after 30 minutes of auxin addition with respect to (W.R.T) time zero and 
normalised to the Pgk1 signal. Error bars = standard error of the mean.  
(C) RT-qPCR analysis of total RNA from the intron-containing gene ACT1 after 15, 30, 45, 60 
and 120 minutes of depletion of Prp22-AID*. Normalised to ALG9 transcript and time zero 
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Figure 4.5 (continued). Prp22 is the latest-acting factor whose depletion causes a 
reduction in H3K4me3 without causing defects in splicing catalysis 
  
(D) RT-qPCR analysis of total RNA from the intron-containing gene ACT1 with on average 
40%, 20% and 9% of Prp22 remaining. Normalised to exon 2 transcript and time zero (without 
auxin addition). Mean of at least 3 biological replicates. Error bars = standard error of the 
mean. 
(E) RT-qPCR analysis of newly synthesised RNA 4-thiouracil labelled for 1, 2, 4, 6 and 8 
minutes were analysed with on average 40%, 20% and 9% of Prp22 remaining. The X-axis in 
the lower panels shows the 4-thiouracil labelling time points (1, 2, 4, 6 and 8 minutes). All 
values are normalised to the 1 minute labelling value and time zero (without auxin addition). 
Mean of 2 biological replicates. Error bars = standard error of the mean 
Figure 4.5.  Prp22 is the latest-acting factor whose depletion causes a reduction in 
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ChIP was performed using antibodies against H3K4me3 and histone H3 followed by 
qPCR across intron-containing genes ACT1, RPS13 and ECM33 before and after 
depletion of Prp22 for 30 minutes and 60 minutes (Figure 4.5F). Depletion of Prp22 
on average significantly reduced level of H3K4me3 on ACT1 at amplicons 1 to 3 (5’-
3’SS) to 65%, 64% and 70% after 30 minutes of depletion, and 63%, 65% and 78% 
after 60 minutes of depletion (student’s t-test, P<0.05), relative to conditions without 
depletion (Figure 4.5F). For RPS13, the level of H3K4me3 was significantly reduced 
at amplicons 2 and 3 (exon 1 and intron) to 69% and 73% after 30 minutes of depletion 
and on average to 61% across RPS13 (all amplicons) after 60 minutes of depletion 
(student’s t-test, P<0.05), relative to conditions without depletion (Figure 4.5F). For 
ECM33, the level of H3K4me3 was significantly reduced at amplicons 1 and 2 (5’ and 
exon 1) to 60% and 66% after 30 minutes of depletion, and on average to 51% across 
ECM33 (all amplicons) after 60 minutes of depletion (student’s t-test, P<0.05), relative 
to conditions without depletion (Figure 4.5F). Therefore, no further Prp22 depletion 
was observed for longer incubation with auxin. 
 
Next, we asked whether other chromatin marks were affected by loss of Prp22 
depletion in these conditions. One chromatin mark of interest was H3K36me3, which 
is enriched over exons of actively expressed genes (these data were generated in 
collaboration with Dr Emanuela Sani, whom I gratefully acknowledge). Following 
depletion of Prp22 for 30 minutes and 60 minutes, ChIP was performed using 
antibodies against H3K36me3 and histone H3, followed by qPCR across intron-
containing genes ACT1, RPS13 and ECM33 (Figure 4.5G). The pattern of H3K36me3 
was correct– an increase in this mark towards the 3’ end of the genes tested. After 30 
minutes of depletion of Prp22, no significant changes in H3K36me3 were detected 
(student’s t-test, P>0.05), relative to conditions without depletion (Figure 4.5G). 
However, after 60 minutes of Prp22 depletion H3K36me3 was significantly reduced 
at positions along the genes tested. For ACT1, the level of H3K36me3 was 
significantly reduced at amplicon 5 (exon 2) to 58% after 60 minutes of depletion 
(student’s t-test, P<0.05), relative to conditions without depletion (Figure 4.5G). For 
RPS13, the level of H3K36me3 was significantly reduced at amplicons 3 to 5 (intron-
exon2) to 62%, 68% and 60% after 60 minutes of depletion (student’s t-test, P<0.05), 
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relative to conditions without depletion (Figure 4.5G). For ECM33, the level of 
H3K36me3 was significantly reduced at amplicons 3 to 5 (intron-exon2) to 56%, 56% 
and 54% after 60 minutes of depletion (student’s t-test, P<0.05), relative to conditions 
without depletion (Figure 4.5G). 
 
 
Figure 4.5 (continued). Prp22 is the latest-acting factor whose depletion causes a 
reduction in H3K4me3 without causing defects in splicing catalysis 
  
(F) Anti-H3K4me3 and (G) Anti-H3K36me3 (from Dr. Emanuela Sani) ChIP followed by qPCR 
analysis of the intron-containing genes ACT1, RPS13 and ECM33 without (-) auxin (blue) or 
after 30 minutes (orange) and 60 minutes (yellow) of auxin addition to deplete Prp22-AID*. 
The X-axis shows the positions of amplicons used for ChIP qPCR analysis – the exons are in 
grey. The data is presented as the mean percentage of input with respect to (W.R.T.) total 
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To test whether H3K4me1 and H3K4me2 were affected by Prp22 depletion, Prp22 
was depleted for 30 minutes and 60 minutes, then ChIP was performed using 
antibodies against H3K4me2, H3K4me1 and histone H3 was performed followed by 
qPCR across intron-containing genes ACT1, RPS13 and ECM33 (Figures 4.5H and 
4.5I). H3K4me2 peaks after H3K4me3, and H3K4me1 peaks after H3K4me2 on 
ACT1, RPS13 and ECM33 – indicating the expected methylation patterns. After 30 
minutes of depletion of Prp22, H3K4me1 was significantly reduced on average to 35% 
at amplicon 4 (exon 2) of ACT1, 24% and 28% at amplicons 2 and 3 (exon 1 and 3’SS) 
of ECM33, respectively, and to 19% at amplicon 5 (exon 2) of RPS13, relative to 
conditions without depletion (student’s t-test, P<0.05) (Figure 4.5H). After 60 minutes 
of depletion of Prp22, H3K4me1 was significantly reduced on average to 47% and 
40% at amplicons 4 and 5 (exon 2) of ACT1, respectively, 46% across amplicons 2 to 
5 (exon 1-exon2) of ECM33, respectively, and to 51% and 44% at amplicons 4 and 5 
(exon 2) of RPS13, respectively, relative to conditions without depletion (student’s t-
test, P<0.05) (Figure 4.5H). After 30 minutes of depletion of Prp22, H3K4me2 did not 
significantly change across ACT1, ECM33 or RPS13 (student’s t-test, P>0.05), but was 
significantly reduced after 60 minutes of depletion to 55% at amplicon 5 of ACT1 
(exon 2), to 53% at amplicons 1 and 2 (5’ and exon 1) of ECM33, and to 46% and 50% 
at amplicons 4 and 5 (exon 2) of RPS13, respectively, relative to conditions without 
depletion (student’s t-test, P<0.05) (Figure 4.5I). 
 
To test whether the effect of Prp22 depletion on H3K4me3 affected intronless genes, 
ChIP was performed using antibodies against H3K4me2 and histone H3 followed by 
qPCR across intronless genes ALG9 and FMP27 after depletion of Prp22 for 30 
minutes and 60 minutes (Figure 4.5J). No significant difference in H3K4me3 levels 
was detected across the intronless genes detected after 30 and 60 minutes of Prp22 








Figure 4.5 (continued). Prp22 is the latest-acting factor whose depletion causes a 
reduction in H3K4me3 without causing defects in splicing catalysis 
 
(H) Anti-H3K4me1 and (I) Anti-H3K4me2 ChIP followed by qPCR analysis of the intron-
containing genes ACT1, RPS13 and ECM33 without (-) auxin (blue) or after 30 minutes 
(orange) and 60 minutes (yellow) of auxin addition to deplete Prp22-AID*. The X-axis shows 
the positions of amplicons used for ChIP qPCR analysis – the exons are in grey. The data is 
presented as the mean percentage of input with respect to (W.R.T.) total histone H3. Mean of 
at least three biological replicates. Error bars = standard error of the mean. 
(J) Anti-H3K4me3 ChIP followed by qPCR analysis of the intronless genes ALG9 and FMP27 
without (-) auxin (blue) or after 30 minutes (orange) and 60 minutes (yellow) of auxin addition 
to deplete Prp22-AID*. The X-axis shows the positions of amplicons used for ChIP qPCR 
analysis – the exons are in grey. The data is presented as the mean percentage of input with 
respect to (W.R.T.) total histone H3. Mean of at least three biological replicates. Error bars = 
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Figure 4.5.  Prp22 is the latest-acting factor whose depletion causes a reduction in 
H3K4me3 without causing defects in splicing catalysis
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Figure 4.5.  Prp22 is the latest-acting factor whose depletion causes a reduction in 
H3K4me3 without causing defects in splicing catalysis
































Figure 4.5.  Prp22 is the latest-acting factor whose depletion causes a reduction in 
H3K4me3 without causing defects in splicing catalysis
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In summary, the primary consequence of Prp22 depletion appears to be accumulation 
of the excised intron-lariat, followed by a second step defect in pre-mRNA splicing 
after further depletion. Depletion of Prp22 for 30 minutes resulted in a reduction in the 
level of H3K4me3 on three intron-containing genes tested, with no defects in splicing 
catalysis observed. Depletion of Prp22 for 60 minutes did not further reduce the level 
of H3K4me3 relative to 30 minutes of depletion. Depletion of Prp22 did not reduce 
the level of H3K4me3 on the intronless genes tested, meaning the effect may be 
specific to intron-containing genes. After 30 minutes of Prp22 depletion, H3K4me1 
was reduced at some positions along the genes tested, and this was increased after 60 
minutes of depletion of Prp22. In contrast, H3K4me2 was not significantly reduced 
after 30 minutes of Prp22 depletion but was significantly reduced after 60 minutes of 
depletion. After 30 minutes of Prp22 depletion, no significant reduction in H3K36me3 






























4.5 Depletion of Prp39, Prp9 and Slu7 reduces co-transcriptional recruitment of 
Prp22 to genes 
 
To test whether depletion of Prp39, Prp9, or Slu7 reduces the recruitment of Prp22 to 
intron-containing genes, Prp22 was C-terminally 13MYC epitope tagged in each of 
the Prp39-AID*, Prp9-AID* and Slu7-AID* strains. The recruitment of Prp22 to the 
intron-containing genes after depletion of these essential splicing factors was tested by 
ChIP-qPCR across ACT1, RPS13 and ECM33. Depletion of Prp39 significantly 
reduced Prp22 recruitment on average to 67% at amplicon 5 (exon 2) on ACT1, 67% 
at amplicon 5 (exon 2) on RPS13 and 68% at amplicon 5 (exon 2) on ECM33 (student’s 
t-test, P<0.05) (Figure 4.6A). Depletion of Prp9 significantly reduced Prp22 
recruitment on average to 44% at amplicon 5 (exon 2) on ACT1, 72% at amplicon 5 
(exon 2) on RPS13 and 75% at amplicon 5 (exon 2) on ECM33 (student’s t-test, 
P<0.05) (Figure 4.6B). Depletion of Prp9 significantly reduced Prp22 recruitment on 
average to 53% at amplicon 5 (exon 2) on ACT1, 46% at amplicon 5 (exon 2) on RPS13 
and 73% at amplicon 5 (exon 2) on ECM33 (student’s t-test, P<0.05) (Figure 4.6C). 
 
As the spliceosome is known to assemble in a step-wise manner on pre-mRNA 
substrates, this finding that depletion of earlier acting splicing factors reduces co-
transcriptional recruitment of Prp22 to genes was not unexpected. As Prp22 was the 
latest-acting factor analysed that caused a reduction in H3K4me3, and as depletion of 
earlier splicing factors reduced co-transcriptional recruitment of Prp22 to genes, we 















Figure 4.6. Depletion of Prp39, Prp9 and Slu7 reduces co-transcriptional recruitment of 
Prp22 to genes 
 
Anti-MYC (Prp22-13MYC) ChIP followed by qPCR analysis of the intron-containing genes 
ACT1, RPS13 and ECM33 without (-) auxin (blue) or with (+) 30 minutes of auxin (orange) 
addition to deplete (A) Prp39-AID*, (B) Prp9-AID* and (C) Slu7-AID*. The X-axis shows the 
positions of amplicons used for ChIP qPCR analysis – the exons are of each gene in grey. 
The data is presented as the mean percentage of input with respect to (W.R.T.) the first 
amplicon of each gene. Mean of at least three biological replicates. Error bars = standard error 
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4.6 Depletion of Prp22 reduces Set1 recruitment 
 
In S. cerevisiae, a single histone methyltransferase, Set1, is required for H3K4me3. To 
test whether the reduced H3K4me3 upon Prp22 depletion was due to loss of Set1 
recruitment, Set1 was N-terminally 9MYC epitope tagged in the Prp22-AID* strain 
(Dehé et al., 2006). Prp22 was depleted using the AID system, and recruitment of 
9MYC tagged Set1 tested by ChIP-qPCR across the intron-containing genes ACT1, 
RPS13 and ECM33 after depletion of Prp22 for 30 minutes and 60 minutes.  
 
Depletion of Prp22 significantly reduced Set1 recruitment across ACT1 on average to 
47% (amplicons 1-4; 5’ – exon 2) and 58% (amplicons 1-5; 5’– exon 2) after depletion 
of Prp22 for 30 minutes and 60 minutes, respectively (student’s t-test, P<0.05), relative 
to conditions without depletion (Figure 4.7A). Across RPS13, depletion of Prp22 
significantly reduced Set1 recruitment on average to 47% (amplicons 1-6; 5’-3’) and 
51% (amplicons 2-5; exon 1 – exon 2) after depletion of Prp22 for 30 minutes and 60 
minutes, respectively (student’s t-test, P<0.05), relative to conditions without 
depletion (Figure 4.7A). Across ECM33, depletion of Prp22 significantly reduced Set1 
recruitment on average to 47% (amplicons 1-4; 5’-exon 2) and 51% (amplicons 1-4; 
5’-exon 2) after depletion of Prp22 for 30 minutes and 60 minutes, respectively 
(student’s t-test, P<0.05), relative to conditions without depletion (Figure 4.7A). 
 
As Set1 is recruited to transcribing RNAPII, it is possible that loss of Set1 recruitment 
upon depletion of Prp22 is caused by reduced RNAPII occupancy. To test whether 
Prp22 depletion resulted in loss of RNAPII occupancy, ChIP was performed using an 
antibody against RNAPII (Rpb1) followed by qPCR across ACT1, RPS13 and ECM33 
depletion (Figure 4.7B). After depletion of Prp22 for 30 or 60 minutes, no significant 
change in RNAPII occupancy was observed across ACT1 or ECM33 (student’s t-test, 
P>0.05), relative to conditions without depletion, although after 60 minutes of auxin 
treatment RNAPII occupancy was reduced to 65% at amplicon 3 of RPS13 (student’s 




More specifically, Set1 is recruited to RNAPII that is phosphorylated at serine 5 on 
the CTD, and therefore another possible explanation for loss of Set1 recruitment is by 
loss of phosphorylation of serine 5 in the CTD of RNAPII. ChIP was performed using 
an antibody against phosphorylated serine 5 (S5P) in the CTD followed by qPCR, as 
before. After 30 and 60 minutes of auxin treatment to deplete Prp22, no significant 
change in serine 5 phosphorylation was observed across ACT1, RPS13 and ECM33 
(student’s t-test, P>0.05), relative to conditions without depletion (Figure 4.7C).  
 
The loss of Set1 occupancy upon Prp22 depletion could be explained by a reduction 
in the total cellular level of Set1. To test this, western blotting was performed with an 
antibody against the MYC epitope tag (to detect 9MYC-Set1) using extracts with and 
without 60 minutes of Prp22 depletion. The average cellular level of Set1 after 
depletion of Prp22 was 87% relative to conditions without depletion, but this 
difference was not statistically significant (student’s t-test, P>0.05) (Figure 4.7D). 
 
In summary, depletion of Prp22 for 30 and 60 minutes reduced Set1 recruitment at 
three intron-containing genes tested. This reduction in Set1 recruitment is apparently 
not due to reduced occupancy of RNAPII or of CTD S5P on these genes. Furthermore, 
















Figure 4.7. Depletion of Prp22 reduces Set1 recruitment to genes 
 
(A) Anti-MYC (9MYC-Set1) ChIP followed by qPCR analysis of the intron-containing genes 
ACT1, RPS13 and ECM33 without (-) auxin (blue) or after 30 minutes (orange) and 60 minutes 
(yellow) of auxin addition to deplete Prp22-AID*. The data is presented as the mean 
percentage of input with respect to (W.R.T) a negative control amplicon.  
(B) Anti-Rpb1 ChIP followed by qPCR analysis of the intron-containing genes ACT1, RPS13 
and ECM33 without (-) auxin (blue) or after 30 minutes (orange) and 60 minutes (yellow) of 
auxin addition to deplete Prp22-AID*. The Rpb1 ChIP data is presented as the mean 
percentage of input W.R.T. a negative control region.  
(C) Anti-S5P ChIP followed by qPCR analysis of the intron-containing genes ACT1, RPS13 
and ECM33 without (-) auxin (blue) or after 30 minutes (orange) and 60 minutes (yellow) of 
auxin addition to deplete Prp22-AID*. The S5P ChIP data is presented as the mean 
percentage of input W.R.T. Rpb1.  
ChIP data (A-C): The X-axis shows the positions of amplicons used for ChIP qPCR analysis 
– the exons are of each gene in grey. Mean of at least three biological replicates. Error bars = 
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Figure 4.7 (continued). Depletion of Prp22 reduces Set1 recruitment to genes 
 
(D) Western blot probed with anti-FLAG, anti-MYC and anti-Pgk1 as a loading control. 
Samples were taken without (-) and with 60 minutes (+60) of auxin treatment to deplete Prp22-
AID*. 9MYC-Set1 was quantified and shown as the percentage mean of 3 biological replicates 
after 60 minutes of auxin addition with respect to (W.R.T) conditions with no auxin addition 
and normalised to the Pgk1 signal. Error bars = standard error of the mean.  
 
 
4.7 Depletion of Prp22 reduces Spp1 recruitment 
 
In S. cerevisiae, the Spp1 subunit of the Set1 complex is required specifically for 
H3K4me3 (not H3K4me1 or H3K4me2) by Set1. As Set1 and H3K4me3 were reduced 
upon Prp22 depletion, one would predict loss of Spp1 recruitment in these conditions, 
as Spp1 is in complex with Set1. To test whether Spp1 recruitment was reduced upon 
Prp22 depletion, Spp1 was C-terminally 13MYC epitope tagged in the Prp22-AID* 
strain, and recruitment of Spp1 was tested by ChIP-qPCR across the intron-containing 
genes ACT1, RPS13 and ECM33 after depletion of Prp22 for 60 minutes. 
 
Spp1 recruitment was significantly reduced across ACT1 on average to 23% 
(amplicons 1-5; 5’ – exon 2) after depletion of Prp22 for 60 minutes (student’s t-test, 
P<0.05), relative to conditions without depletion (Figure 4.8A). For RPS13, Spp1 
recruitment was significantly reduced on average to 23% at amplicon 4 (exon 2) after 
depletion of Prp22 for 60 minutes (student’s t-test, P<0.05), relative to conditions 
without depletion (Figure 4.8A). For ECM33, Spp1 recruitment was significantly 

















































for 60 minutes (student’s t-test, P<0.05), relative to conditions without depletion 
(Figure 4.8A). 
  
The loss of Spp1 occupancy upon Prp22 depletion could be explained by a reduction 
in the total cellular level of the Spp1. To test this, western blotting was performed with 
an antibody against the MYC epitope tag (to detect Spp1-13MYC) using extracts with 
and without 60 minutes of Prp22 depletion. The average cellular level of Spp1 after 
depletion of Prp22 was 101% relative to conditions without depletion, and this 
difference was not statistically significant (student’s t-test, P>0.05) (Figure 4.8B). 
 
In summary, in addition to Set1 recruitment being reduced upon Prp22 depletion, Spp1 










Figure 4.8. Depletion of Prp22 reduces Spp1 recruitment to genes 
 
(A) Anti-MYC (Spp1-13MYC) ChIP followed by qPCR analysis of the intron-containing genes 
ACT1, RPS13 and ECM33 without (-) auxin (blue) or after 60 minutes (orange) of auxin 
addition to deplete Prp22-AID*. The X-axis shows the positions of amplicons used for ChIP 
qPCR analysis – the exons are of each gene in grey. The data is presented as the mean 
percentage of input with respect to the (W.R.T.) a negative control amplicon. Mean of at least 
three biological replicates. Error bars = standard error of the mean. 
(B) Western blot probed with anti-FLAG, anti-MYC and anti-Pgk1 as a loading control. 
Samples were taken without (-) and with 60 minutes (+60) of auxin treatment to deplete Prp22-
AID*. Spp1-13MYC was quantified and shown as the percentage mean of 3 biological 
replicates after 60 minutes of auxin addition with respect to (W.R.T) conditions with no auxin 
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4.8 Is the effect of Prp22 depletion on H3K4me3 dependent on its physical 
presence or ATPase activity? 
 
The effect of Prp22 on H3K4me3 could be due to the loss of the physical presence of 
Prp22, or loss of its ATPase activity. To distinguish between these two possibilities, 
Prp22 ATPase mutants were used that were previously characterised in vitro (kind gift 
from Prof. Beate Schwer (Schneider et al., 2004)). As a DEX(H/D) box protein, Prp22 
has seven conserved motifs (I-VII) that are important for ATP hydrolysis, coupling 
ATP hydrolysis to RNA unwinding and catalysing mRNA release. One mutant was 
selected that exhibited underactive ATPase activity (T757A) and the other selected 
exhibited overactive ATPase activity (I764A) in vitro (Figure 4.9A) (Schneider et al., 
2004). Both mutations were in motif V of Prp22, and both mutants were able to bind 
RNA in vitro, however both had lost the ability to unwind RNA/DNA duplexes 
(Schneider et al., 2004). An ATPase assay showed that T757A had 8% of WT Prp22 
ATPase activity, and I764A had 259% of WT Prp22 ATPase activity (Schneider et al., 
2004) (Figure 4.9A). Whilst the ATPase activity of I764A was stimulated by the 
addition of an RNA co-factor, the ATPase activity of T757A was not. These mutants 
did not inhibit the second step of splicing but failed to release the mRNA from the 
spliceosome after splicing catalysis. Both mutants are lethal - T757A is lethal because 
the ATP hydrolysis of Prp22 is essential to release the mRNA, whereas I764A is lethal 
because ATP hydrolysis and RNA unwinding are uncoupled, and the mRNA cannot 
be released (Schneider et al., 2004).  
 
As both mutants are lethal, full-length PRP22 (WT), T757A or I764A were cloned 
into a centromeric plasmid that allowed conditional expression from a β-estradiol-
inducible promoter (McIsaac et al., 2014; Mendoza-Ochoa et al., 2018). Additionally, 
each WT/mutant Prp22 was C-terminally V5 epitope tagged to allow 
immunodetection. Each plasmid with WT/mutant Prp22-V5 was transformed into the 
Prp22-AID* strain, so that each WT/mutant Prp22 could be expressed at the same time 







Figure 4.9. Is the effect of Prp22 depletion on H3K4me3 dependent on its physical 
presence or ATPase activity? 
 
(A) ATPase activity of WT and mutant Prp22 in the absence (-RNA) and presence (+RNA) of 
poly(A) (+RNA). The underactive ATPase mutant of Prp22 used in the present work is 
highlighted in red, the overactive ATPase mutant of Prp22 highlighted in blue, and wild-type 
(WT) Prp22 highlighted in grey. Figure taken from Schneider et al., 2004. 
(B) Schematic showing the strains used to determine effects of Prp22 ATPase activity on 
H3K4me3. The parental strain for each was the Prp22-AID* AID degron strain, which was 
transformed with either (i) WT Prp22-V5, (ii) T757A Prp22-V5 or (iii) I764A Prp22-V5 which 
were present on centromeric plasmids and inducible by β-estradiol addition.  
(C) Growth of the Prp22-AID* strains containing either (i) WT Prp22-V5 (grey), (ii) T757A 
Prp22-V5 (red) or (iii) I764A Prp22-V5 (blue) was measured over a period of 11 hours without 




The effects of induction of WT or mutant Prp22-V5 at the same time as depleting 
endogenous Prp22-AID* was assessed by growth analysis (Figure 4.9C). In the 
absence of auxin and β-estradiol, the strains with the WT or mutant Prp22 plasmids 
grew comparably to each other (Figure 4.9C).  With auxin and β-estradiol treatment, 
the growth of the strain with WT Prp22-V5 was unaffected, however the strains with 
T757A Prp22-V5 and I764A Prp22-V5 grew more slowly than the parental strain 
(Figure 4.9C). Therefore, induction of WT Prp22-V5 can prevent the growth defect 
normally found upon Prp22-AID* depletion, and the mutants cannot and, in fact, 
appear to make it worse.  
 
Depletion and induction were checked by western blotting, splicing defects 
determined by splicing RT-qPCR, and effects on H3K4me3 tested by ChIP using 
antibodies against H3K4me3 and histone H3 followed by qPCR across intron-
containing genes ACT1, RPS13 and ECM33. Samples were taken: (i) without the 
addition of auxin (to deplete Prp22-AID*) and β-estradiol (to induce WT/mutant 
Prp22-V5), (ii) with the addition of auxin only for 60 minutes, and (iii) with the 
addition of β-estradiol for 30 minutes followed by auxin for 60 minutes. Each sample 
was taken at the same logarithmic growth stage. These depletion and induction timings 
were previously optimised (data not shown).  
 
To confirm induction of the proteins by the β-estradiol system, western blotting was 
performed. Prp22-AID* was depleted on average to 14% and 7% after 90 minutes of 
auxin treatment and 90 minutes of auxin and β-estradiol treatment, respectively 
(student’s t-test, P<0.05) (Figure 4.9D) (relative to conditions without auxin or β-
estradiol addition). Wild-type (WT) Prp22-V5 was induced on average to 83% relative 
to the level of endogenous Prp22-AID* (Figure 4.9D). Underactive (T757A) Prp22-
V5 was induced on average to 67% relative to the level of endogenous Prp22-AID* 
(Figure 4.9D). Overactive (I764A) Prp22-V5 was induced on average to 47% relative 
to the level of endogenous Prp22-AID* (Figure 4.9D). The difference in expression 
between induced WT Prp22-V5 and endogenous Prp22-AID* was not statistically 
significant (student’s t-test, P>0.05), however the reduced expression of the mutants 
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T757A Prp22-V5 and I764A Prp22-V5 relative to Prp22-AID* was statistically 








Figure 4.9 (continued). Is the effect of Prp22 depletion on H3K4me3 dependent on its 
physical presence or ATPase activity? 
  
(D) Western blots probed with anti-FLAG, anti-V5 and anti-Pgk1 as a loading control. Samples 
were taken (i) without (-) auxin or β-estradiol, (ii) with 60 minutes of auxin treatment (+A), or 
(iii) with 30 minutes of β-estradiol treatment followed by 60 minutes of auxin treatment. Prp22-
AID* depletion was quantified (upper graph, blue bars) and shown as the percentage mean of 
3 biological replicates after auxin treatment with respect to (W.R.T) conditions without auxin 
and normalised to the Pgk1 signal. Induction of WT/mutant Prp22-V5 was quantified (lower 
graph, grey/red/blue bars) and shown as the percentage mean of 3 biological replicates after 
β-estradiol and auxin treatment with respect to (W.R.T) the level of endogenous Prp22-AID* 
prior to depletion. Error bars = standard error of the mean. 
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Prp22 is present at approximately 232 molecules/cell, therefore after 90 minutes of 
auxin treatment and 90 minutes of auxin and β-estradiol treatment, there were 
approximately 32 and 16 molecules/cell remaining, respectively (Kulak et al., 2014). 
WT Prp22-V5, T757A Prp22-V5 and I764A Prp22-V5 were present at approximately 
193, 155 and 100 molecules/cell respectively. Longer inductions of WT/mutant Prp22-
V5 were performed in an attempt to overexpress them, however this was apparently 
not successful within a three-hour time-frame (data not shown). At this stage, it is not 
clear why the mutant versions of Prp22 were less well induced in comparison to the 
WT version.  
 
To test whether the chromatin-associated pool of Prp22-AID* was depleted, and 
whether each WT or mutant Prp22-V5 was recruited co-transcriptionally (to 
chromatin), ChIP was performed using antibodies against FLAG (Prp22-AID*) and 
V5 (WT/mutant Prp22-V5), followed by qPCR across the intron-containing genes 
ACT1, RPS13 and ECM33. ChIP-qPCR showed that endogenous Prp22-AID* was 
significantly depleted from the genes tested after 60 minutes of auxin treatment 
(student’s t-test, P<0.05) (Figure 4.9E). Additionally, ChIP-qPCR showed that each 
WT and mutant Prp22-V5 was recruited to chromatin upon induction with β-estradiol, 
with no significant difference observed between the WT and mutant proteins (student’s 


















Figure 4.9 (continued). Is the effect of Prp22 depletion on H3K4me3 dependent on its 
physical presence or ATPase activity? 
 
(E) Anti-FLAG ChIP (Prp22-AID*) followed by qPCR analysis of the intron-containing genes 
ACT1, RPS13 and ECM33 (i) without (-) auxin and β-estradiol (dark blue) and with auxin to 
deplete endogenous Prp22-AID* and β-estradiol treatment to induce WT (grey), T757A (red) 
and I764A (light blue). The X-axis shows the positions of amplicons used for ChIP qPCR 
analysis – the exons are of each gene in grey. The data is presented as the mean percentage 
of input normalised to the first amplicon. Mean of at least three biological replicates. Error bars 
= standard error of the mean.  
(F) Anti-V5 (WT/mutant Prp22-V5) ChIP followed by qPCR analysis of the intron-containing 
genes ACT1, RPS13 and ECM33 with auxin to deplete endogenous Prp22-AID* and β-
estradiol treatment to induce WT (grey), T757A (red) and I764A (light blue). The X-axis shows 
the positions of amplicons used for ChIP qPCR analysis – the exons are of each gene in grey. 
The data is presented as the mean percentage of input normalised to the first amplicon. Mean 
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Next, a splicing RT-qPCR assay was used to determine whether depletion of Prp22-
AID* or depletion of Prp22-AID* and induction of WT/mutant Prp22-V5 resulted in 
the expected splicing defects. As in previous experiments, depletion of Prp22-AID* 
for 60 minutes resulted in significant accumulation of pre-mRNA (3’SS and BP) and 
lariat species of ACT1 (student’s t-test, P<0.05), pre-mRNA (5’SS and 3’SS) of RPS13 
(student’s t-test, P<0.05), and pre-mRNA (5’SS) of ECM33 (student’s t-test, P<0.05), 
indicating a likely first and second step splicing defect in these conditions (Figure 
4.9G). As expected, induction of WT Prp22-V5 prior to depleting Prp22-AID* 
prevented any splicing defects normally observed upon Prp22-AID* depletion, with 
no significant changes to any pre-mRNA species observed for ACT1, RPS13 and 
ECM33 relative to conditions without depletion (Figure 4.9H, grey bars). Induction of 
T757A/I764A mutant Prp22-V5 at the same time as depleting Prp22-AID* resulted in 
significant accumulation of pre-mRNA (3’SS and BP) and lariat species of ACT1 
(student’s t-test, P<0.05), pre-mRNA (5’SS and 3’SS) of RPS13 (student’s t-test, 
P<0.05), and pre-mRNA (5’SS) of ECM33 (student’s t-test, P<0.05), indicating a 
likely first and second step splicing defect in these conditions (Figure 4.9H, red and 
blue bars). The induction of T757A/I764A mutant Prp22-V5 resulted in significant 
reduction in the levels of mRNA and exon 2 levels of all genes tested (which is 
analogous to depletion of Prp39, Prp9 and Slu7). The induction of the mutants results 
in a more severe defect in splicing catalysis than depletion of Prp22-AID* alone in 
this time-frame, meaning that these mutants are probably dominant, which fits with 















Figure 4.9 (continued). Is the effect of Prp22 depletion on H3K4me3 dependent on its 
physical presence or ATPase activity? 
 
(G) RT-qPCR analysis of total RNA from the intron-containing genes ACT1, RPS13 and 
ECM33 after depletion of Prp22-AID* with 60 minutes of auxin treatment. Primers used 
detected pre-mRNA (3’SS or BP), lariat (excised or intron-exon 2), exon 2 (ex 2) and mRNA. 
Normalised to SCR1 PolIII transcript and undepleted (without auxin addition). Mean of at least 
3 biological replicates. Error bars = standard error of the mean. 
(H) RT-qPCR analysis of total RNA from the intron-containing genes ACT1, RPS13 and 
ECM33 after induction of WT (grey), T757A (red) and I764A (blue) Prp22-V5 for 30 minutes 
of β-estradiol treatment followed by depletion of Prp22-AID* with 60 minutes of auxin 
treatment. Primers used detected pre-mRNA (3’SS or BP), lariat (excised or intron-exon 2), 
exon 2 (ex 2) and mRNA. Normalised to SCR1 PolIII transcript and undepleted (without auxin 
addition). Mean of at least 3 biological replicates. Error bars = standard error of the mean. 
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In summary, depletion of Prp22-AID* by auxin addition and β-estradiol induction of 
WT or mutant Prp22-V5 worked well – western blotting showed the WT/mutant 
Prp22-V5 proteins were induced at the same time as endogenous Prp22-AID* was 
depleted. Additionally, all three WT/mutant Prp22-V5 proteins were recruited to 
chromatin and therefore acting co-transcriptionally. RT-qPCR showed expected 
splicing defects upon induction of the Prp22 mutants, and no splicing defects were 
observed upon induction of WT Prp22 – meaning induction of the WT protein could 
prevent splicing defects normally observed upon Prp22 depletion. Induction of 
T757A/I764A mutant Prp22 proteins resulted in a reduction in exon 2 and mRNA 
species, which was similarly observed upon depletion of Prp39, Prp9 and Slu7. As 
pre-mRNA species accumulate, it is not indicative of a transcription defect and is 
probably explained by degradation of spliced RNA. 
 
4.9 An overactive ATPase mutant of Prp22 supports normal levels of H3K4me3 
and Set1 recruitment 
 
To test whether the effect of Prp22 depletion on H3K4me3 was dependent on its 
ATPase activity, the WT/mutant Prp22-V5 proteins were induced followed by 
depletion of endogenous Prp22-AID*. Each strain (i) WT (ii) T757A or (iii) I764A 
Prp22-V5 was induced by β-estradiol addition for 30 minutes, followed by the addition 
of auxin to deplete Prp22-AID* for 60 minutes. Effects on H3K4me3 were tested by 
ChIP using antibodies against H3K4me3 and histone H3 followed by qPCR across 
intron-containing genes ACT1, RPS13 and ECM33. 
 
Induction of WT Prp22-V5 prior to Prp22-AID* depletion prevented the loss in 
H3K4me3 previously observed upon Prp22-AID* depletion (Figure 4.5F), with no 
significant changes in H3K4me3 levels observed across the intron-containing genes 
tested, relative to conditions without auxin and β-estradiol addition (Figure 4.10A). 
Induction of the underactive ATPase mutant T757A Prp22-V5 prior to Prp22-AID* 
depletion did not prevent the significant reduction in H3K4me3 on average to 68% 
across amplicons 1-4 (5’-exon 2) of ACT1, 65% across amplicons 2-5 (exon 1-exon 2) 
of RPS13 and 52% across amplicons 2 and 3 (exon 1 and 3’SS) of ECM33 (student’s 
t-test, P<0.05) (Figure 4.10A), relative to conditions without auxin and β-estradiol 
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addition. The induction of T757A Prp22-V5 at the same time as depletion of Prp22-
AID* was comparable to depletion of Prp22-AID*. Significantly, induction of the 
overactive ATPase mutant I764A Prp22-V5 prior to Prp22-AID* depletion prevented 
the loss in H3K4me3 observed upon Prp22-AID* depletion – no significant changes 
in H3K4me3 were observed across the intron-containing genes tested, relative to 
conditions without auxin and β-estradiol addition (Figure 4.10A). This suggests that 
the ATPase activity of Prp22-AID* in the absence of RNA unwinding activity is 
sufficient to prevent the loss of H3K4me3 observed upon Prp22-AID* depletion.  
 
To test whether induction of WT or I764A Prp22-V5 was also able to prevent the loss 
of 9MYC-Set1 observed upon Prp22 depletion (Figure 4.7A), ChIP of 9MYC-Set1 
was performed followed by qPCR across the intron-containing genes ACT1, RPS13 
and ECM33 (in the same experimental conditions described above). Induction of WT  
Prp22-V5 prevented the loss of Set1 recruitment previously observed upon Prp22 
depletion – there was a significant increase in 9MYC-Set1 occupancy on average to 
134% across all amplicons of ACT1, to 156%, 155% and 158% at amplicons 2, 4 and 
5 (exon 1, 3’SS, exon 2) of RPS13, and to 131% and 151% at amplicons 4 and 5 (exon 
2) of ECM33 (student’s t-test, P<0.05), relative to conditions without auxin and β-
estradiol addition (Figure 4.10B). Induction of underactive T757A Prp22-V5 caused a 
significant decrease in 9MYC-Set1 occupancy on average to 48% across all amplicons 
of ACT1, to 34% across all amplicons of RPS13 and to 49% across all amplicon of 
ECM33 (student’s t-test, P<0.05), relative to conditions without auxin and β-estradiol 
addition (Figure 4.10B). Induction of overactive I764A Prp22-V5 prior to depletion of 
Prp22-AID* prevented the loss of Set1 occupancy observed upon Prp22-AID* 
depletion – no significant changes in H3K4me3 were observed across the intron-
containing genes tested, relative to conditions without auxin and β-estradiol addition 
(student’s t-test, P>0.05) (Figure 4.10B). To test whether RNAPII occupancy was 
affected by induction of WT and mutants of Prp22-V5, ChIP was performed using an 
antibody against RNAPII (Rpb1) followed by qPCR across ACT1, RPS13 and ECM33 
depletion (Figure 4.10C). No significant change in RNAPII occupancy was observed 





































Figure 4.10. An overactive ATPase mutant of Prp22 supports normal levels of H3K4me3 
and Set1 recruitment 
 
(A) Anti-H3K4me3 ChIP followed by qPCR analysis of the intron-containing genes ACT1, RPS13 and 
ECM33 after induction of WT (grey), T757A (red) and I764A (blue) Prp22-V5 for 30 minutes of β-estradiol 
treatment followed by depletion of Prp22-AID* with 60 minutes of auxin treatment. Control conditions 
with no auxin and β-estradiol treatment is shown in black. The data is presented as the mean percentage 
of input with respect to (W.R.T.) total histone H3.  
(B) Anti-MYC (9MYC-Set1) ChIP followed by qPCR analysis of the intron-containing genes ACT1, 
RPS13 and ECM33 after induction of WT (grey), T757A (red) and I764A (blue) Prp22-V5 for 30 minutes 
of β-estradiol treatment followed by depletion of Prp22-AID* with 60 minutes of auxin treatment. Control 
conditions with no auxin and β-estradiol treatment is shown in black. The data is presented as the mean 
percentage of input with respect to (W.R.T.) total histone H3.  
(C) Anti-Rpb1 ChIP followed by qPCR analysis of the intron-containing genes ACT1, RPS13 and ECM33 
after induction of WT (grey), T757A (red) and I764A (blue) Prp22-V5 for 30 minutes of β-estradiol 
treatment followed by depletion of Prp22-AID* with 60 minutes of auxin treatment. Control conditions 
with no auxin and β-estradiol treatment is shown in black. The data is presented as the mean percentage 
of input with respect to (W.R.T.) total histone H3.  
ChIP data (A-C): The X-axis shows the positions of amplicons used for ChIP qPCR analysis – the exons 
are of each gene in grey. Mean of at least three biological replicates. Error bars = standard error of the 
mea 
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In summary, as predicted, induction of WT Prp22-V5 prior to depletion of Prp22-
AID* prevents the reduction in Set1 recruitment and H3K4me3 previously observed 
upon Prp22-AID* depletion. Induction of an underactive Prp22 ATPase mutant, 
T757A Prp22-V5, did not prevent the reduction of Set1 and H3K4me3 observed by 
depletion of Prp22-AID*. Induction of the overactive Prp22 ATPase mutant, I764A 
Prp22-V5, prior to depletion of Prp22-AID* prevents the reduction in Set1 recruitment 
and H3K4me3 previously observed upon Prp22-AID* depletion, analogous to 
induction of WT Prp22-V5. The overactive ATPase mutant of Prp22 exhibits the same 
splicing defects as the underactive mutant, the difference between the two mutants 
being the ATPase activity. The overactive mutant of Prp22 is unable to couple ATP 
hydrolysis to RNA unwinding, and these data therefore suggest that the ATPase 
activity of Prp22 (normally coupled to RNA unwinding and splicing completion) may 






















4.10 Prp22 and Set1 interact  
 
One way in which the loss of Prp22 might affect H3K4me3 and Set1 recruitment is by 
a physical interaction. Our collaborator, Prof. Vincent Géli (CRCM, Marseille, 
France) performed a yeast two-hybrid screen with full-length Set1, Set1 1-754 and 
Set1 754-1081 as baits and found a physical interaction between Prp22 and Set1 in all 
three screens (Figure 4.11A). The region of Prp22 common to all three baits is amino 
acids 508 to 762, which includes the ATP binding part of the helicase domain of Prp22 
(Prof. Vincent Géli, personal communication). 
 
Figure 4.11. Prp22 and Set1 interact 
 
(A) Diagram showing the functional domains of S. cerevisiae Set1. Two RNA recognition 
motifs (RRM) are shown toward the N-terminus, and the N-SET and SET domains at the C-
terminus. The regions detected by yeast two-hybrid to interact with Prp22 are indicated by 
arrows: Set1 1-754 and Set1 754-1081. Set1 is 1081 amino acids long in S. cerevisiae. Data 
and diagram from Prof. Vincent Géli (CRCM, Marseille, France).  
 
To confirm the physical interaction between Set1 and Prp22, co-immunoprecipitation 
experiments were performed in the Prp22-AID*-6FLAG in which Set1 had a N-
terminal 9MYC epitope tag. Prp22-AID*-6FLAG was pulled down using a FLAG 
antibody, followed by Western blotting using an antibody against the MYC tag 
(Figures 4.11B and 4.11C). A reproducible interaction between Prp22 and Set1 was 
detected (Figures 4.11B and 4.11C). No pull down of Set1 was detected using a control 
strain with no FLAG-tagged Prp22, meaning the co-immunoprecipitation was specific. 
The interaction between Prp22 and Set1 was not RNA-dependent, as treatment with 
RNase did not abolish it (Figures 4.11B and 4.11C). 
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Figure 4.11 (continued). Prp22 and Set1 interact 
  
(B) Western blots from a co-immunoprecipitation experiment in which Prp22-AID*-6FLAG was 
pulled down using a FLAG antibody with or without RNase treatment. Additionally, a strain 
with 9MYC-Set1 with no flag-tagged Prp22 was used as a negative control. Input, non-bound 
and immunoprecipitation (IP) samples were loaded. The blot was probed with an antibody 
against the MYC epitope tag (Set1). 
9MYC-Set1 is indicated by the black asterisk.  
(C) The blot in (B) was probed with a FLAG antibody to show that Prp22-AID*-6FLAG was 






















































































As Set1 interacts with RNAPII, and splicing happens co-transcriptionally, the 
interaction observed between Prp22 and Set1 could be indirect, via RNAPII. Western 
blotting was performed using an antibody against RNAPII (Rpb1). In these conditions, 
Prp22-AID*-6FLAG did not pull down Rpb1 (Figure 4.11D). 
 
 
Figure 4.11 (continued). Prp22 and Set1 interact 
 
(D) The blot in (B) was probed with an antibody against Rpb1 (RNAPII). Rpb1 is indicated by 
the orange asterisk.  
Predicted molecular weights (kDa): Prp22-AID*-6FLAG = 143 kDa, 9MYC-Set1 = 140 kDa. 
 
In summary, Set1 and Prp22 interact by yeast two-hybrid and co-immunoprecipitate 
in a manner stimulated by RNase addition. This interaction is not via RNAPII and 
gives a possible way by which Prp22 depletion could cause a reduction in Set1 




















































4.11 Use of the AID system to conditionally reduce the level of H3K4me3  
 
An important question is what the biological significance of loss of H3K4me3 could 
be. One possibility was the level of H3K4me3 affects future rounds of co-
transcriptional spliceosome assembly or pre-mRNA splicing, as has been reported in 
mammalian cells (Sims et al., 2007). To determine whether loss of H3K4me3 affects 
co-transcriptional spliceosome assembly or pre-mRNA splicing in S. cerevisiae, Spp1, 
which is a core member of the Set1 complex specifically required for H3K4me3, was 
C-terminally AID*-tagged in a strain that constitutively expresses Tir1 that enables 
conditional depletion of Spp1 in the presence of auxin (described in section 3.1). 
 
Western blotting showed that depletion of Spp1 for 30 or 60 minutes resulted in a 
significant reduction, to 25% and 23% of Spp1 left relative to cells with no depletion 
(P<0.05) (Figure 4.12A). It is estimated that Spp1 is present at approximately 449 
molecules/cell (Kulak et al., 2014), and therefore there are approximately 112 and 103 
molecules/cell of Spp1 left after 30 and 60 minutes of depletion, respectively. Despite 
a significant reduction in Spp1 protein level, Western blotting showed that the level of 
H3K4me3 did not decrease accordingly, with on average 78% and 75% of H3K4me3 
remaining after 30 and 60 minutes of depletion, respectively (Figure 4.12B).   
 
To test whether there was an effect on H3K4me3 under these depletion conditions on 
a gene-by-gene basis, ChIP was performed using antibodies against H3K4me3 and 
histone H3 followed by qPCR across intron-containing genes ACT1, RPS13 and 
ECM33 after depletion of Spp1 for 30 minutes and 60 minutes (Figure 4.12C). 
Depletion of Spp1 for 30 minutes significantly reduced the level of H3K4me3 on 
ACT1 on average at amplicons 2 to 5 (exon 1 to exon 2) to 78% after 30 minutes of 
depletion, relative to conditions without depletion (student’s t-test, P<0.05) (Figure 
4.12C). For RPS13, the level of H3K4me3 was significantly reduced on average at 
amplicons 4 to 6 (3’SS to 3’) to 82%, 81% and 74%, respectively after 30 minutes of 
depletion, relative to conditions without depletion (student’s t-test, P<0.05) (Figure 
4.12C). For ECM33, the level of H3K4me3 was significantly reduced on average at 
amplicons 2, 3 and 4 (5’, exon 1 and 3’SS) to 82%, 73% and 82% respectively after 
30 minutes of depletion, relative to conditions without depletion (student’s t-test, 
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P<0.05) (Figure 4.12C). Further depletion of Spp1 for 60 minutes significantly 
reduced the level of H3K4me3 on ACT1 on average at amplicons 1 to 5 (5’ to exon 2) 
to 67% after 60 minutes of depletion, relative to conditions without depletion 
(student’s t-test, P<0.05) (Figure 4.12C). For RPS13, the level of H3K4me3 was 
significantly reduced at amplicons 2 to 6 (exon 1 to 3’) on average to 65% after 60 
minutes of depletion, relative to conditions without depletion (student’s t-test, P<0.05) 
(Figure 4.12C). For ECM33, the level of H3K4me3 was significantly reduced on 
average across the gene to 62% after 60 minutes of depletion, relative to conditions 
without depletion (student’s t-test, P<0.05) (Figure 4.12C). 
 
Despite a significant reduction in Spp1 protein after 30 and 60 minutes of depletion, 
the reduction in H3K4me3 was modest. For the purposes of determining the effects of 
loss of H3K4me3 on co-transcriptional spliceosome assembly and splicing, a much 
greater loss of H3K4me3 was desired, so Spp1 was further depleted for 120 minutes 
(Figure 4.12D). Western blotting showed that depletion of Spp1 for 120 minutes 
resulted on average in a significant reduction to 12% of Spp1 left relative to cells with 
no depletion (student’s t-test, P<0.05) (Figure 4.12D). Therefore, there were 
approximately 54 molecules/cell of Spp1 left after 120 minutes of depletion. Western 
blotting showed that the level of H3K4me3 significantly decreased to 22% after 120 
minutes of Spp1 depletion (Figure 4.12E). 
 
To test whether Spp1 was depleted from chromatin, ChIP was performed using a 
FLAG antibody followed by qPCR analyses across intron-containing genes ACT1, 
RPS13 and ECM33 (Figure 4.12F). ChIP-qPCR showed that, in addition to being 
depleted in whole cell extracts, each Spp1 was well depleted from chromatin after 120 
minutes of auxin treatment (Figure 4.12F). Spp1 was significantly depleted to 62% 
across amplicons 2 to 5 (exon 1 to exon 2) of ACT1, 45% across amplicons 2 to 5 
(exon 1 to exon 2) of RPS13 and 56% across amplicons 2 to 4 (exon 1 to exon 2) of 






Figure 4.12. Use of the AID system to conditionally reduce the level of H3K4me3  
 
A) Western blot probed with anti-FLAG and anti-Pgk1 as a loading control. Samples were 
taken before (T0), 30 minutes (T30) and 60 minutes (T60) after addition of auxin to deplete 
Spp1-AID*. Depletion was quantified and shown as the percentage mean of 3 biological 
replicates after 30 minutes of auxin addition with respect to (W.R.T) time zero and normalised 
to the Pgk1 signal. Error bars = standard error of the mean. 
(B) Western blot probed with anti-H3K4me3 and anti-H3 as a loading control. Samples were 
taken before (T0), 30 minutes (T30) and 60 minutes (T60) after addition of auxin to deplete 
Spp1-AID*. H3K4me3 levels were normalised to H3 and shown as the percentage mean of 3 
biological replicates after 30 or 60 minutes of auxin addition with respect to (W.R.T) time zero. 
Mean of three biological replicates. Error bars = standard error of the mean. 
(C) Anti-H3K4me3 ChIP followed by qPCR analysis of the intron-containing genes ACT1, 
RPS13 and ECM33 before (- auxin, blue), 30 minutes (+ 30 mins auxin, orange) and 60 
minutes (+ 60 mins auxin, grey) after addition of auxin to deplete Spp1-AID*. The X-axis shows 
the positions of amplicons used for ChIP qPCR analysis – the exons are of each gene in grey. 
The data is presented as the mean percentage of input normalised to total histone H3. Mean 
of at least three biological replicates. Error bars = standard error of the mean.  
Spp1-AID*
T0        T30        T60
Spp1-AID*-6FLAG
Pgk1





















































1 2 3 4 5 6
+ 60 mins auxin



























































































Figure 4.12 (continued). Use of the AID system to conditionally reduce the level of 
H3K4me3  
 
D) Western blot as in (A) with samples taken without auxin (-) and with 120 minutes (120) of 
auxin treatment to deplete Spp1-AID*. 
(E) Western blot as in (B) with samples taken without auxin (-) and with 120 minutes (120) of 
auxin treatment to deplete Spp1-AID*. 
(F) Anti-FLAG ChIP followed by qPCR analysis of the intron-containing genes ACT1, RPS13 
and ECM33 without (-) auxin (blue) or with (+) 120 minutes of auxin (yellow) addition to deplete 
Spp1-AID*. The X-axis shows the positions of amplicons used for ChIP qPCR analysis – the 
exons are of each gene in grey. The data is presented as the mean percentage of input 
normalised to a negative control amplicon. Mean of at least three biological replicates. Error 
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To test whether depletion or Spp1 for 120 minutes was sufficient to reduce H3K4me3, 
ChIP was performed using antibodies against H3K4me3 and histone H3 followed by 
qPCR across intron-containing genes ACT1, RPS13 and ECM33 (Figure 4.12G). On 
ACT1, the level of H3K4me3 was significantly reduced on average at amplicons 1 to 
5 (5’ to exon 2) to 46%, 37%, 35%, 35% and 40% respectively after 120 minutes of 
depletion, relative to conditions without depletion (student’s t-test, P<0.05) (Figure 
4.12G). On RPS13, the level of H3K4me3 was significantly reduced on average at 
amplicons 1 to 5 (5’ to exon 2) to 53%, 59%, 53%, 37% and 22% respectively after 
120 minutes of depletion, relative to conditions without depletion (student’s t-test, 
P<0.05) (Figure 4.12G). On ECM33, the level of H3K4me3 was significantly reduced 
on average at amplicons 1 to 5 (5’ to exon 2) to 49%, 32%, 23%, 34% and 45% 
respectively after 120 minutes of depletion, relative to conditions without depletion 
(student’s t-test, P<0.05) (Figure 4.12G). Therefore, depletion of Spp1 for 120 minutes 
was suitable for a greater depletion of H3K4me3, and these conditions were used to 




















Figure 4.12 (continued). Use of the AID system to conditionally reduce the level of 
H3K4me3  
 
 (G) Anti-H3K4me3 ChIP followed by qPCR as in (C) with samples were taken without auxin 
(- auxin, blue) and with 120 minutes (+ 120 mins auxin, yellow) of auxin treatment to deplete 
Spp1-AID*. The X-axis shows the positions of amplicons used for ChIP qPCR analysis – the 
exons are of each gene in grey. The data is presented as the mean percentage of input 
normalised to a negative 
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In summary, it took 120 minutes of Spp1 depletion to greatly reduce H3K4me3 levels 
in whole cell extracts and across the genes tested. In S. cerevisiae, the average doubling 
time is 90 minutes, and the finding that it took 120 minutes of Spp1 depletion to greatly 
reduce H3K4me3 levels fits with previous findings that H3K4me3 is mostly lost by 
dilution of histones during DNA replication (Ng et al., 2003b; Radman-Livaja et al., 
2010). The reduction in H3K4me3 observed after 60 minutes of Spp1 depletion was 
similar the reduction observed with Prp22 depletion.  
 
4.12 Loss of H3K4me3 does not affect co-transcriptional spliceosome assembly 
 
To determine whether the loss of H3K4me3 affects co-transcriptional spliceosome 
assembly, ChIP-qPCR was performed across intron-containing genes ACT1, RPS13 
and ECM33. Antibodies were used that detect core members of the spliceosome: the 
U1 snRNP (Prp40), U2 snRNP (Lea1-3HA) and U5 snRNP (Prp8), which allowed a 
detailed picture of which stage, if any, of co-transcriptional spliceosome assembly may 
be affected by loss of H3K4me3. In addition, ChIP using an antibody against RNAPII 
(Rpb1) was performed to test for changes in RNAPII occupancy.  
 
ChIP-qPCR analyses showed no significant change in the occupancy of U1, U2 or U5 
snRNPs upon Spp1 depletion for 120 minutes, relative to conditions without auxin 
(student’s t-test, P>0.05) (Figures 4.13A-4.13C). ChIP-qPCR analyses showed no 
significant change in RNAPII occupancy upon Spp1 depletion across ACT1 (student’s 
t-test, P>0.05) (Figure 4.13D). There was a significant increase in RNAPII occupancy 
at amplicon 3 (3’SS) of RPS13 to 117% (student’s t-test, P<0.05) (Figure 4.13D), 
relative to conditions without depletion. In contrast, for ECM33 there was a significant 
decrease in RNAPII occupancy at amplicon 2 (exon 1) to 67% (student’s t-test, 
P<0.05) (Figure 4.13D), relative to conditions without depletion. 
 
Therefore, under these conditions, in vivo loss of H3K4me3 via Spp1 depletion does 
not affect co-transcriptional spliceosome assembly. This is in contrast to findings in 
mammalian cells where the recruitment of the U2 snRNP to chromatin is reduced by 




Figure 4.13. Loss of H3K4me3 does not affect co-transcriptional spliceosome 
assembly 
 
(A) Anti-Prp40 (U1 snRNP) (B) Anti-Lea1-3HA (U2 snRNP) (C) Anti-Prp8 (U5 snRNP) and (D) 
Anti-Rpb1 ChIP followed by qPCR analysis of the intron-containing genes: ACT1, RPS13, 
ECM33 without auxin (blue) and with 120 minutes (yellow) of auxin addition to deplete Spp1-
AID*. The X-axis shows the positions of primers used for ChIP qPCR analysis – the exons are 
in grey. The data is presented as the mean percentage of input normalised to the first amplicon 
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Figure 4.13. Loss of H3K4me3 does not affect co-transcriptional spliceosome assembly













4.13 Loss of H3K4me3 does not affect pre-mRNA splicing 
 
To test whether loss of H3K4me3 in these conditions affected pre-mRNA splicing, 
RT-qPCR was performed on total (steady-state) RNA, as described in section 3.5. No 
significant accumulation of pre-mRNA species upon depletion of Spp1 was observed 
for ACT1, RPS13 and ECM33 (student’s t-test, P>0.05) (Figure 4.14A). For ECM33, 
there was a small but significant reduction in the levels of the 5’SS, mRNA and exon 
2 (student’s t-test, P<0.05) (Figure 4.14), indicating a possible transcription defect for 
this gene that was not observed for ACT1 or RPS13. 
 
Overall, depletion of Spp1 and loss of H3K4me3 does not result in defects in pre-
mRNA splicing, which fits with the ChIP-qPCR data that showed no effect on co-
transcriptional spliceosome assembly upon Spp1 depletion and loss of H3K4me3 
(Figure 4.13). This is in contrast to the findings in mammalian cells where loss of 
H3K4me3 reduced pre-mRNA splicing efficiency and affects patterns of alternative 
splicing (Sims et al., 2007; Luco et al., 2010). 
 
 
Figure 4.14. Loss of H3K4me3 does not affect pre-mRNA splicing 
 
RT-qPCR analysis of total RNA from the intron-containing genes ACT1, RPS13 and ECM33 
after 120 minutes of depletion of Paf1-AID* (A). Normalised to the SCR1 PolIII transcript and 
conditions without auxin. Primers used detected pre-mRNA (3’SS or BP), lariat (excised or 
intron-exon 2), exon 2 (ex 2) and mRNA and are depicted in Figure 4.3D.  Mean of 3 biological 
















































Evidence that splicing affects H3K4me3 comes from experiments that make use of a 
splicing inhibitor drug (spliceostatin A) to block the first step of splicing of 
endogenous transcripts or transcripts of a reporter gene with a cis-acting 3’SS mutation 
that blocks the second step of splicing catalysis (Sims et al., 2007; Bieberstein et al., 
2012). These studies effectively demonstrate that splicing is important for proper 
levels of H3K4me3. Spliceostatin inhibits SF3b (U2 snRNP) and inhibits spliceosome 
assembly between the A and B complex formation (Roybal and Jurica, 2010). In the 
case of a 3’SS mutant, the spliceosome can assemble, the first step of splicing occurs 
but the second step of splicing does not. These data point to spliceosome assembly and 
the second step as important for proper levels of H3K4me3 in mammalian cells, but 
do not pin-point precisely which factors may be important – particularly as the 
spliceosome assembles in a step-wise manner and inhibiting earlier stages by 
definition inhibits later stages and so it is difficult to distinguish between primary and 
secondary effects. Additionally, these experiments were all performed in mammalian 
systems, and it was not clear whether splicing affects H3K4me3 in S. cerevisiae. 
Experiments here describe the use of the AID system to conditionally deplete essential 
splicing factors that act throughout the splicing cycle to address whether splicing 
affects H3K4me3 in S. cerevisiae, and if so to pin-point a particular stage, or particular 
protein, that may be important for proper levels of H3K4me3.  
 
Here, the AID system was effective in conditionally depleting the essential splicing 
factors from whole cell extracts and chromatin, and the expected splicing defects were 
observed upon their depletion. Depletion of first step splicing factors Prp39 (U1 
snRNP) and Prp9 (U2 snRNP) for 30 minutes caused defects in the first step of splicing 
on the intron-containing genes tested, whilst depletion of second step splicing factor 
Slu7 caused defects in the first and second step of splicing (Figure 4.3). This is likely 
because a recycling defect, in which snRNPs are stuck in arrested spliceosomes, is 
caused by Slu7-AID* depletion, which feeds back to the first step of splicing, giving 
a secondary effect of a first step splicing defect. A recycling defect upon depletion of 
U5 snRNA has been previously demonstrated, and Gonzalo Mendoza-Ochoa (Beggs 
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lab) has also extensively demonstrated recycling defects upon splicing factor depletion 
by the AID system (Tardiff and Rosbash, 2006; Gonzalo Mendoza-Ochoa, personal 
communication). In 30 minutes, Prp22 was less well depleted than the other splicing 
factors, and this milder depletion did not result in defects in splicing catalysis, but the 
accumulation of the excised intron-lariat (Figure 4.3). This observation fits with the 
primary role of Prp22 in the release of the mRNA after splicing catalysis has occurred 
(Wagner et al., 1998; Aronova et al., 2007; Schwer, 2008; Fica et al., 2017). 
 
Depletion of factors that affected the first (Prp39 and Prp9), or first and second (Slu7), 
step of splicing caused a significant reduction in H3K4me3 on the intron-containing 
genes tested (Figure 4.4). This observation fits with the evidence from mammalian 
cells that inhibiting the first or second step of splicing reduces the level of H3K4me3 
(Sims et al., 2007; Bieberstein et al., 2012). Unexpectedly, depletion of Prp22 to a 
level where no defects in splicing catalysis were observed by splicing RT-qPCR also 
caused a significant reduction in H3K4me3 (Figure 4.5A). No splicing defects 
observed upon mild depletion of Prp22 was verified by a time course experiment with 
more thorough depletion of Prp22 and 4-thiouracil labelling of newly synthesised 
RNA (Figures 4.5B-4.5E). These experiments showed again that milder depletion of 
Prp22 did not cause defects in splicing catalysis, but longer depletion of Prp22 showed 
first and second step splicing defects, likely due to a recycling defect (as in the case of 
Slu7 depletion). From this point I decided to focus on Prp22 as the factor that may 
regulate the level of H3K4me3 on intron-containing genes because the spliceosome is 
well-established to assemble on pre-mRNA substrates in a step-wise manner, and 
depletion of the earlier acting splicing factors (Prp39, Prp9 and Slu7) caused a 
reduction in the co-transcriptional recruitment of Prp22 to the intron-containing genes 
tested (Figure 4.6). 
 
Analysis of the effects of depletion of Prp22 on other histone modifications 
(H3K36me3, H3K4me1, H3K4me2) revealed most consistently that these 
modifications were reduced after an hour of Prp22 depletion (where defects in the first 
and second steps of splicing were detected), not in the milder 30 minute depletion (no 
defects in splicing catalysis detected) (Figures 4.5G-4.5I). The finding that a mild 
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depletion of Prp22 did not affect H3K36me3 fits with the findings of Dr. Emanuela 
Sani (Beggs lab), who has investigated the effects of splicing on H3K36me3 and found 
that blocking pre-spliceosome formation, but not later steps, leads to loss of 
H3K36me3 and recruitment of H3K36 methyltransferase Set2 (Dr. Emanuela Sani, 
personal communication). The delay in loss of H3K4me2 and H3K4me1 is consistent 
with previous studies that show loss of H3K4me3 and Set1 without loss of H3K4me2 
and H3Kme1 (Schlichter and Cairns, 2005; Luciano et al., 2017; Sayou et al., 2017). 
These data suggest specificity of the effect of Prp22 depletion to H3K4 methylation 
states.  
 
How might depletion of Prp22 result in a reduction in H3K4me3? One possibility was 
that the recruitment of Set1, the only histone methyltransferase responsible for 
H3K4me3 in S. cerevisiae, was reduced. ChIP experiments showed that Set1 
recruitment was reduced on the intron-containing genes tested upon Prp22 depletion, 
giving an explanation as to why H3K4me3 was reduced after Prp22 depletion (Figure 
4.7A). Set1 is recruited to the CTD of transcribing RNAPII via the Paf complex which 
interacts with the serine 5 phosphorylated CTD of RNAPII (Krogan et al., 2003; Ng 
et al., 2003b). It was possible that Set1 recruitment was reduced because RNAPII was 
reduced, however no significant changes to RNAPII occupancy or serine 5 
phosphorylation of the CTD were observed in the present work, and therefore I 
discount this possibility (Figures 4.7B and 4.7C). To fit with the reduction of Set1 
recruitment upon Prp22 depletion, recruitment of Spp1, a member of the S. cerevisiae 
Set1 complex required for H3K4me3 was also reduced after Set1 depletion (Figure 
4.8).  
 
Currently, it is unclear how widely in the genome loss of Set1 recruitment and 
H3K4me3 occurs upon Prp22 depletion, though we have some evidence that it is 
specific to intron-containing genes and not intronless genes (Figure 4.5J). To address 
this, ChIP-sequencing has been performed of 9MYC-Set1 after Prp22 depletion by our 
collaborator, Vincent Géli, and we are awaiting the results (Prof. Vincent Géli, 
personal communication). The observation that blocking spliceosome assembly and 
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splicing-dependent Prp22 recruitment reduces H3K4me3 suggests that the 
phenomenon is splicing-dependent. 
 
The loss of Set1 recruitment and H3K4me3 upon Prp22 depletion could be solely due 
to loss of the physical presence of Prp22 (presumably co-transcriptionally) or due to 
the loss of its ATPase activity. To determine this, WT Prp22-V5, underactive ATPase 
T757A Prp22-V5 and overactive ATPase I764A Prp22-V5 were each conditionally 
expressed (using the β-estradiol system) prior to depletion of endogenous Prp22. ChIP 
experiments showed each WT/mutant Prp22 protein were recruited co-
transcriptionally to the intron-containing genes tested (Figure 4.9F). Splicing RT-
qPCR demonstrated in vivo defects in the first and second step of splicing upon 
induction of the mutants, and not in the expression of WT Prp22-V5 (Figure 4.9H). 
Therefore, WT Prp22-V5 could prevent splicing defects observed upon Prp22 
depletion, and the mutants appeared to have a dominant affect and compound the 
splicing defects, probably because the spliceosome cannot disassemble, and recycling 
defects occur (as was observed with depletion of Slu7). These data agree with the in 
vitro data that showed that the ATPase mutants allowed the second step of splicing but 
caused defects in mRNA release (Schneider et al., 2004), and the in vivo data of 
Gonzalo Mendoza-Ochoa (Beggs lab), who similarly used the mutants. As the mutant 
Prp22 proteins were recruited co-transcriptionally to the intron-containing genes 
tested, this means the proteins are recruited, this blocks spliceosome recycling and 
defects in pre-mRNA splicing occur.  
 
These experiments demonstrated that expression of WT Prp22-V5 can prevent the 
reduction in Set1 recruitment and H3K4me3 observed upon Prp22 depletion, and so 
can expression of an overactive ATPase mutant of Prp22 (I764A) that can hydrolyse 
ATP but not couple ATP hydrolysis to RNA unwinding (Figures 4.10A and 4.10B). 
Expression of an underactive ATPase mutant (T757A Prp22-V5) could not prevent the 
reduction in Set1 recruitment and H3K4me3 observed upon Prp22 depletion (Figures 
4.10A and 4.10B). No significant differences in RNAPII occupancy were observed, 
and therefore this cannot explain the differences (Figure 4.10C). The main difference 
between the Prp22 mutants was their ability to hydrolyse ATP – both can bind RNA 
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but lack RNA unwinding activity. Therefore, the ATPase activity of Prp22 without its 
RNA unwinding activity is sufficient to prevent loss of Set1 recruitment and 
H3K4me3 normally observed upon Prp22 depletion. Of course, this is an abnormal 
situation – the ATP hydrolysis of Prp22 is normally coupled to 3’-5’ RNA unwinding 
and mechanical work to disrupt the contacts between the U5 snRNP and mRNA. The 
ATPase activity of Prp22 is not required for the second step, and therefore any effects 
of Prp22 depletion are not due to second step splicing defects. This latter statement fits 
with the fact that depletion of Prp22 without defects in splicing catalysis reduced Set1 
recruitment and H3K4me3, and also fits with the finding that induction of the 
overactive ATPase mutant could prevent loss of H3K4me3 in the presence of first and 
second step defects in pre-mRNA splicing. 
 
An interesting observation was that expression of mutant Prp22 proteins resulted in 
reduction in exon 2 and mRNA levels of the intron-containing genes tested, whilst pre-
mRNA species accumulate (Figure 4.9H). As pre-mRNA accumulates, this indicates 
that specifically spliced RNA is degraded. This is likely important, as aberrant mRNAs 
produced may translate into aberrant proteins that have negative consequences to the 
cell. It is curious that pre-mRNAs are not degraded, but it suggests that pre-mRNA 
that is spliced in these conditions is degraded in a manner perhaps triggered by failure 
to satisfy a Prp22-dependent checkpoint. This effect was much more dramatic upon 
expression of the Prp22 mutants in comparison to depletion of Prp22 alone (Figure 
4.9G), which supports the idea that the mutants can trigger degradation. As there are 
secondary defects in splicing catalysis upon expression of the mutants (due to 
spliceosome recycling defects), eventually no mRNA would be produced which means 
mRNA and associated exon 2 levels decrease and pre-mRNA species accumulate as 
they are protected from degradation by the spliceosome or synthesised at a rate such 
that the degradation machinery cannot keep up (Schwer and Meszaros, 2000; Hicks et 
al., 2006; Mayas et al., 2006). Previously, Gonzalo Mendoza-Ochoa also observed this 
phenomenon with the same Prp22 mutants. In this case, UPF1 was deleted, and 
therefore this phenomenon is not Upf1-dependent (Gonzalo Mendoza-Ochoa, Beggs 
lab, personal communication). It is possible that failure to satisfy a Prp22-dependent 
checkpoint recruits the nuclear exosome. This could be tested by deletion of nuclear 
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3’ to 5’ exonuclease Rrp6 in the strains with Prp22 WT/mutant. It is suggested that 
splicing factors could facilitate recruitment of the exosome (reviewed in Bresson and 
Tollervey, 2018) and it has been shown in S. pombe that sequences within a subset of 
introns can promote recruitment of the exosome and degradation of pre-mRNA, which 
is important for regulation of gene expression in different environmental conditions, 
including stress conditions (Kilchert et al., 2015). It is not known whether intron-
dependent recruitment of the exosome could degrade mRNA.   
 
Yeast-2-hybrid experiments found that Prp22 and Set1 interact, and this seemed quite 
robust as Prp22 was found in all three screens, using full-length Set1, Set1 1-754 or 
Set1 754-1081 as baits (Figure 4.11A) (Prof. Vincent Géli, personal communication). 
The region of Prp22 common to all three screens is amino acids 508 to 762, which is 
the ATP binding part of the helicase domain of Prp22. Validating the yeast-2-hybrid 
results, co-immunoprecipitation experiments showed that Prp22 pulled-down Set1 
(Figures 4.11B and 4.11C). Further, this interaction was not abolished by RNase 
treatment. Though the co-immunoprecipitation experiments show that Set1 co-
immunoprecipitates with Prp22, and yeast-2-hybrid data (Prof. Vincent Géli, personal 
communication) show interaction between Set1 and Prp22, at this stage I cannot 
determine whether this interaction is direct or indirect. As Set1 is recruited to 
transcribing RNAPII, one possibility was that the interaction was indirect, via 
RNAPII. There are two reasons I discard this possibility. Firstly, as Prp22 does not 
pull-down Rpb1 (the largest subunit of RNAPII, containing the CTD), this suggests 
that the co-immunoprecipitation is not via RNAPII (Figure 4.11D). Secondly, the 
reduction in Set1 recruitment observed upon Prp22 depletion occurred without 
changes to RNAPII occupancy or serine 5 phosphorylation of the CTD. Another 
possibility is that the interaction between Prp22 and Set1 is indirect, via other splicing 
factors, as has been observed in mammalian cells where Set1 was detected by mass 
spectrometry to interact with the U2 snRNP (Allemand et al., 2016). Further, Chd1 
which binds to H3K4me3, was shown to interact with SF3a (U2 snRNP) (Sims et al., 
2007). To test this, co-immunoprecipitation experiments with other splicing factors to 
look for interaction with Set1 should be performed. Another possibility was that the 
interaction is independent of splicing and the spliceosome. To test this splicing could 
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be blocked by depletion of an earlier splicing factor that is required for the first step of 
splicing (such as Prp39 or Prp9) using the AID system. Experiments here showed that 
co-transcriptional recruitment of Prp22 was reduced upon their depletion, and 
therefore pull-down Prp22 in these conditions would test whether the pull-down of 
Set1 by Prp22 is dependent on splicing. As the expression of an ATPase mutant of 
Prp22 was able to reverse the effects of Prp22 depletion on Set1 recruitment and 
H3K4me3, an intriguing hypothesis is that ATP hydrolysis by Prp22 stimulates its 
interaction with Set1, possibly by conformational changes to Prp22. The fact that the 
ATP binding part of the helicase domain of Prp22 interacts with Set1 fits with this 
hypothesis. This could be tested by performing co-immunoprecipitation experiments 
with the WT and ATPase mutant Prp22 proteins. Presumably, Prp22 lets go of the 
mRNA after ATP hydrolysis and as Prp22 is an RNA-stimulated ATPase, this may 
expose the ATP binding site in Prp22, allowing it to bind set1. 
 
Together, these data suggest a way by which at least the physical presence of Prp22 
could affect Set1 recruitment and subsequently H34Kme3 – by a physical interaction 
that is possibly stimulated by the ATP hydrolysis of Prp22 and therefore its ATP-
dependent RNA helicase activity (Figure 4.15). In agreement with the role of Prp22 in 
modulating chromatin, a previous study in Drosophila oocytes found that RNAi 
knockdown of peanuts (Prp22) resulted in splicing factor recycling defects and failures 
of chromatin decondensation in nurse cells (Klusza et al., 2013). The mechanism and 
significance of chromatin decondensation in Drosophila nurse cells is unclear, 
however in other systems chromatin decondensation is associated with H3K4me3 and 




























Figure 4.15. Prp22 affects Set1 recruitment and H3K4me3 in S. cerevisiae 
 
Depletion of Prp22 in the absence of defects in splicing catalysis reduces Set1 recruitment 
and H3K4me3. This phenomenon seems to be dependent on the ATPase activity of Prp22. 
Prp22 also interacts (genetically and in co-immunoprecipitation experiments) with Set1, 
suggesting that Prp22 (directly or indirectly) helps to recruit Set1 to genes. We propose that 
Prp22 hydrolyses ATP and signals splicing has occurred. Without Prp22 and its ATPase 
activity, Set1 recruitment and H3K4me3 are reduced. 
 
In the present work, ChIP data of Prp22 occupancy show that Prp22 peaks towards the 
3’end of genes (Figure 4.3C), whereas Set1 is in gene bodies and H3K4me3 peaks at 
the 5’ end of genes. The ChIP data here raise the question as to how Prp22 toward the 
3’end of the gene might affect H3K4me3 at the 5’end? Firstly, ChIP is an indirect 
assay that provides a delayed snapshot of co-transcriptional splicing factor occupancy, 
meaning splicing factors are detected by ChIP downstream to where they bind pre-
mRNA (this could be because the pre-mRNA is not aligned in parallel with the DNA). 
This means that Prp22 is likely present upstream to where it is detected by ChIP. It is 
known from in vitro cross-linking studies that Prp22 binds 13-33 nucleotides 
downstream of the 3’SS (Schwer, 2008), and the recent structure of the postcatalytic 
splicing complex shows Prp22 binding 15-21 nucleotides downstream of the exon-
exon junction (Liu et al., 2017). We have performed ChIP-sequencing of Prp22 which 
shows that although Prp22 occupancy peaks toward the 3’ends of some genes, on 
many it is present within introns (Dr. Alastair Kerr, Dr Gabriele Schweikert and Dr 
Guido Sanguinetti personal communication). The sequencing data also show that the 
mRNA
Exon 1 Exon 2













level of Prp22 occupancy correlates with RNAPII occupancy which is consistent with 
ChIP-sequencing of earlier-acting splicing factors in S. cerevisiae (Moore et al., 2006). 
Set1 also associates with RNAPII and was recently shown to associate with nascent 
RNAPII transcripts (Battaglia et al., 2017; Luciano et al., 2017; Sayou et al., 2017). 
The CTD of RNAPII is proposed to be a ‘landing pad’ for co-transcriptional 
recruitment of splicing factors, and it is possible that Prp22 (with other splicing 
factors) generally associates with RNAPII, and in this way influences Set1 recruitment 
and therefore H3K4me3 over multiple rounds of transcription. Another possibility is 
that the genes are looped – where the 5’ and 3’ ends of a gene come into close contact 
during transcription (O’Sullivan et al., 2004; Ansari and Hampsey, 2005). It is 
hypothesized that the presence of an intron may facilitate gene looping (Moabbi et al., 
2012).  
 
What is the biological significance of this phenomenon whereby Prp22 affects Set1 
recruitment and H3K4me3? Prp22 is an ATPase that acts at the very late stages of the 
splicing cycle to release the mRNA after splicing catalysis is complete. Prp22 was 
shown to bind in the second exon of pre-mRNA substrates 17 nucleotides downstream 
of the exon-exon junction, and then acts as a 3’ to 5’ ATP-dependent RNA helicase to 
unwind contacts between the mRNA and U5 snRNA (Wagner et al., 1998; Aronova 
et al., 2007; Schwer, 2008; Fica et al., 2017; Liu et al., 2017). Additionally, Prp22 was 
reported to have roles in fidelity; rejecting sub-optimal splice sites via its ATP-
dependent RNA unwinding activity before exon ligation has occurred (Mayas et al., 
2006). Both these roles of Prp22 are dependent on its ATPase activity, and the finding 
that the effect of Prp22 depletion on H3K4me3 and Set1 recruitment can be prevented 
by expression of an overactive ATPase mutant of Prp22 that is unable to couple ATP 
hydrolysis to RNA unwinding suggests that the phenomenon is dependent on the 
ATPase activity of Prp22. This indicates either that ATP hydrolysis by Prp22 could be 
a signal that splicing is complete and mRNA released, or it could be a signal that the 
substrate is sub-optimal and rejected.  
 
As H3K4me3 is generally thought of as an ‘activating’ chromatin mark, it would make 
more sense to stimulate transcription of a gene the transcript of which has been 
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correctly spliced than one that has been incorrectly spliced, although you could argue 
either way. H34Kme3 stimulated by splicing might be important in serving as a 
memory that stimulates future rounds of transcription and splicing, perhaps by 
providing a platform to enhance co-transcriptional recruitment of splicing factors. 
There is precedent for this - in mammalian cells, loss of H3K4me3 or H3K4me3 reader 
Chd1 was shown to cause a reduction in pre-mRNA splicing efficiency and U2 snRNP 
recruitment to chromatin (Sims et al., 2007). Further, in mammalian cells it was shown 
by metabolic labelling that the loss of an intron in a reporter gene reduced 
transcriptional output, and treatment with splicing inhibitor drug spliceostatin globally 
reduced transcription (Bieberstein et al., 2012). A caveat here is that splicing is 
sensitive to transcription speed, and any changes to transcription could lead to changes 
in co-transcriptional spliceosome assembly and splicing, and a steady-state is reached 
for each gene. In the present work, no consistent changes in RNAPII occupancy were 
observed upon loss of H3K4me3 (Figure 4.13D), though it could be during steady-
state differences are difficult to detect. There is precedent this – a study found that 
effects of Set2 (methyltransferase for H3K36) on gene expression were only detectable 
on inducible genes and in certain environmental conditions (Kim et al., 2016). It may 
be informative to perform experiments on an inducible reporter gene that could be 
more sensitive to changes in H3K4me3.  
 
In order to gauge whether H3K4me3 was important for co-transcriptional spliceosome 
assembly and splicing in S. cerevisiae, Spp1 was conditionally depleted by the AID 
system (Figure 4.12). The average doubling time of S. cerevisiae is 90 minutes, and 
the finding that it took 120 minutes of Spp1 depletion to greatly reduce H3K4me3 
levels fits with previous findings that H3K4me3 is mostly lost by dilution of histones 
during DNA replication (Ng et al., 2003b; Radman-Livaja et al., 2010). The reduction 
in H3K4me3 observed after 60 minutes of Spp1 depletion was similar the reduction 
observed by Prp22 depletion, meaning the relative kinetics of H3K4me3 loss are 
comparable. No effects on co-transcriptional spliceosome assembly or splicing were 
observed, nor any effects on RNAPII occupancy (Figures 4.13 and 4.14). This is 
consistent with findings that deletion of Set1 did not affect co-transcriptional 
spliceosome assembly in yeast and only affected splicing of a subset of yeast genes 
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(approximately 40) (Hérissant et al., 2014), but is in contrast to findings in mammalian 
cells (as discussed above) (Bieberstein et al., 2012). These differences could be due to 
differences in splicing complexity between mammalian cells and yeast cells in terms 
of splicing – the core splicing factors (approximately 90) are conserved between S. 
cerevisiae and mammals, but mammals have approximately double this number due 
to alternative splicing, which is rare in S. cerevisiae (Fabrizio et al., 2009). The finding 
here that loss of H3K4me3 does not affect RNAPII occupancy fits with previous 
studies in S. cerevisiae where loss of H3K4me3 did not result in significant changes 
to gene expression (Briggs et al., 2001; Miller et al., 2001) and the role for H3K4me3 
in transcription is currently unclear (Howe et al., 2017).  
 
It is possible that any effects of H3K4me3 on co-transcriptional spliceosome assembly 
and splicing are undetected by the experiments described here because the level of 
H3K4me3 was not depleted enough. However, Set1 is non-essential and its deletion 
did not show wide-spread splicing defects (Hérissant et al., 2014). Further, David 
Barrass (Beggs lab) performed 4-thiouracil labelling of newly synthesised RNA in 
Set1 and Spp1 deletion strains, which did not show defects in transcription or splicing 
catalysis relative to wild-type conditions (data not shown). It may be that H3K4me3 
could be particularly important in certain conditions – such as stress or meiosis. In 
comparison to other chromatin marks, H3K4me3 was shown to be a very stable mark 
in S. cerevisiae - remaining on genes after transcription shutdown during meiosis and 
osmotic stress, and it is suggested that H3K4me3 could serve as a transcriptional 
memory that allows more rapid changes in gene expression (Borde et al., 2009; 
Magraner-Pardo et al., 2014; Weiner et al., 2015; Howe et al., 2017). Therefore, it 
may be that testing for splicing defects upon loss of H34Kme3 in stress conditions or 
meiosis would be informative. Alternatively, any defects in splicing could be hard to 
detect due to pre-mRNA species being degraded by the degradation machinery, which 
has been demonstrated previously (Hossain et al., 2011; Kawashima et al., 2014). 
Most recently, a role for H2A.Z in splicing was only apparent in cells in which 






Whilst the finding that splicing affects H3K4me3 is conserved between S. cerevisiae 
and mammalian cells, whether the observed links between Prp22, Set1 and H3K4me3 
are conserved is currently unclear. Prp22 is conserved from yeast to mammals, and 
experiments could be performed in mammalian systems to test whether the links are 
conserved. Certainly, effects of loss of H3K4me3 on splicing and co-transcriptional 
spliceosome assembly are clearer in mammalian systems (Sims et al., 2007; 
Bieberstein et al., 2012). 
 
It is currently unclear whether in S. cerevisiae there is an increased level of H3K4me3 
on intron-containing genes in comparison to intronless genes, and the loss of 
H3K4me3 simply reduces the level of H3K4me3 to the level of intronless genes. This 
may be a difficult question to address, as intron-containing genes are more highly 
expressed than intronless genes, however we are currently investigating this question 
bioinformatically (in collaboration with Dr Alastair Kerr, Dr Gabriele Schweikert and 
Dr Guido Sanguinetti). It is also hard to distinguish whether splicing promotes 
H3K4me3 or loss of splicing removes H3K4me3. It is difficult to address this question, 
as during gene expression genes are expressed and spliced. Importantly, in the mild 
depletion of Prp22, transcription and splicing are both wild-type but H3K4me3 is still 
reduced. This suggests that a stage of splicing Prp22 and beyond is important for this 
phenomenon.  
 
In summary, depletion of factors that result in first (Prp39, Prp9), or first and second 
(Slu7), step splicing defects resulted in reduced H3K4me3 on the intron-containing 
genes tested. Most interestingly, a mild depletion of Prp22 reduced Set1 recruitment 
and H3K4me3 without causing defects in splicing catalysis or transcription. As the 
spliceosome assembles on pre-mRNA substrates in a step-wise manner, depletion of 
earlier-acting factors also reduces co-transcriptional recruitment of Prp22, and for this 
reason we focused on Prp22 as the latest-acting factor required for proper levels of 
H3K4me3 on intron-containing genes. Notably, expression of an overactive ATPase 
mutant of Prp22 prevented the loss of Set1 recruitment and H3K4me3 normally 
observed upon Prp22 depletion. This suggests that the effect of Prp22 depletion on 
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Set1 and H3K4me3 is due to the loss of Prp22 ATPase activity. Together, these data 
highlight a previously unknown link between a late-acting splicing factor Prp22, Set1 
and H3K4me3. We favour the idea that ATP hydrolysis by Prp22 after correct pre-
mRNA splicing has occurred stimulates an interaction between Prp22 and Set1 
(brought about perhaps by conformational changes in Prp22 during ATP hydrolysis 
and release of mRNA) which affects the recruitment of Set1 and subsequently 
H3K4me3. Our hypothesis therefore is that H3K4me3 may reflect the status of co-
transcriptional splicing, as signalled by the ATPase activity of Prp22 (Figure 4.15). 
Currently, the biological significance of such a phenomenon is unclear, but it may be 
important in stress conditions or meiosis and difficult to detect by assays used in the 
present work. We hypothesise that the level of H3K4me3 may act as a memory that 
the gene has been spliced and promote transcription through the intron or nucleosomes 




Chapter 5. Closing remarks 
 
In the present study, the use of the AID system has been an effective and novel way to 
characterise the links between splicing and transcription and splicing and chromatin in 
S. cerevisiae. Until now, most studies examining the functions of transcription 
elongation factors have made use of mutants or deletions if non-essential. Splicing 
inhibitor drugs are not available for use in S. cerevisiae so that most studies have made 
use of mutants. Such studies have undoubtedly been fruitful, however in some cases 
adaptation may have occurred and important functions may have been missed or 
effects observed indirectly. The AID system bypasses these problems and has the 
potential to provide novel insights into the functions of both non-essential and essential 
proteins in a wide-variety of biological processes in a variety of systems. 
 
It was already known that mutations or depletion of particular elongation factors 
resulted in defects in pre-mRNA splicing, but it was not known mechanistically how 
these effects came about. For example, previous studies had shown mutants and 
depletion of core transcription elongation factor Spt5 caused splicing defects in yeast, 
but why this should be was unknown. The present work has shown that Spt5 is required 
for proper co-transcriptional recruitment/stability of the U5 snRNP and that, without 
Spt5, the B complex fails to form co-transcriptionally. Further, Spt5 co-
immunoprecipitates with U5 snRNP, showing a possible mechanism as to how Spt5 
could affect U5 snRNP recruitment and B complex formation co-transcriptionally; this 
also provides mechanistic insight into how Spt5 depletion/mutation could cause 
splicing defects. The AID system proved an effective way to examine the functions of 
the core elongation machinery not only in co-transcriptional spliceosome assembly, 
but also their documented functions. In the present work, some findings did not agree 
with the literature; for example, finding that depletion of Bur1 or Bur2 did not affect 
serine 2 phosphorylation of the CTD of RNAPII. These differences are probably due 
to the fact that most studies have made use of mutants or deletions, which may have 




The present work also highlighted apparent differences between lower and higher 
eukaryotes. For example, serine 2 phosphorylation was shown to be important for pre-
mRNA splicing in mammals, however in the present work depletion of Ctk1 in S. 
cerevisiae effectively abolished serine 2 phosphorylation of the CTD and did not affect 
co-transcriptional spliceosome assembly and splicing. As splicing is more complicated 
in mammals, this finding may reflect the need for more advanced regulation of co-
transcriptional splicing. Collectively, these data provide systematic and mechanistic 
insight into the contribution of the core transcription elongation machinery to co-
transcriptional spliceosome assembly and splicing in S. cerevisiae. 
 
The AID system was a particularly powerful approach for depleting essential splicing 
factors that act at different stages of the splicing cycle and asking whether splicing 
affects H3K4me3 in S. cerevisiae and, if so, which stage of splicing. Whilst there were 
known links between H3K4me3 and splicing in mammals, no such links had been 
observed in S. cerevisiae and mechanistically, how splicing might affect H3K4me3. 
The present work has shown that defects in the first or first and second steps of pre-
mRNA splicing reduces H3K4me3 on intron-containing genes. Furthermore, depletion 
of late-acting factor Prp22, without defects in splicing catalysis, reduces H3K4me3. 
The AID system pin-pointed Prp22 as the latest-acting factor required for proper levels 
of H3K4me3 on the intron-containing genes tested. This work has also shown that 
Prp22 depletion reduces Set1 methyltransferase recruitment and that Prp22 interacts 
with Set1, showing how the loss of Prp22 could affect H3K4me3 – via Set1 
recruitment. Use of Prp22 ATPase mutants showed it was not just the physical 
presence of Prp22, but its ATP hydrolysis that is important for Set1 recruitment and 
H3K4me3 on intron-containing genes in S. cerevisiae. The biological significance of 
these links is currently unclear. It is possible that these links become more important 
under certain environmental conditions. 
 
Together, work presented here shows new insight into the connections between 
splicing and transcription and splicing and chromatin in a relatively simple biological 
system. It is clear from the present work and the literature that there are key differences 
in the links between splicing and transcription and splicing and chromatin from lower 
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to higher eukaryotes, likely due to differences in complexity of these biological 
processes. The work described here was carried out on a gene-by-gene basis which has 
obvious limitations and important insights may have been missed. Genome-wide 
studies would ensure that important phenomena do not go unmissed.  
 
Several key questions remain, including: how conserved are these connections 
between splicing and transcription and splicing and chromatin? What is their 
biological significance? Are the effects genome-wide? The AID system is applicable 
in yeast and in mammals, and it would be interesting to perform genome-wide studies 
in both systems with and without depletion of some of the transcription elongation 
factors/chromatin modifiers examined in the present work to gauge effects on co-
transcriptional spliceosome assembly and splicing. The degree of conservation of this 
phenomenon would also be examined. It would be interesting to conditionally deplete 
conserved splicing factors and examine effects on a variety of histone modifications 
genome-wide. Further, whether the links between splicing and transcription and 
splicing and chromatin are more important in certain environmental conditions is 
unclear, and it would be interesting to perform genome-wide studies to address this. 
Such genome-wide studies could be complimented by mechanistic studies, and 
together these data would combine to provide clearer insight into the links between 





















Appendix 1. Table of S. cerevisiae strains used in this study 
 
Name Genotype Source 
W303 MATα ade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 
can1-100 
Beggs lab 
































































































































MATα his3-del’1 leu2-del’0 met15-del’0 ura3-del’0 
bur1-as PAF1-13XMYC::HIS3 spt5-del’::NatMX 
pHQ1494 [SPT5-3XHA, LEU2, CEN4] 
LEA1::LEA1-V5-HygMX 
Qiu et al., 2012 






MATα his3-del’1 leu2-del’0 met15-del’0 ura3-del’0 
bur1-as PAF1-13XMYC::HIS3 spt5-del’::NatMX 
pHQ1494 [spt5-S1-15A-3XHA, LEU2, CEN4] 
LEA1-V5-HygMX 
Qiu et al., 2012 






MATα his3-del’1 leu2-del’0 met15-del’0 ura3-del’0 
bur1-as PAF1-13XMYC::HIS3 spt5-del’::NatMX 
pHQ1494 [spt5-S1-15E-3XHA, LEU2, CEN4], 
LEU2, CEN4] 
LEA1-V5-HygMX 
Qiu et al., 2012 





























































Appendix 2. Oligonucleotides used for strain construction and cloning 
 
















Reverse primer to 
AID-degron tag 
Spt5 
Spt5-CF GGGGTGGCCAAGGTAATGGAGG To check tagging of 
Spt5 

















Reverse primer to 
AID-degron tag 
Bur1 
BUR1-CF CGGTTCTCGCAATATGGCTGGT To check tagging of 
Bur1 

















Reverse primer to 
AID-degron tag 
Bur2 
Bur2-CF CCCTATCGAAGTAACGCCGGA To check tagging of 
Bur2 















Reverse primer to 
AID-degron tag 
Ctk1 
CTK1-CF GCTGGCCAACGCTTTACGATAT To check tagging of 
Ctk1 















Reverse primer to 
AID-degron tag 
Paf1 
Paf1-CF GAAGGCGATTCAAAAACAGAAGGT To check tagging of 
Paf1 







Forward primer to 








Reverse primer to 
epitope tag Lea1 
Lea1-CF CGATGGAGATCATGAATTTGG To check tagging of 
Lea1 







Forward primer to 






Reverse primer to 
epitope tag Prp22 
PRP22-
CF 












Forward primer to 







Reverse primer to 














Reverse primer to 
AID-degron tag 
Spp1 
Spp1-CF CTACATACGAGCGAATACCC To check tagging of 
Spp1 
Spp1-CR AAAACTATACTCCTAAGTGT To check tagging of 
Spp1 
Set1-CF ACAATGTTGGACTTGTTGCA To check tagging of 
Set1 





















CCAAACGAAGGTGACCCCTTCG  Forward primer to 
TAP tag RPB3 
(designed by Dr 




AAGCAAGGTTAGCCCTTCCTTTC  Reverse primer to 
TAP tag RPB3 
(Designed by Dr 






Forward primer for 
Gibson assembly to 












Reverse primer for 
Gibson assembly to 






















































Appendix 3. Table of plasmids used in this study 
 
Name Description Source 
pHYG-AID*-
6FLAG 
To C-terminally AID*-6FLAG tag a gene-
of-interest (HYG selection) 
Ulrich lab 




To C-terminally AID*-9MYC tag a gene-
of-interest (HYG selection) 
Ulrich lab 
(Morawska and Ulrich, 
2013) 
pHYG-AID*-6HA To C-terminally AID*-6HA tag a gene-of-
interest (HYG selection) 
Ulrich lab 
(Morawska and Ulrich, 
2013) 
pZTRL To express OsTIR1 using the B-
estradiol system on a centromeric 
plasmid (LEU2 selection) 
Gonzalo Mendoza-
Ochoa (Beggs lab)  
(Mendoza-Ochoa et al., 
2018) 
pRS426–FUI1  Yeast uracil permease (FUI1) on the 2 
micron plasmid pRS425 (URA3) 
David Barrass (Beggs 




C-terminally V5 tagged version of WT 
PRP22 in a centromeric plasmid (TRP 
selection) 
Prof. Beate Schwer 
(Schneider et al., 2004) 
and Gonzalo Mendoza-
Ochoa (Beggs lab) 
p360-T757A-V5 C-terminally V5 tagged version of T757A 
PRP22 in a centromeric plasmid (TRP 
selection) 
Prof. Beate Schwer 
(Schneider et al., 2004) 
and Gonzalo Mendoza-
Ochoa (Beggs lab) 
p360-I764A-V5 C-terminally V5 tagged version of I764A 
PRP22 in a centromeric plasmid (TRP 
selection) 
Prof. Beate Schwer 
(Schneider et al., 2004) 
and Gonzalo Mendoza-
Ochoa (Beggs lab) 
pZL-PRP22WT-
V5 
C-terminally V5 tagged version of WT 
PRP22 in a centromeric plasmid that 
allows β-estradiol inducible expression 





C-terminally V5 tagged version of T757A 
PRP22 in a centromeric plasmid that 
allows β-estradiol inducible expression 





C-terminally V5 tagged version of I764A 
PRP22 in a centromeric plasmid that 
allows β-estradiol inducible expression 





To C-terminally 13XMYC tag a gene-of-







To C-terminally 3XHA tag a gene-of-
interest (KAN selection) 






To C-terminally 3XV5 tag a gene-of-






 PubMed 19243080 
p9MycSET1-
TRP1 
To N-terminally 9XMYC tag a Set1 (TRP 
selection) 
Vincent Géli (CNRS, 

























































Appendix 4. Table of oligonucleotides used for Splicing RT-qPCR  
 
Name Sequence (5’-3’) Use 
ALG9_F TAAGCTGGCATGTGCTGCATTC To detect ALG9 mRNA 
using RT-qPCR 
ALG9_R TTTGCATGATTCGGTTGATTGG To detect ALG9 mRNA 
using RT-qPCR 
SCR1-F TCTCTGTCTGGTGCGGCAAG To detect SCR1 mRNA 
using RT-qPCR 




AGGGGCTTGAAATTTGGAAAAA  To detect the ACT1 BP/ 
lariat using RT-qPCR 
YFL039C_ACT_B
_R 
































































































































GCCTCCGCTCTAGCTGCTAACTC To detect ECM33 
mRNA using RT-qPCR 
YBR078W_ECM3
3_m_R 
TTGAGCAGTAGCAGTGGCAGAAGT To detect ECM33 
mRNA using RT-qPCR 
YBR078W_ECM3
3_E_F  
CTTCTGCCACTGCTACTGCTCAAG To detect ECM33 exon 
2 using RT-qPCR 
YBR078W_ECM3
3_E_R  





































Appendix 5. Table of oligonucleotides used for ChIP-qPCR  
 














































































































Act1 -139 F TTCCCCTTTCTACTCAAACCAAGAAG To amplify the 
promoter of 
ACT1 (amplicon 
1) using qPCR 
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Act1 -43 R AAGCGTGAAAAATCTAAAAGCTGATG To amplify the 
promoter of 
ACT1 (amplicon 
1) using qPCR 
Act1 -71 (5SS) F TACATCAGCTTTTAGATTTTTCACGCTTAC
TGCTT 
To amplify the 
first exon of 
ACT1 (amplicon 
2) using qPCR 
Act1 +34 (5SS) R GATGGTGCAAGCGCTAGAACATACCAGA
AT 
To amplify the 
first exon of 
ACT1 (amplicon 
2) using qPCR 
Act1 +368 (3SS) F TGTACTAACATCGATTGCTTCATTCTTTTT
GTTGC 
To amplify the 
3’ss of ACT1 
(amplicon 3) 
using qPCR 
Act1 +413 (3SS) R GACGATAGATGGGAAGACAGCACGAGGA To amplify the 
3’ss of ACT1 
(amplicon 3) 
using qPCR 
Act1 +561 F ATCTGGCATCATACCTTCTACAACGA To amplify a 
amplicon in the 
second exon of 
ACT1 (amplicon 
4) using qPCR 
Act1 +653 R GTTTGATTTAGGGTTCATTGGAGCTT To amplify a 
amplicon in the 
second exon of 
ACT1 (amplicon 
4) using qPCR 
Act1 +1119 F TCTGCCGGTATTGACCAAACTACTTA To amplify a 
amplicon in the 
second exon of 
ACT1 (amplicon 
5) using qPCR 
Act1 +1210 R CCGGACATAACGATGTTACCGTATAA To amplify a 
amplicon in the 
second exon of 
ACT1 (amplicon 
5) using qPCR 
Act1 +1595 F ATGTGTTTTGTCTCTCCCTTTTCTACGAAA
ATTTC 
To amplify a 
amplicon in the 
3’ UTR of ACT1 
(amplicon 6) 
using qPCR 
Act1 +1734 R TGATCATATGATACACGGTCCAATGGATA
AACAT 
To amplify a 
amplicon in the 
3’ UTR of ACT1 
(amplicon 6) 
using qPCR 












ECM33 +9_F CAAGAACGCTTTGACTGCTACTG  To amplify the 
5’ss of ECM33 
(amplicon 2) 
using qPCR 
ECM33 +145 _R GAAGAGGACCACGAATCTACTCG  To amplify the 
5’ss of ECM33 
(amplicon 2) 
using qPCR 
ECM33 +430_F ACTTCTGCCACTGCTACTGCTC  To amplify the 
3’ss of ECM33 
(amplicon 3) 
using qPCR 
ECM33 +562_R AGGAACCATCAATCTCTTGGATAC  To amplify the 
3’ss of ECM33 
(amplicon 3) 
using qPCR 
ECM33 +1073_F TTGGTCAATCTTTGTCTATCGTCTC  To amplify a 
amplicon in the 




ECM33 +1173_R TGTGTTGTTAGCAATGATGAAACC  To amplify a 
amplicon in the 




ECM33 +1531_F TCTAAGAAGTCTAAGGGTGCTGCTC  To amplify a 
amplicon in the 




ECM33 +1582_R TGAATGAAGTGGCTGGAACAAG  To amplify a 
amplicon in the 




ALG9+3F GAATTGCAAGGCGGTAACCA To amplify ALG9 
(amplicon 1) 
using qPCR 
ALG9+86R GAAATTAACGAGAATGTCGGCTGAA To amplify ALG9 
(amplicon 1) 
using qPCR 
ALG9+326F TGAAATTGCAGGCAGCTTGG To amplify ALG9 
(amplicon 2) 
using qPCR 





ALG9+630F CGCATTCGACTGCTGTTTGA To amplify ALG9 
(amplicon 3) 
using qPCR 
ALG9+715R CAGGAGCAAGCTTCCCGTAA To amplify ALG9 
(amplicon 3) 
using qPCR 
ALG9+1079F GCCAGGCAATGTCACGGATA To amplify ALG9 
(amplicon 4) 
using qPCR 
ALG9+1118F GGTGCCTTCACACCACCTTG To amplify ALG9 
(amplicon 4) 
using qPCR 
ALG9+1486F AAGCTGGCATGTGCTGCATT To amplify ALG9 
(amplicon 5) 
using qPCR 
ALG9+1567R GGTTGATTGGCTCCGGTACG To amplify ALG9 
(amplicon 5) 
using qPCR 








RPL28_7_F    TCCAGATTCACTAAGACTAGAAAGCACAG

















































FMP27 -427 F TTCAATTGATCAAATTTATGGAAGATCCTC
AAGAA 





FMP27 -336 R GGAACAAAAACTTGACAAATTTGAAACTC
TGGAT 









To amplify a 
amplicon in the 
exon of FMP27 
(amplicon 2) 
using qPCR 
FMP27 +63 R CCATAAGAAAGTCACTGCAAATATAAGCC
ACTTGT 
To amplify a 
amplicon in the 
exon of FMP27 
(amplicon 2) 
using qPCR 
FMP27 +474 F AAGATTTGATTCCTTTTTGAGAAAACTTCT
TTGGA 
To amplify a 
amplicon in the 
exon of FMP27 
(amplicon 3) 
using qPCR 
FMP27 +593 R CCATCCTTCAGAGGATTCATAATTTCACC
AATT 
To amplify a 
amplicon in the 
exon of FMP27 
(amplicon 3) 
using qPCR 
FMP27 +1051 F TTGAATCTAAATCGAAAACATCAAAGCCA
CG 
 
To amplify a 
amplicon in the 
exon of FMP27 
(amplicon 4) 
using qPCR 
FMP27 +1154 R AATTTTTGAGAGAACAAATTGGTTTCGCC
A 
 
To amplify a 
amplicon in the 
exon of FMP27 
(amplicon 4) 
using qPCR 
FMP27 +4525 F AGACCTAGTACCAATACAATGTTCATTCC
AAACCA 
To amplify a 
amplicon in the 






FMP27 +4642 R CCTTGTCTGCTTTTTCGTTTTTACTTGATG
TAGTG 
To amplify a 
amplicon in the 
exon of FMP27 
(amplicon 5) 
using qPCR 
FMP27 +7589 F TGAACAGCTTCAAACTTTGTATCAGTTATA
AGGGC 
To amplify a 
amplicon in the 
exon of FMP27 
(amplicon 6) 
using qPCR 
FMP27 +7673 R GGGAAATTGAAAACAAAGTTAGTAACGTT
AGCCAA 
To amplify a 
amplicon in the 
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